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Summary
Interdomain interactions within the complex three-dimensional architecture of the cardiac 
ryanodine receptor (RyR2) are pivotal in channel regulation. Acquired or genetic 
abnormalities that perturb these stabilising intra-molecular interactions are pathogenic. This 
laboratory identified the interacting- or 1-Domain of human RyR2 that mediated interaction 
between cytoplasmic and transmembrane (TM) assemblies. To further elucidate the precise 
roles of functional motifs within the 1-Domain, three contiguous fragments spanning RyR2 
amino acid residues 3722-4610 were synthesised using a cell-free system. One fragment 
termed ID8 (amino acid residues 4353-4499) profoundly modulated cellular Ca2+ cycling and 
resulted in the remarkable normalisation of intercellular synchrony following its microinjection 
into ouabain-treated cardiomyocyte monolayers. These phenomena were linked to ID8- 
mediated stabilisation of RyR2 and were fully corroborated using ID8 purified from a bacterial 
expression system. Bioinformatic analysis revealed striking structural homology between 
sub-fragments of the RyR2 l-Domain and l-Domain-like regions of inositol 1,4,5- 
trisphosphate receptors (IP3R). Recombinant expression of l-domain sub-fragments in RyR- 
null human embryonic kidney (HEK) cells remodelled carbachol-evoked Ca2+-responses and 
suppressed homeostatic Ca2+ signalling events indicating that ID8 also modulated IP3R 
signalling mechanisms. In both HL-1 and HEK cells, ID8-dependent Ca2+ modulation 
extended to surrounding cells that were not microinjected with recombinant protein. This so- 
called ‘bystander effect’ was mediated by the transfer of signalling molecules via direct cell- 
to-cell coupling (gap junctions) and also by the extracellular transmission of diffusible 
effectors. This thesis supports the concept that RyR2 stabilisation rescues pathogenic Ca2+ 
dysregulation and suggests that there is substantial merit in developing further epitope- 
targeting strategies for the therapeutic normalisation of Ca2+ cycling in cardiac disease.
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General Introduction
Chapter 1
1.1 Calcium signalling in the heart
Calcium (Ca2+) is a universal biological signal responsible for the modulation of a vast 
range of cellular processes, including neurotransmission, secretion, proliferation, fertilisation 
and apoptosis (see Berridge et al. 2003; Clapham 2007 for reviews). Perhaps one of the 
most widely studied Ca2+-dependent mechanisms is muscle contraction. In cardiac muscle, 
Ca2+ is essential in cardiac electrical activity and is the direct activator of the myofilaments, 
which cause myocyte contraction.
This functional versatility of a simple divalent cation is intriguing, particularly since Ca2+ 
cannot be made or metabolised, and despite its importance in cell function sustained or 
abnormally high concentrations of Ca2+ are cytotoxic in most cells (Berridge et al. 2000). 
This property makes Ca2+ unique amongst second messengers, and its functional versatility 
stems from highly orchestrated release and sequestration (Summarised in Figure 1.1). Cells 
at rest maintain a low intracellular concentration of Ca2+ of ~100 nM, but this increases 
rapidly into the millimolar range upon cell activation. This mobilisation of intracellular Ca2+ 
takes place over periods ranging from microseconds to hours, to regulate a wide range of 
different cellular processes. Some of these transients result in highly localised brief bursts of 
Ca2+, while others produce longer-lasting global increases in Ca2+ in the form of repetitive 
waves (Berridge 1997).
The versatility of Ca2+ signalling is extended by complex spatial and temporal patterns 
underlying its release and sequestration. Release of Ca2+ from internal stores in cardiac 
muscle is modulated by various channels, including the ryanodine receptor (RyR) and the 
inositol-1,4,5-triphoshpate receptor (IP3R). Calcium movement through single RyR channels 
or lnsP3R channels produce highly localised elementary signals, termed a quark or blip 
respectively. These elementary signals can either activate highly localised cellular 
processes in the immediate vicinity of the Ca2+ channel, or by activating other channels 
throughout the cell. Alternatively they may initiate more complex Ca2+ signalling events 
resulting from the coordinated opening of clusters of RyRs or IP3Rs, known as sparks or
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puffs, respectively (Berridge 1997; Bootman et al. 1997; Lipp & Niggli 1998). Sparks and 
puffs contribute to Ca2+ waves and oscillations, which are global Ca2+ release events.
Stimulus
PMCA
Plasma Membrane
Resting [Ca2+]
Cytoplasm
Ca2+ -mobilising 
signals
SR SR
SERCA
RyR Na NaNC
Activated [Ca2*]
Ca2+
buffers
OFF mechanismsON m echanism s j EFFECTORS
Downstream processes
e.g. muscle contraction 
Figure 1.1. The Ca2+ signalling network
Maintaining Ca2+ homeostasis in the cell depends on highly-regulated interaction between numerous 
channels, pumps and exchangers, and the Ca2+ signalling network can be simplified into four 
functional units (Berridge et al. 2000): 1. The generation of Ca2+-mobilising signals: Signalling is 
triggered by a stimulus (normally acting via a plasma membrane receptor (R)) that generates various 
Ca -mobilising signals. 2. ON mechanisms: During the ON reactions, stimuli induce both the entry 
of external Ca and the formation of second messengers that release internal Ca2+ stored within the 
SR. Most of this Ca2+ (shown as red circles) is bound to buffers, whereas a small proportion binds to 
the effectors that activate various cellular processes operating over a wide temporal spectrum. 3. 
Ca2+-sensitive processes: The resultant Ca2+ signal activates various Ca + binding proteins 
(effectors), which undergo conformational change thereby modulating downstream processes, e.g. 
troponin C in muscle contraction. 4. OFF mechanisms: These remove Ca2+ from the cytoplasm using 
a combination of different pumping mechanisms. During the OFF reactions, Ca2+ leaves the effectors 
and buffers and is removed from the cell by various exchangers and pumps. The Na+/Ca2+ exchanger 
(NCX) and the plasma-membrane Ca2+-ATPase (PMCA) extrude Ca2+ to the outside, whereas the 
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps Ca2+ back into the ER. Mitochondria 
also have an active function during the recovery process in that they sequester Ca2+ rapidly through a 
uniporter, and this is then released more slowly back into the cytosol to be dealt with by the SERCA 
and the PMCA. When the cells are at rest, the OFF mechanisms maintain a low concentration of 
Ca2+, but are temporarily overwhelmed when external stimuli activate the ON mechanisms (Adapted 
from Berridge et al. 2003).
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In the heart, carefully regulated Ca2+ fluxes achieve a synchronised cellular depolarisation 
and subsequent activation of the contractile proteins by excitation-contraction (EC) coupling 
(Bers 2002). To maintain this process, intracellular Ca2+ homeostasis must be carefully 
regulated to synchronise depolarisation and contraction during systole (i.e. the time at which 
ventricular contraction occurs) and that relaxation occurs fully during diastole (i.e. the time at 
which ventricular relaxation occurs) before the start of the next cycle.
1.1.1 The cardiac action potential
The initiating event in cardiac EC coupling is the action potential (AP). The AP causes a 
reversal of the membrane potential to a positive value which is controlled by the complex 
interplay of many ion channels and transporters, and results in the generation of a Ca2+ 
transient. The AP is also responsible for the intercellular propagation of excitation in the 
heart, which allows the heart to function as a syncytium (Bers 2001). The cardiac AP 
consists of five distinct phases (numbered 0-4), each corresponding to a different pattern of 
ion flux (Figure 1.2) (Keating & Sanguinetti 2001).
The resting cardiac myocyte membrane is preferentially permeable to K+, and it is this 
efflux of K+ along an electrochemical gradient that dictates the negative membrane potential. 
Phase 0 represents rapid depolarisation of the myocyte, which is initiated by the rapid 
opening of voltage-gated Na+ channels which causes a rapid influx of Na+ ions. Early 
repolarisation (Phase 1) is then caused by an outward current of K+ ions (lt0) through 
transiently opened K+ channels due to the inactivation of cardiac Na+ channels. This occurs 
immediately after the peak of depolarisation and is recognised as a partial repolarisation of 
the membrane. The plateau that follows early repolarisation (Phase 2) is the result of the 
slowly decreasing inward current of Ca2+ ions caused by the opening of the L-type Ca2+ 
channel (LTCC, also termed dihydropyridine receptors (DHPRs) or Cav1.2) and gradually 
increasing outward current through several types of K+ channels. The process of final 
repolarisation (Phase 3) starts at the end of the plateau phase when the efflux of K+ from the
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myocyte begins to exceed the influx of Ca2+. The excess Na+ that had entered the cell 
during rapid depolarisation (Phase 0) is removed by the Na+/K+-ATPase. Similarly, most of 
the excess Ca2+ is eliminated by the Na+/Ca2+ exchanger (NCX) and plasma membrane 
Ca2+-ATPase (PMCA) as well as being pumped back into the store to restore the resting 
potential.
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Figure 1.2. Schematic representations of the cardiac action potential (AP) in a ventricular 
myocyte showing timing and morphology.
Panel A: The five phases of the AP are mediated by ion fluxes, summarised as follows: Phase 0 -  
rapid depolarisation caused by an inward Na+ current, signalling the onset of systole; Phase 1 -  early 
repolarisation, mediated bv a transient outward K+ current (lt0) and closure of the Na+channels; Phase 
2 -  the LTCC inward Ca + (lCa) current contributes to the long plateau duration; Phase 3 -  many 
outward K+ currents and Na+ and Ca2+ efflux contributes late repolarisation and the restoration of the 
resting membrane potential, seen in Phase 4. Thus, the coordinated opening and closing of cardiac 
ion channels is responsible for cardiac excitability. Panel B: The time course of an AP, Ca2+ transient 
and contraction measured in a rabbit ventricular myocyte at 37*C. (adapted from Keating & 
Sanguinetti, 2001 and Bers, 2002).
1.1.2 The cardiac myocyte
The human myocyte is typically 10-20 pm in diameter and 50-100 pm long with a single 
central nucleus. Cardiac myocytes form a branched network of cells, known as a functional 
syncytium, and individual myocytes interconnect via specialised regions of cell membranes 
known as intercalated discs, which help multiple cardiac muscle cells contract rapidly and 
synchronously as a unit (Figure 1.3). Each individual cardiomyocyte is composed of bundles 
of myofibrils. Each myofibril is composed of smaller units called sarcomeres, which are the 
basic units of contraction and contain two types of interdigitating myofilament: a thick 
filament made of the protein myosin and a thin filament composed chiefly of actin, which 
overlap each other (Klabunde 2005).
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Figure 1.3. Cardiac myocyte machinery
Panel A: Thin-section electron micrograph of a single ventricular cardiomyocyte, x1,500 
magnification. Panel B: Electron micrograph of ventricular cells showing details of ultrastructure 
(adapted from Berne & Levy, 1993). The sarcolemma (SL) is the boundary of the muscle cells and is 
extensively folded where the cells meet at the intercalated disc (ID) region. The prominent myofibrils 
(MF) show distinct banding patterns, including the A band (A), dark Z lines (Z), I band regions (I), and 
M lines (M) at the centre of each sarcomere unit. Mitochondria (Mito) occur either in rows between 
myofibrils or in masses just underneath the sarcolemma. Regularly spaced t-tubules (TT) appear at 
the Z line levels of the myofibrils. Panel C: Schematic representation of cardiac contractile
machinery. Panel D: Single ventricular myocyte viewed by confocal microscopy. Image prepared by 
combining a stack of serial optical sections through the cell. Myofibrils (seen as striations) visualised 
by immunostaining with an antibody against a-actin (a component of the myofibril Z-bands) (Severs
2000).
Chemical interactions between the actin and myosin filaments cause the sarcomeres to 
shorten as the overlap between the two types of filaments increases via a sliding 
mechanism. This occurs via cross-bridge formation, whereby the myosin head units bind to
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actin (Summarised in Figure 1.4). At rest, the myosin binding sites on the actin filaments are 
blocked by tropomyosin. During systole, contraction of the myocyte is initiated by a rapid 
increase in free intracellular Ca2+ which is released from the SR. Ca2+ binds to the troponin 
C subunit of the troponin complex, causing a conformational change and displacing 
tropomyosin. This frees the binding site and allows the interaction of actin and myosin. 
Filament sliding then occurs via a change in the angle of the cross bridge, after which the 
myosin head disengages, and the process is repeated. The energy for contraction is 
provided by adenosine trisphosphate (ATP), which binds to the myosin head units and upon 
hydrolysis yields energy for cross-bridge movement. Myocyte contraction is an ATP- 
expensive process, explaining the numerous mitochondria present in myocytes. The onset 
of relaxation and diastole is subsequently initiated by the removal of free Ca2+ from the 
cytosol, by extrusion via the sarcolemmal pumps and exchangers as well as by re-uptake of 
Ca2+ into the SR (Klabunde 2005).
Ca2* is rapidly released 
from SR during systole
myosin
myosin /  
heads ^ "
C a2* binds troponin C, and 
causes a transformational 
change to displace tropomyosintroponin C
At rest, myosin binding 
sites are blocked by 
tropomyosin
tropomyosin
The binding site on actin 
is now free .allowing 
interaction with myosin
Free Ca2tis removed '  
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Hydrolysis of ATP 
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Figure 1.4. Schematic diagram of cardiac cross bridge-formation
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1.1.3 Cardiac excitation-contraction (EC) coupling
Cardiac EC coupling is the key Ca2+ signalling process within the heart, and refers to the 
co-ordinated cellular depolarisation and movement of intracellular Ca2+ around the cardiac 
cell in order to bring about contraction of the heart. The ubiquitous second messenger Ca2+ 
is essential in cardiac electrical activity and is the direct activator of the myofilaments which 
cause contraction. Myocyte mishandling of Ca2+ is a central cause of both contractile 
dysfunction and arrhythmias in pathophysiological conditions.
In the normal heart, intracellular Ca2+ movements critically regulate subsequent 
mechanical contractions. In cardiac EC coupling, a small amount of Ca2+ first enters through 
the LTCCs during membrane depolarisation. This Ca2+ influx triggers a large-scale Ca2+ 
release - a process termed ‘Ca2+ induced Ca2+ release’ (CICR) - through RyR, the Ca2+ 
release channel of the sarcoplasmic reticulum (SR). The synchronised release of multiple 
Ca2+ sparks throughout the cell increases the concentration of free Ca2+ within the cytosol 
from -100 nM to -1000 nM during systole (Bers 2001), creating a global intracellular Ca2+ 
transient of sufficient magnitude to bring about contraction. Due to the high buffering 
capacity of the cytosol, which contains numerous Ca2+ binding proteins (e.g. troponin, 
calmodulin), the amount of Ca2+ entering the cytoplasm must be of the order of 100 pM in 
order for this increase in cytosolic Ca2+ concentration to be achieved and cause contraction 
(Bers 2001). Relaxation is initiated by dissociation of Ca2+ from troponin C, followed by its 
reuptake into the SR through phospholamban (PLB) regulated Ca2+-ATPase (SERCA2a) 
and subsequent trans-sarcolemmal Ca2+ removal through the Na+/Ca2+ exchanger (NCX) 
operating in its forward mode as well as by mitochondrial uptake (Bassani et al. 1994; Bers 
2002). These two processes balance systolic cellular influx and SR release of Ca2+ such 
that there is no net gain or loss of cellular Ca2+ with each contraction-relaxation cycle. 
Additionally, it has been shown that RyR2 gating can also be controlled in a concentration- 
dependent fashion by SR luminal free Ca2+ (Ching et al. 2000) , and as SR Ca2+ content 
increases a greater proportion of this Ca2+ pool will be released for any given trigger
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(Bassani et al. 1995; Janczewski et al. 1995; Scoote & Williams 2004). Spontaneous Ca2+ 
release from the SR, independent of /Ca mediated release, also occurs during normal cellular 
physiology, although the frequency of Ca2+ sparks is low and not sufficient to precipitate 
either a significant change in the cellular membrane potential or the activation of contractile 
proteins. However, in situations of SR Ca2+ overload, the frequency of spontaneous Ca2+ 
sparks is significantly increased, corresponding to an higher probability of RyR2 activation by 
an augmented luminal free [Ca2+] (Cheng et al. 1996). This correlation between SR Ca2+ 
load and spontaneous SR Ca2+ release is a key property in the development of Ca2+ 
dependent arrhythmias, and the increased Ca2+ load or increased sensitivity to normal store 
load is involved in the generation of cardiac glycoside-linked arrhythmia (such as ouabain, 
discussed in Chapter 5). Consequently, the inter-reliance of processes involved in EC 
coupling means that a defect or mutation in any one of its components could lead to 
abnormal Ca2+ handling, such as cardiac arrhythmia.
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Figure 1.5. Schematic representation of cardiac EC coupling
After depolarisation, Ca2+ enters the cell (lCa) (1). evoking release from the SR via the RyR (2), After 
initiation of contraction (3), Ca2+ is extruded from the myofilaments and cytosol by the SR Ca2+- 
ATPase pump modulated by phospholamban (PLB), sarcolemmal Ca2+-ATPase pump, Na+/Ca2+ 
exchanger (NCX), and mitochondrial uniporter (Bers 2002) (4).
1.1.3.1 Tuning EC coupling by phosphorylation
An important influence on myocardial Ca2+ cycling is (3-adrenergic receptor ((3-AR) 
stimulation mediated by sympathetic nerves and circulating catecholamines. Activation of 
these receptors can alter the properties of EC coupling components through signal 
amplification cascades that results in the phosphorylation of either the ion channels and 
pumps themselves, or the regulatory proteins attached to them (Scoote & Williams 2004). It 
has been appreciated for some years that the amplitude of Ca2+ transients generated by 
release of SR Ca2+ into the cytosol determines the contractile force (inotropy) of the heart. 
Catecholamine mediated phosphorylation will increase (1) the inward Ca2+ current, (2) SR
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Ca2+ loading and (3) its release into the cytosol, thereby enhancing contractile force. The 
effects of (3-AR activation are complex, with the function of most EC coupling proteins being 
affected by PKA and CaMKII mediated phosphorylation. Phosphorylation is the most 
important post-translational mechanism for synchronising the Ca2+ handling machinery and 
defective phosphorylation has long been viewed as a cause of EC coupling dysfunction in 
cardiac disease (Bers 2001; George etal. 2007a; 2008a).
This signalling cascade begins with (3-AR activation, either by sympathetic nerves or 
circulating catecholamines. As summarised in Figure 1.6, this subsequently allows the 
activation of adenylate cyclase and the generation of cAMP, which in turn switches on 
phosphorylation enzymes such as PKA and CaMKII (Scoote & Williams 2004). The 
functional consequences of phosphorylation can be grouped into inotropic and lusitropic 
effects. Inotropic effects include: (1) A 2-4 fold greater influx of Ca2+ through the
phosphorylated LTCC channel for any given excitation (Tsien et al. 1986; McDonald et al. 
1994); (2) Phosphorylation of RyR2 increases its sensitivity to activation by Ca2+ (Valdivia 
et al. 1995; Marx et al. 2000a) and this directly increases SR Ca2+ release. Lusitropic effects 
include: (1) Greater SR Ca2+ re-uptake through SERCA as a result of phosphorylation of its 
regulatory protein PLB, so that a larger SR load is expected; (2) A decrease in myofilament 
Ca2+ sensitivity (due to phosphorylation of troponin and the dissociation of Ca2+); (3) 
Enhanced NCX activity due to its phosphorylation and hence an increase in Ca2+ efflux, 
again increasing the rate of relaxation. These lusitropic effects are key to ensuring that there 
is sufficient SR Ca2+ available for the next cellular depolarisation, since reduced SR Ca2+ 
could result in weakened contractile force (Scoote & Williams 2004).
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Figure 1.6. Schematic representation of the p-AR pathway
3-AR dependent EC coupling augmentation in the heart. In the human heart pi and (32-adrenergic 
receptor signal transduction pathways activate protein kinase A (PKA), causing target protein 
phosphorylation, which enhances both inotropic and lusitropic aspects of EC coupling. p3-AR 
activation inhibits protein kinase activation. Phosphorylation of p-AR via (3-AR kinase (PARK) 
uncouples the receptor from its signal transduction pathways, acting as a negative feedback 
mechanism in situations of hyper-catecholaminergic drive. Experience with positive inotropic drugs in 
heart failure demonstrates that maximal functional augmentation via this process is rapidly achieved. 
Ongoing p-AR activation produces no further functional improvement, rather detrimental functional 
states are induced which lead to contractile dysfunction and arrhythmogenesis. (Scoote & Williams
2004).
1.2 EC coupling in cardiac disease
As discussed above, normal cellular Ca2+ homeostasis and co-ordinated ion flux is 
maintained by the balanced activities of EC coupling machinery. Defects in any of the 
components of the EC machinery would lead to abnormal Ca2+ handling, and has been 
implicated in cardiac disease.
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1.2.1 Heart failure
Heart failure (HF) is the leading cause of mortality, affecting 5.3 million and 3.8 million 
people in the USA and Europe respectively (Rosamond et al. 2008), with a 2-year mortality 
rate of -50% in advanced HF cases (NYHA class lll-IV) (Lehnart et al. 2005a). HF is 
characterised by contractile dysfunction and activation of neurohormonal factors (Braunwald 
& Bristow 2000; Yano 2008). In a heart that has suffered myocardial damage, regardless of 
the initial cause of the damage (such as hypertension, myocardial ischaemia, or 
cardiomyopathy), HF eventually occurs if such damage persists for a prolonged period 
(Braunwald & Bristow 2000; Yano et al. 2005a, 2008). In the initial stages, compensation for 
the myocardial damage and maintenance of haemodynamics can occur via activation of both 
the sympathetic nervous system and the renin-angiotensin (RA) system, resulting in 
ventricular dilatation and/or hypertrophy. However, if the decreased cardiac function 
persists, the myocardial damage becomes progressive and irreversible, and the heart can no 
longer meet the metabolic demand of the body; this is widely regarded as the ‘classic’ HF 
phenotype (Braunwald & Bristow 2000; Yano et al. 2005a, 2008).
The physiological process that determines contractile performance is EC coupling, and it 
is appreciated that detrimental alteration of the proteins involved in this process is a potential 
factor in the pathogenesis of HF. Evidence has accumulated that abnormal intracellular Ca2+ 
handling by the SR plays a central role in the pathogenesis of HF, via reduced SR uptake 
and abnormal SR Ca2+ release (Hasenfuss & Pieske 2002; Yano et al. 2005a, 2008). The 
reduced SR Ca2+ uptake leads to a depleted Ca2+ store, which in turn limits Ca2+ release. As 
a result of this, a reduced contractile force is generated (Lindner et al. 1998).
A hallmark feature of HF pathogenesis is impaired SR function that predominantly 
manifests as reduced SR Ca2+ load via decreased SR Ca2+-ATPase (SERCA) activity (Bers 
2001; Pogwizd et al. 2001; Houser et al. 2000). Both an upregulation of NCX and a 
reduction in SERCA2a activity may be responsible for the reduced SR Ca2+ content 
observed in HF (Hasenfuss & Pieske 2002). Both of these alterations could impair the
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restoration of SR Ca2+ stores during diastole, therefore reducing the amount of Ca2+ 
available for the next wave of depolarisation. This is believed to be the primary factor in the 
defective EC coupling seen in HF (Lindner et al. 1998).
Since the SR Ca2+ content is reduced in HF, the threshold SR content for Ca2+ release 
may be reduced, leading to a susceptibility to aberrant Ca2+ release (or spontaneous Ca2+ 
leak) at lower cytosolic [Ca2+]. RyRs are coupled to proteins at the luminal SR surface 
(triadin, junctin, and calsequestrin) (Bers 2004). Since these proteins buffer luminal Ca2+ and 
modulate the Ca2+ release process (Bers 2004), structural and functional alterations in these 
proteins may be causally involved in the development of defective intraluminal [Ca2+] 
regulation seen in HF. A hypersensitivity of RyR2 channel opening to entirely ‘normal’ 
cytosolic [Ca2+] may contribute to the presence of a spontaneous Ca2+ leak at much lower 
levels of cytosolic [Ca2+] in HF than in the normal SR (i.e., approximately 100 nM during 
diastole). This spontaneous Ca2+ leak may lead to a delayed after-depolarisation (DAD), 
which can trigger lethal arrhythmias (Brini 2004; Yano et al. 2005a).
1.2.2 Sudden Cardiac Death (SCD)
Sudden cardiac death can be defined as natural, nonviolent, unexpected death, occurring 
within 6 hours of the onset of symptoms from a stable medical condition (Virmani 2001). 
The rate of cardiac deaths that are sudden is approximately 50%, and decreases with age. 
The causes of sudden cardiac death are diverse, and are a function of age. In children and 
adolescents, coronary anomalies, hypertrophic cardiomyopathy and myocarditis are frequent 
substrates for lethal arrhythmias; in adults, coronary atherosclerosis and acquired forms of 
cardiomyopathy are the most common findings at autopsies of sudden cardiac death. 
Congenital coronary artery anomalies, result in sudden death almost exclusively in adults 
younger than age 35. In the older population (> 35 years old), approximately 60% of sudden 
coronary death is caused by coronary thrombosis, the rest die with severe coronary disease 
in the absence of thrombosis. The two major substrates of coronary thrombosis are plaque
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rupture and plaque erosion, and are not only different pathologically, but are seen in patients 
with divergent risk factor profiles. Plaque rupture is the most common cause of fatal coronary 
thrombus, and is characterized by necrotic core with a thin fibrous cap, infiltrated by 
macrophages. The factors that result in plaque instability and rupture are largely unknown, 
and are under intense scrutiny; morphologic studies have identified serum lipid abnormalities 
as a key risk factor in the development of plaque rupture. Plaque erosion, in contrast to 
plaque rupture, is seen in younger men and women, is not associated with lipid 
abnormalities, and does not result from exposure of the lipid core to the lumen (Virmani 
2001).
1.2.3 Cardiac arrhythmia
Arrhythmia results from perturbation of the robustly controlled fluxes of Na+, K+, and Ca2+ 
ions both within cardiomyocytes and between the myocardium and the external milieu (Bers
2001) and are responsible for >70% of out-of-hospital cardiac arrests (George et al. 2008b). 
These ionic fluxes are highly interdependent, and therefore localised disruption may 
exacerbate global ion flux imbalance resulting in complete ablation of synchronous cardiac 
electrical activity. Over the last two decades, defective mechanisms in arrhythmogenic ion 
fluxes have been elucidated by functional characterisation of Na+ and K+ channels containing 
genetic mutations (termed cardiac channelopathies). One such channelopathy is long QT 
syndrome, which affects the plateau and repolarisation phases of the human ventricular AP, 
and has been linked to mutations in both Na+ and K+ channels (specifically Kir2.1, KCNQ1, 
KCNH2 and Nav1.5) (Kass 2005; Meisler & Kearney 2005; Moss & Kass 2005). Currently 
the genetic basis of Ca2+ handling dysfunction in arrhythmia is the focus of widespread 
attention.
Intracellular and trans-plasmalemmal Ca2+ fluxes coordinate multiple facets of cardiac 
function, and precisely controlled Ca2+ cycling is a prerequisite for normal cardiac rhythm 
and contractility. The role of Ca2+ in arrhythmogenesis falls broadly into two categories -  a
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direct role by generating afterdepolarisations, and an indirect role by modulating the duration 
and time course of the cardiac AP (Antoons & Sipido 2008). Afterdepolarisations are carried 
by a net inward current and can occur within the plateau or repolarisation phase of the AP 
(early afterdepolarisations, EADs) or after repolarisation has completed (delayed 
afterdepolarisations, DADs). DADs can directly trigger APs to initiate arrhythmias, and are 
discussed in greater detail in Chapter 5.
Genetic mutations underlying malignant arrhythmias have recently been identified in 
cardiac Ca2+ channels such as LTCCs (Splawski et al. 2004) and ryanodine receptors 
(RyR2), both of which are large multifunctional Ca2+ release channels that are crucial for 
cardiac development EC coupling (For reviews see Bers 2004; Chelu et al. 2004; Fill & 
Copello 2002; George et al. 2005; Meissner 1994; 2004). However, unlike defects in Na+ 
and K+ ion handling, cellular Ca2+ dysfunction in arrhythmia does not arise exclusively from 
Ca2+ channel abnormalities, but also from mutation-linked defects in intra-organellar Ca2+ 
storage (Calsequestrin (CSQ) -  a major Ca2+ binding protein in the SR, implicated in 
catecholaminergic polymorphic ventricular tachycardia (CPVT) (see Section 1.4.1.2)) (Lahat 
et al. 2004; Postma et al. 2002; Terentyev et al. 2006), Ca2+ sequestration (phospholamban 
(PLB) -  a regulator of SERCA) (Haghighi et al. 2006; Schmitt et al. 2003), and altered 
cytoplasmic Ca2+ signals by Ca2+-binding proteins involved in EC coupling (tropomyosin and 
troponin) (Hedman etal. 2004; Watkins et al. 1995). Furthermore, alterations in cytoskeletal 
architecture that disrupt the spatial organisation of Ca2+ signalling networks may be highly 
arrhythmogenic in the absence of any genetic defects in Ca2+ handling machinery. 
Consequently, the complex physical and functional interplay between Ca2+ pumps, channels, 
stores and exchangers predicts that defects in diverse aspects of cardiomyocyte Ca2+ 
cycling directly contribute to an increased arrhythmogenic propensity (George et al. 2007a) 
and RyR is a pivotal component which modulates these interactions.
40
Chapter 1
1.3 The ryanodine receptor
The ryanodine receptor (RyR) is an intracellular Ca2+ release channel located on the 
SR/ER of muscle and non-muscle cells, which regulates the release of stored Ca2+ from the 
SR lumen during Ca2+ signalling processes such as EC coupling. RyRs were initially 
observed in skeletal muscle, visualised in electron-micrographs as large electron-dense 
bridging structures (termed ‘feet’) situated along the SR (Figure 1.7), between the 
sarcolemmal t-tubule and the junctional SR (Franzini 1970). Caldwell & Caswell (1982) later 
provided biochemical evidence for a high molecular weight protein which potentially 
represented these junctional feet. The RyR later gained its name in the late 1980s after it 
was found to bind ryanodine (Pessah et al. 1985), a plant alkaloid that enabled purification 
and molecular characterisation of the protein by its selective and specific affinity for the 
channel.
Figure 1.7. An electron micrograph of a section through a triad junction of a frog muscle cell
Shows a central t-tubular element flanked on either side by a terminal cisternae element of the SR. 
The arrows point to electron dense junctional feet spanning the junctional gap on either side of the t- 
tubule between the t-tubule and terminal cisternae (Franzini-Armstrong 1973).
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Ryanodine is a natural product found in the stems and roots of members of the genus 
Ryania, which grows as a shrub found in Central and South America, and was originally 
used as an insecticide (Sutko et al. 1997). Ryanodine was found to cause irreversible 
contracture of skeletal muscle and progressive decline in cardiac muscle twitches (Jenden & 
Fairhurst 1969; Sutko & Willerson 1980). It was later found that ryanodine appeared to bind 
specifically to the junctional regions of the SR, where the electron-dense “feet” were initially 
seen (Flucher & Franzini-Armstrong 1996). The RyR is the only cellular target of ryanodine 
reported to date, which it binds with high affinity and specificity, when in its open 
conformation, and thus, ryanodine-binding is often used as an index of channel activation in 
vitro.
RyR has been purified from skeletal (Inui et al. 1987a; Lai et al. 1987) and cardiac muscle 
(Inui et al. 1987a; Lai et al. 1988a) using [3H]-ryanodine as a selective marker and found to 
exist in a tetrameric form that sediments as a very large complex by sucrose density gradient 
centrifugation. The purified protein, incorporated into an artificial planar lipid bilayer, 
functions as a Ca2+ channel, with characteristics identical to the Ca2+ release channel 
observed upon incorporation of the crude SR fraction (Fill & Copello 2002; Hymel et al. 
1988; Imagawa etal. 1987; Lai etal. 1987).
The RyR was found to be a 2.2 MDa homotetramer (Lai & Meissner 1989a) comprising of 
four 560 kDa subunits (Takeshima et al. 1989), and it was later demonstrated that the 
individual RyRs were organised in a distinct pattern on the SR closely associated with the 
LTCCs -  so-called couplons or Ca2+ release units (CRUs) (Franzini-Armstrong et al. 1999). 
A typical cardiac couplon may have about 100 RyRs and 10-25 L-type channels (Bers 2001), 
and the spatial distribution of these two Ca2+ channels is crucial to the co-ordination of CICR. 
The importance of this spatial organisation is emphasised by reports that ventricular 
myocytes from spontaneously hypertensive rats that develop HF, displayed both a reduced 
ability to trigger SR Ca2+ release and increased spatial dispersion of the transverse tubules 
(TTs). The remodelled TTs in these myocytes no longer exhibited regularly organised 
structures, and moved within the sarcomere away from the Z-line structures and associated
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RyRs. These ‘orphaned’ RyRs were found to be responsible for the dyssynchronous Ca2+ 
sparks that have been linked to blunted contractility and, probably Ca2+-dependent 
arrhythmias in diverse models of HF (Song et al. 2006).
1.3.1 Molecular cloning of RyR isoforms and their tissue distribution
In mammals, three isoforms of RyR each encoded by a separate gene and each with 
specific tissue distribution, have been cloned and fully sequenced. RyRs were first cloned 
from mammalian skeletal (RyR1) and cardiac muscle (RyR2) (Marks et al. 1989; Otsu et al. 
1990; Takeshima et al. 1989). A third mammalian isoform (RyR3) was cloned from rabbit 
brain and a mink lung epithelial cell line (Giannini et al. 1992; Hakamata et al. 1992). 
According to the most recent GenBank entries for RyR, the gene for RyR1 is located on 
chromosome 19q13.1 in humans, and spans 106 exons. RyR2 spans 105 exons on 
chromosome 1q42.1-43, and RyR3 has been mapped to chromosome 15q14-15 and 
comprises 104 exons.
Similar isoforms have been cloned from non-mammalian vertebrates, including chicken 
and bullfrog (Ottini et al. 1996; Oyamada et al. 1994), though they express only two distinct 
isoforms -  a and p. The non-mammalian vertebrate RyRa isoform is homologous to the 
mammalian skeletal muscle isoform RyR1, while the RyRp is a homologue of the 
mammalian RyR3. Although RyRs were originally discovered in vertebrates, they have more 
recently been identified in invertebrates, including C. elegans and D. melanogaster (Maryon 
etal. 1996; Takeshima etal. 1994).
Expression of RyR1 is relatively abundant in skeletal muscle, although it is also 
expressed at lower levels in cardiac and smooth muscle, cerebellum and adrenal glands 
(Kuwajima et al. 1992; Marks et al. 1989; Ottini et al. 1996; Takeshima et al. 1989). RyR2 is 
predominantly expressed in cardiac tissue, but is also found in brain, and at lower levels, in 
the stomach, lungs and thymus (Giannini et al. 1995; Nakai et al. 1990), while RyR3 is 
expressed in a variety of tissues including the brain, diaphragm and slow twitch skeletal
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muscle (Giannini et al. 1992, 1995; Hakamata et al. 1992; Ottini et al. 1996). Despite the 
differences in tissue distribution, the three isoforms exhibit significant sequence homology. 
RyR1 and RyR2 are 66% identical, and RyR3 is 67-70% identical to RyR1 and RyR2 
(Franzini-Armstrong & Protasi 1997; Sutko & Airey 1996). The isoform sequences differ in 
three divergent regions (DR) which are thought to underpin the different physiological roles 
of the isoforms. The three isoforms of RyR share a common structure, exhibiting an overall 
mushroom shape with a 4-fold cyclic symmetry around an axis perpendicular to the 
membrane, consistent with the tetrameric nature of the channel (see Figure 1.8).
1.3.2 Structure of the RyR
Three-dimensional structural information is essential to an understanding of the functional 
properties of RyRs. However, because RyRs are very large integral membrane proteins, the 
detailed atomic three-dimensional structure of the RyR is not known and awaits 
crystallisation of the protein though this is proving far more complex than first anticipated due 
to its large size (George et al. 2005). In the absence of atomic resolution of RyR structure, 
cryo-electron microscopy (cryo-EM) has, to date, been the only feasible technique for 
obtaining reliable information about the 3D architecture of RyRs. In conjunction with 
computerised single particle image processing, this method is a powerful approach for 
determining the 3D structures of macromolecules and macromolecular assemblies. Cryo- 
EM has eliminated the artefacts associated with chemical fixation, dehydration, and contrast 
enhancement by heavy metals, which have limited EM in the past, and it permits resolution 
of the ‘true’ structure of the specimen. However, to compensate for the low signal-to-noise 
ratio inherent in micrographs of ice-embedded macromolecules, it is necessary to average 
thousands of images of individual macromolecules to achieve even a moderate resolution 
(20 A) (Franzini-Armstrong et al. 1999; George et al. 2005).
The RyR is the largest known ion channel, with a total molecular mass of -2.2 MDa. 
Based on gel permeation chromatography characteristics (Inui et al. 1987b), stoichiometry of
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ryanodine binding (Lai et al. 1988b, 1989b) and its quatrefoil appearance, it was deduced 
that the RyR exists as a homotetramer (Lai et al. 1988b; Wagenknecht et al. 1989), with 
each subunit consisting of approximately 5000 residues (Franzini-Armstrong & Protasi 1997; 
Mackrill 1999). The structure consists of two major components; firstly, a large, quatrefoil 
cytoplasmic assembly (28 nm x 28 nm x 12 nm) widely assigned ten distinct interconnected 
globular domains, which contain "clamps” located at the corners of the cytoplasmic structure 
and connecting structures termed “handles” (Radermacher et al. 1994), and secondly a 
differentiated small transmembrane assembly (12 nm x 12 nm x 7 nm) (Figure 1.8).
Recently, computational advances have facilitated the resolution of RyR1 at 9.6 A 
(Serysheva et al. 2008), using cryo-EM of frozen-hydrated, detergent solubilised individual 
isolated channels in conjunction with single-particle image processing (Radermacher et al. 
1994; Samsb et al. 2005; Serysheva et al. 2005, 2008; Sharma et al. 2000; Wagenknecht et 
al. 1989,1995). The three-dimensional reconstruction revealed that the cytoplasmic domain 
of RyR is a very open structure with clearly identifiable regions and solvent accessible 
spaces (Williams et al. 2001). The structure of RyR1 has also been determined in both 
closed and open conformations (Orlova et al. 1996; Samso & Wagenknecht 1998). Although 
the overall shape of the protein was similar in both conformations, there were some 
structural differences between the channel states (Serysheva et al. 1995; Orlova et al. 1996; 
Sharma et al. 2000) which indicate that alterations in the functional state of the RyR involve 
long-range conformational ordering of both the cytoplasmic and TM domains of the channel:
• Most significantly, the open state showed the presence of a low central density 
(approximately 2 nm in diameter) in the TM assembly of the open form connecting the 
luminal and cytoplasmic sides, indicating a single pore within a tetrameric channel.
• In the open state, the channel is slightly taller due to an elongation of the TM assembly 
and the clamp-shaped domains at the corners of the structure.
• The TM assembly is rotated by approximately 4°wit h respect to the cytoplasmic region.
• Two subdomains of the clamp region that are adjacent in the closed state are separated
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Figure 1.8. The three-dimensional structure of RyR
Panel A: A 9.6-A resolution cryo-EM density map of RyR1 in closed state, viewed from cytoplasm 
(top panel) and in a side view (bottom panel). Domains are shown within one of the RyR1 subunits. 
A domain is interpreted as compact protein density, and the boundary of a domain tends to be weakly 
connected with its adjacent densities. Poorly connected densities between subregions 6 and 8a and 
between 10 and 8b may be hinges between domains with high local structural flexibility. The individual 
domains are mapped into the distinct morphological units: clamp is formed by subregions 5, 7a, 7b, 
8b, 9, and 10 from one monomer and by subregions 6 and 8a from adjacent subunit; handle is formed 
by subregions 3 and 4; the central rim is formed by subregions 1, 2a, and 2b; and column is formed 
by subregions 11 and 12 (Serysheva et al. 2008). Panel B: Putative helices in the RyR1 membrane- 
spanning region. The top panel shows a stereoview of the membrane-spanning region viewed from 
the SR luminal side along the 4-fold axis. The densities attributable to a helices are annotated as 
colour ribbons: red, the inner helix; green, the pore helix; blue and purple, the other helices. The 
bottom panel shows a side view (normal to the 4-fold axis) of two of the four subunits of RyR1 with 
annotated helices showing the relative positions of putative a helices within the SR membrane. A high 
contour level is used in to emphasise the strongest densities interpreted as a helices (Ludtke et al.
2005).
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Although the resolution of the RyR three-dimensional structure using cryo-EM is 
constantly improving with the advent of more sophisticated sample preparation techniques 
and analysis software (Serysheva et al. 2005, 2008), the determination of the exact nature of 
the protein’s conformation is only likely to be achieved by atomic resolution, which would be 
particularly useful in determining the precise topology of the C-terminal TM domains. These 
membrane-spanning fragments are the most important elements in the structure of an ion 
channel because they delineate the pore, and constrain the structure of the entire molecule 
by anchoring the protein into the membrane (Dulhunty & Pouliquin 2003; Williams et al.
2001).
1.3.3 Correlating the linear sequence to the three-dimensional structure using 
recombinant RyR
Although all three RyR isoforms have been successfully purified from native tissues, more 
recently an alternative source of RyRs has been expression systems in which recombinant 
wild type or genetically modified RyR proteins can be produced from cDNAs. Gene fusions 
of RyRs and Glutathione-S-Transferase (GST) or green fluorescent protein (GFP) have been 
shown to be useful for ‘epitope-mapping’ within the three-dimensional cryo-EM. In this 
approach, since the GFP or GST are covalently attached to the RyR, every receptor image 
contains the label within each of the four RyR subunits, and the positions of various residues 
can be located on the three-dimensional structure (Liu et al. 2004; Zhang et al. 2003a). This 
is an efficient experimental approach for mapping the locations of surface exposed amino 
acid residues onto the tertiary architecture of the receptor, although is limited by the fact that 
the presence of the fusion protein may inadvertently cause other, non-directed changes in 
the three dimensional structure of the RyR.
To date, the amino terminus has been localised on the 3D structure of RyR using a GST 
fusion protein. Residues Asp-4365, Thr-1366 and Thr-1874 which lie within DR1, DR2 and 
DR3 respectively, have been located on the three-dimensional structure of RyR2 using
47
Chapter 1
appropriate RyR2-GFP fusion proteins (Liu et al. 2002, 2004; Zhang et al. 2003a). DR1-3 
refer to 3 divergent regions where the amino acid sequences of the three isoforms are highly 
variable relative to the average sequence identity among the isoforms, which is nearly 70% 
(Sorrentino & Volpe 1993). These DRs have been the focus of a number of structural and 
functional studies, as they are thought to be largely responsible for the differing properties of 
the RyR isoforms. For example, sequence variations in DR2 between RyR1 and RyR2 have 
been show to account for these isoforms' differing sensitivities to Ca2+ inactivation (Du et al. 
2000).
A similar approach was used to localise the binding sites of various ligands, and the 
binding sites for two accessory proteins calmodulin (CaM) and FKBP12 have been localised 
by determining differences in shape between free RyR and RyR protein-bound complexes 
(Wagenknecht et al. 1997). Both CaM and FKBP12 are situated > 10 nm away from the TM 
pore, suggesting that conformational changes can be transmitted over long distances within 
the protein structure.
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Figure 1.9. Three-dimensional structure of RyR2, indicating various regions that have been 
located using difference maps.
Correlation of RyRs amino acid sequence to its three-dimensional structure; showing the three- 
dimensional mapping of several domains as depicted on the schematic in the top panel. Three- 
dimensional structure of RyR2, indicating various regions that have been located using difference 
maps. DR1-3 refers to divergent regions of RyR (DR1-D4365, DR2-T1366, and DR3-T1874) (Liu et 
al. 2004). CPVT l-IV refers to domains of identified as CPVT-linked mutational hotspots in RyR2 
(George et al. 2008b).
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1.3.4 Topology of RyR transmembrane domains
Putative membrane-spanning domains are located at the C-terminus of RyR, and 
comprise 10-20% of the protein (500-1000 residues). At the current level of resolution in 
three-dimensional structure of RyR, it is not possible to elucidate the number of 
transmembrane helices, though a number of models have been proposed (Figure 1.10). 
Higher resolutions as well as additional reconstructions of the channel in different 
conformational states are required to further define the organisation and function of the RyR 
transmembrane domain (Hamilton 2005; Hamilton & Serysheva 2008).
From the analysis of the RyR1 primary sequence, Takeshima et al. (1989) originally 
predicted that the channel would have four membrane-spanning helices. Subsequent to this 
seminal paper, Zorzato et al. (1990) reported cloning of the cDNA encoding both the human 
and rabbit forms of this channel. However, these models based on sequence predictions 
require experimental verification. Recently, Du et al. (2002) proposed eight TM helices 
based on studies using eGFP fused in-frame to the C-terminus of RyR1, and a series of C- 
terminal deletions starting near either end of the predicted TM helices M1-M10. The 
subcellular localisation of the constructs expressed in HEK293 cells was determined with 
confocal microscopy of intact and saponin-permeabilised cells. The role of the M4a/4b 
hairpin loop in channel is thought to act as a negative regulatory module to stabilise the 
channel in its closed state (Du et al. 2004). This theory was supported by the observation 
that removal of this region increased the magnitude of voltage-gated SR release, and also 
resulted in increased channel sensitivity to activation by caffeine and Ca2+, and reduced 
sensitivity to Ca2+ dependent inactivation (Du et al. 2004). In Du’s proposed model, TM9 
appears as a ‘P-loop’, containing a selectivity filter, based on mutational analyses and 
analogies with better characterised ion channels, such as the inositol 1,4,5-trisphosphate 
receptor (IP3R) and the bacterial KcsA channel (MacKinnon 2003), which are all tetrameric 
and structurally homologous.
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Figure 1.10. Models for the transmembrane regions of RyR1.
Schematic representations of the proposed models of TM topology. The validation of these putative 
TM models requires unequivocal structural data, and recent structural data shows that some of that 
TM8 may lie in the plane of the membrane (Hamilton & Serysheva 2008).
51
Chapter 1
1.3.5 Regulation of RyR by the macromolecular complex
In vivo, RyR channels exist as a molecular scaffold for numerous accessory co-proteins - 
the macromolecular complex -  including regulatory proteins (calmodulin (CaM), FK506- 
binding proteins (FKBP), sorcin, CSQ, triadin, junctin), protein kinases (cAMP-dependent 
protein kinase (PKA), Ca2+/CaM dependent protein kinase type II (CaMKII)) and protein 
phosphatases (PP1, PP2A) (for reviews see (Bers 2004; Benkusky et al. 2004; Chelu et al. 
2004; Marks 2001, 2002). Figure 1.11 provides an up-to-date summary of the components 
of the RyR macromolecular signalling complex. The physical and functional interplay 
between the components of the macromolecular complex exquisitely regulates RyR2 Ca2+ 
release in response to a diverse array of cellular signals such as phosphorylation, localised 
cytoplasmic and SR luminal Ca2+ environments, Mg2+/ATP and ambient redox status (Fill & 
Copello 2002; Marks et al. 2002; Meissner 2004; Wehrens et al. 2006; Zissimopoulos & Lai 
2006). The macromolecular complex is modulated by a vast number of proteins and 
endogenous factors, but for the purposes of this thesis only phosphorylation status, FKBP, 
CSQ and Ca2+ will be discussed.
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Figure 1.11. The RyR2 macromolecular signalling complex
Four RyR2 monomers contribute to the tetrameric Ca2+ release channel macromolecular complex. 
Regulatory proteins and enzymes associate with the large cytoplasmic RyR2 domain. CaM, 
FKBP12.6, and sorcin are thought to bind directly to the RyR2 monomers, whereas binding of other 
subunits is mediated by specific targeting proteins. Leucine-isoleucine zipper (LIZ) motifs on RyR2 
bind to corresponding LIZ peptides in anchoring proteins spinophilin (targeting PP1), PR130 (targeting 
PP2A), and mAKAP (targeting PKA and PDE4D3). The mechanism for CaMKII binding to RyR2 is 
currently unknown. Triadin, junctin and CSQ interact with RyR2 on the luminal side of the channel 
complex. CaM acts as an intracellular Ca2+ sensor (Levitan 1999) and also+ influences SR Ca2+ 
release through a direct interaction with RyRs. At stimulatory Ca2+ levels, Ca2+ cooperatively binds 
CaM such that CaM can bind to and activate target proteins with high affinity. When CaM binds to 
target proteins the Ca2+ affinity is typically altered significantly. Sorcin is a soluble protein, which 
binds to RyR2 only when [Ca2+] is elevated, and rapidly reduces RyR open probability and inhibits the 
channel, though this is reversed by PKA-dependent phosphorylation of sorcin. This suggests that p- 
adrenergic stimulation decreases sorcin-mediated inhibition of RyR2, allowing for increased Ca2+ 
release during EC coupling. Mg2+ is a potent inhibitor of RyR, and exerts its inhibitory effects by 
competing with Ca2+ for the high-affinity Ca2+-binding site, and by binding the low affinity inactivation 
sites with an affinity comparable to that of Ca2+ (Copello et al. 2002; Laver et al. 1997). ATP 
increases the sensitivity of the channel to Ca2+ activation and decreases its sensitivity to Ca2+ 
inactivation (Meissner et al. 1997).
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1.3.5.1 Regulators of RyR2 phosphorylation - PKA, CaMKII and phosphatases
As depicted in Figure 1.11, Marx et al. (2000, 2001b) showed that PKA is anchored to the 
cardiac RyR via a muscle A kinase anchoring protein (mAKAP). Residues 3003-3039 in the 
cytosolic domain of RyR2 participate in a leucine-isoleucine zipper (LIZ) interaction with 
mAKAP which in turn binds to the regulatory subunit of PKA. PP1 and PP2A, which are 
involved in RyR dephosphorylation, are also associated with RyR2 via LIZ motifs (Marx et al. 
2000), and possibly function to dephosphorylate distinct sites or to modulate phosphorylation 
resulting from the action of different kinases. PP1 associates with residues 554-588 on 
RyR2 (and to RyR1) via a LIZ motif on spinophilin. Marx et al. (2001b) also showed that 
PP2A associates with a targeting protein PR130 which interacts with RyR2 (but not RyR1) 
via leucine zipper motifs at residues 1603-1631. CaMKII also co-immunoprecipitates with 
RyR2 (Zhang et al. 2003b), but the molecular site of interaction has not yet been elucidated. 
As discussed above, CaM also binds directly to the RyR, thus the requisite molecular 
machinery for both phosphorylation and dephosphorylation of the RyR are anchored directly 
to the protein. Macromolecular complexes within EC coupling are common. For example, 
the LTCC (£ 10nm away) also appears to have its own distinct complement of associated 
PKA, CaM and CaMKII (Ruehr et al. 2004), and may directly associate with p-AR, G-protein 
or adenyl cyclase, thus localising cAMP signals to activate RyR-associated PKA. This 
emphasises the likely functional importance of these local signalling complexes, in the direct 
vicinity of target proteins (Bers 2004).
Initially, RyR2 was proposed to have a single phosphorylation site (Ser2808) and it was 
originally described as the site for CaMKII phosphorylation (Witcher et al. 1991). Although 
several recent studies have suggested that Ser2808 is the major PKA substrate in HF 
pathogenesis (Marx et al. 2000), Ser2808 is a target for multiple kinases (Huke & Bers 2008; 
Xiao et al. 2006) and its constitutive high-level phosphorylation in both normal and failing 
hearts (Carter et al. 2006) suggests that the phosphorylation status of Ser2808 is not a 
reliable index of abnormal PKA-mediated phosphorylation of RyR2 in HF.
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Many studies aiming to identify the PKA-mediated phosphorylation sites have provided 
conflicting results with respect to the number of PKA sites, and which of them is PKA 
specific. Although RyR2 S2808 was initially reported to be CaMKII specific (Witcher et al. 
1991), it was later proposed that this residue is the sole PKA site and is phosphorylated 
exclusively by PKA (Marx et al. 2000b; Reiken et al. 2003; Wehrens et al. 2004a). However, 
many studies have shown that S2808 is already phosphorylated to up to 75% even in normal 
hearts (Carter et al. 2006), and can be efficiently phosphorylated by several protein kinases 
including PKA, PKG and CaMKII (Stange et al. 2003; Witcher et al. 1991; Xiao et al. 2005, 
2006). Furthermore, recent studies have identified a second PKA site at RyR2 residue 
S2031, and both appeared to be phosphorylated in vivo, whereby S2808 is constitutively 
phosphorylated and S2031 was phosphorylated by PKA under conditions of cellular 
activation (Xiao et al. 2005, 2006). Expression of constitutively dephosphorylated mutant 
channels containing a Ser->Ala substitution at the putative phosphorylation sites (S2808A, 
S2031A) either individually or as a double mutant, did not resolve this discrepancy. Marks’ 
group observed that a single S2808A substitution abolished PKA dependent 
phosphorylation, whereas S2031A did not (Lehnart et al. 2005a; Wehrens et al. 2006). 
Contrastingly, another group demonstrated that PKA-dependent phosphorylation occurred 
with either individual mutant and was abolished only in the double mutant (Xiao et al. 2005, 
2006).
Dephosphorylation of RyR2 is carried out primarily by PP1 and PP2A (Marx et al. 2000; 
2001b). The phosphorylation status of RyR2 is a result of the regulated balance between 
protein kinases and phosphatases. Therefore disease-linked RyR2 ‘hyperphosphorylation’ 
may arise from decreased activity of channel-associated phosphatases (PP1 and 2A), and 
this will be discussed further in Section 1.4.1.1.
The functional effects of RyR phosphorylation/dephosphorylation have been examined by 
SR Ca2+ flux measurements, single channel recordings, and by ryanodine-binding assays. 
Addition of exogenous PKA results in increased RyR activity because of enhanced 
sensitivity to Ca2+ activation, and substantially reduced Mg2+ inhibition, and these effects
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were reversed by PP (Marx et al. 2000; Reiken et al. 2003; Takasago et al. 1991; Valdivia et 
al. 1995). One study reported that PKA activated RyR but only during rapid rises in local 
Ca2+ concentration, whereas under fixed Ca2+ levels, it promoted channel closure (Valdivia et 
al. 1995). Exogenous CaMKII displayed enhanced RyR channel activity (Currie et al. 2004; 
Wehrens & Marks 2004b; Witcher et al. 1991), and interestingly, PKA- and CaMKII- 
dependent phosphorylation produced different functional effects in parallel investigations, 
suggesting that they target different residues, or a different number of residues (Takasago et 
al. 1991). Furthermore, Rodriguez et al. (2003) showed that CaMKII phosphorylates RyR2 to 
a four-fold higher stoichiometry than PKA, suggesting that sites in addition to Ser-2808 are 
CaMKII targets, and could be critical mediators of RyR2 function.
1.3.5.2 FK-binding proteins (FKBP)
FKBPs bind to and co-purify with RyRs (Jayaraman et al. 1992; Marks et al. 1989; 
Timerman et al. 1993, 1994, 1996). FKBP12 binds tightly to RyR1, and while the heart 
expresses both FKBP12 and 12.6, the latter preferentially associates with RyR2, due to a 
much higher affinity (Timerman et al. 1996). FKBPs also catalyse peptidylprolyl-c/s-frans- 
isomerisation, a function believed to be involved in protein folding, but their isomerase 
activity is not essential for RyR effects (Bers 2004; Kay 1996; Mackrill 1999; Marks 2000).
The molar ratio of FKBP to RyR is one-to-one i.e., one FKBP protein is bound to each of 
the four subunits of the RyR channel complex (Timerman et al. 1993; 1996). The binding 
site for FKBP12.6 on RyR2 was initially proposed to be in the central domain of the protein 
(aa 2361-2496), which was identified using yeast two-hybrid analysis (Marx et al. 2000). 
This region corresponded to that in RyR1 which interacts with FKBP12 (Bultynck et al. 2001; 
Cameron et al. 1997; Gaburjakova et al. 2001). However, other loci for FKBP12.6 binding 
have recently been mapped to the N- and C-termini (Masumiya et al. 2003; Zissimopoulos & 
Lai 2005). Nonetheless, due to the complexity of the tetrameric RyR2 structure and the fact 
that this domain was assigned functionality on the basis of the study of fragments of the
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RyR2 rather than the full length protein, it is entirely feasible that all of these loci contribute 
to a single FKBP12.6 binding site in the intact molecule (George et al. 2005).
Removal of FKBP12.6 from the RyR2 (using FK506 or rapamycin) activates the RyR 
(Kaftan et al. 1996; Xiao et al. 1997), and studies in intact myocytes showed that removal of 
FKBP12.6 by FK506 increased the resting spark frequency and enhanced Ca2+ transients 
(McCall et al. 1996). Contrastingly, other groups have reported that FKBP12.6 removal has 
very little impact on RyR2 channel function (Barg et al. 1997; Timerman et al. 1996; Xin et al.
2002). Several studies have shown that FKBP12/12.6 removal promotes the appearance of 
subconductance states in single channel experiments (Ahern et al. 1994; 1997; Brillantes et 
al. 1994; Kaftan et al. 1996; Marx et al. 2000). This observation led to the proposal of a 
controversial model where FKBP physically stabilises the coordinated gating of the four 
RyRs in one RyR homotetramer so that openings go from the fully closed to the fully open 
state, and the proposal that FKBP could be involved in coupled gating mediating the 
simultaneous opening and coordinated closure of channels In vivo (Marx et al. 2000). 
However, recent evidence shows that although synchronous RyR opening does occur 
(Wang et al. 2004), it is unlikely to be directly mediated by FKBPs since the region which 
mediates inter-tetrameric interaction (encompassing domains 6 and 10) is spatially distinct 
from the FKBP binding site (Yin et al. 2005a) (see Section 1.3.3).
There are reports that suggest that FKBP12.6 is critical to normal RyR2 function in the 
heart (Kaftan et al. 1996; McCall et al. 1996), and that abnormal FKBP12.6-RyR2 
interactions, occurring as a result of channel hyperphosphorylation may be implicated in HF 
(Marks 2000; Marx et al. 2000; Ono et al. 2000; Yano et al. 2000). This 
hyperphosphorylation was proposed to cause a persistent diastolic SR Ca2+ leak, thought to 
limit the SR load and contraction in the failing heart. This model is the focus of much 
controversy, and will be discussed in more detail in Section 1.4.1.1.
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1.3.5.3 Calsequestrin
Calsequestrin (CSQ) is a high-capacity Ca2* binding protein, localised to the junctional SR 
membrane and whose primary function appears to be buffering of intra-luminal Ca2+ (Yano & 
Zarain-Herzberg 1994). Cardiac CSQ is a highly acidic 45kDa protein with 119 Glu and Asp 
residues that permit it to bind 20-40 Ca2+ ions per molecule (Yano & Zarain-Herzberg 1994). 
Triadin (~35kDa) and junctin (~26kDa) are integral SR proteins which physically couple CSQ 
to the RyR2 via ‘polar zippers’ formed between ‘KEKE’ motifs present in their primary 
structures and acidic moieties near the inner mouth of the RyR channel domain (Lee et al. 
2004; Zhang etal. 1997), forming a quaternary complex (Mackrill 1999; Zhang et al. 1997).
Transgenic mice in which CSQ had been overexpressed >10-fold developed cardiac 
hypertrophy (Sato et al. 1998). Cardiomyocytes from these mice display a 10-fold increase 
in the amplitude of caffeine induced Ca2* release compared to controls, as would be 
expected for cells possessing a greater level of intra-SR Ca2+ buffer. Conversely, these cells 
exhibited a decreased spontaneous RyR2 activity, which was explained by a decrease in 
free SR Ca2+. More moderate levels of adenoviral CSQ expression (2-4 fold) in adult 
ventricular myocytes resulted in enhanced Ca2* transient and spark amplitude (Terentyev et 
al. 2003a). These results, along with the implication of CSQ in heart disease (see Section 
1.4.1.2), indicate that cardiac CSQ plays pivotal roles both in Ca2* storage and in regulation 
of Ca2+ release via RyR2.
1.3.6 Regulation of the RyR macromolecular complex by endogenous factors
RyR channel activity is regulated by a wide variety of endogenous molecules, with Ca2*, 
Mg2* and ATP being the key regulators, but for the purposes of this thesis only Ca2* will be 
discussed.
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1.3.6.1 Cytosolic Ca2*
Ca2* is an important physiological regulator of the channel and other ligands either cannot 
activate the channel in its absence (e.g. CaM) or they require Ca2+ for maximum effect (e.g. 
ATP). Cytosolic Ca2+ has a biphasic effect on RyR1 channel activity; the threshold for 
channel activation is approximately 100 nm with a maximum range of 10-100 pM, whereas 
millimolar Ca2+ inhibits the channel. This bell-shaped dependence suggests that RyR 
contains high-affinity Ca2+ binding sites that stimulate the channel and low-affinity sites that 
inhibit it (Chu et al. 1993; Copello et al. 2002; Laver et al. 1995). RyR2 and RyR3 are less 
sensitive to inhibition by high Ca2* concentrations and almost maximal activation can be 
achieved by Ca2+ alone at approximately 100 pM, unlike RyR1 which can not be fully 
activated by Ca2+ alone (Jeyakumar et al. 1998; Murayama & Ogawa 2002; Rousseau & 
Meissner 1989).
1.3.6.2 Luminal Ca2*
The rate of Ca2+ release from the SR is sensitive to the store Ca2+ content and single 
channel recordings have demonstrated RyR regulation by luminal Ca2+ (Gydrke & Gyorke 
1998; Sitsapesan & Williams 1994, 1995). Although differences exist between RyR1 and 
RyR2, increasing luminal Ca2* concentration augments channel activity by increasing the 
channel sensitivity to agonists such as cytoplasmic Ca2*, ATP and caffeine and by alleviating 
Mg2* inhibition. However, increasing luminal Ca2* levels above a threshold causes a 
decrease in channel activity. The mechanism of RyR activation by luminal Ca2* is thought to 
involve either Ca2* regulatory sites through an allosteric effect in single isolated channels, 
whereas in close-packed RyR1 arrays, luminal Ca2* flowing through one channel directly 
interacts with cytosolic regulatory sites of neighbouring channels (Laver et al. 2004). The 
luminal Ca2* sensor can either be an intrinsic property of RyR or is imparted by accessory 
proteins. Evidence for the former is provided by proteolysis studies suggesting the presence 
of both activating and inactivating Ca2* sites on the RyR luminal side (Ching et al. 2000).
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Contrastingly dissociation of CSQ, triadin and junction abolished RyR2 regulation by luminal 
Ca2* (Gydrke et al. 2004), whereas CSQ association amplified channel responses to luminal 
Ca2* (Beard et al. 2005).
1.3.7 Functional Interactions within the RyR
1.3.7.1 Inter-channel interaction
A characteristic feature of RyRs is their organisation into ordered two-dimensional arrays 
within the membrane, observed in both skeletal and cardiac muscle by EM (Protasi et al. 
1996; Saito et al. 1988; Yin et al. 2008). This regular organisation is an intrinsic property of 
the RyR, as recombinant RyR1 forms extensive arrays in vivo (Takekura et al. 1995) and 
purified RyR1 self-assembles into large two-dimensional crystalline arrays in vitro (Yin & Lai 
2000; Yin et al. 2005a). In these checkerboard-like lattices, each RyR is interlocked with 
four adjacent channels through a specific intermolecular domain-domain interaction that 
appears to involve sequences in the proximity to the region identified as DR2 (Liu et al. 
2004; Yin et al. 2005b). In arrays, the cytoplasmic assembly of each RyR interacts along the 
edges of the clamp domain with the corresponding regions of its nearest neighbours such 
that the edges of adjoining RyRs overlap by ~12 nm (Saito et al. 1988). Biochemical 
evidence has suggested residues 2540-3207 in the central region of RyR2 are responsible 
for the tetramer-tetramer interactions in array formation (Blayney et al. 2004). It has been 
proposed that inter-tetramer contact in this array formation is mediated by an accessory 
protein (FKBP) and that these interactions could be responsible for the concerted opening 
and closing of channels seen in vivo (Marx et al. 1998). However, as discussed above, this 
notion has been disputed by three-dimensional modelling which suggests that domains most 
likely to undergo protein-protein interactions are spatially distinct from the FKBP binding site 
(Wagenknecht et al. 1997), suggesting that the intrinsic structure of the RyR is responsible 
for the formation of these ordered arrays (Liu et al. 2004; Yin et al. 2005b, 2008).
Theoretical modelling (Stern etal. 1997,1999) and experimental observations (Marx etal.
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1998b, 2001a; Wang et al. 2004) of E-C coupling in muscle cells have suggested that RyR 
behaves in an intermolecular allosteric manner in native SR membranes. The contact 
between RyRs in the array provides potential mechanistic insight. In the native 
checkerboard array, RyRs are interlocked through intermolecular domain-domain interaction 
(i.e. they are ‘physically coupled’), whereby a conformational change of one activated RyR 
can likewise be communicated to four adjacent RyRs through intermolecular domain- 
domain interaction. Thus, allosterically mediated conformational changes induced in these 
neighbouring RyRs trigger their activation and consequent Ca2+ release and may explain 
how a number of RyRs within a cluster open and close simultaneously during a Ca2* spark. 
The existence of an allosteric coupling mechanism for RyR activation would help to address 
a variety of fundamental issues that are crucial to Ca2* signalling and E-C coupling in 
muscle cells (Yin et al. 2008).
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Figure 1.12. Physical coupling between skeletal muscle RyRs in the native ‘checkerboard’ 
array
Panel A: Electron micrographs showing RyRs in the native checkerboard-like array. Scale bar: 
100nm; Panel B: Calculated projection maps showing RyRs in the lattice formation. The square box 
outlines one RyR molecule; the arrows indicate the physical coupling occurring between adjacent 
RyRs in the native checkerboard-like array; Panel C: RyR molecules are linked to form a two-row 
array as is found in skeletal muscle. Domain 6, which lies in the clamp structure, where DR2 has been 
located by GFP insertion (in green), is one of the domains that is likely, based upon its location, to be 
involved in RyR-RyR interactions (Liu et al. 2004).
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1.3.7.2 Inter-domain interaction within the RyR tetramer
As well as being involved in inter-tetramer interactions, regions of the cytoplasmic domain 
of RyR1 and RyR2 have also been implicated in inter-domain interactions within the 
tetrameric channel, and it is these interactions which are thought to mediate the global 
conformational change associated with Ca2* release.
The extreme RyR C-terminus is known to be capable of self-association (Stewart et al.
2003). This region has been identified as a molecular determinant of oligomerisation since 
deletion of the final 15 amino acids from RyR1 resulted in an inactive channel, due to 
impaired assembly of a tetrameric complex (Gao et al. 1997), while the extreme C-terminal 
100 residues form dimers and tetramers (Stewart et al. 2003).
Studies using synthetic peptides and site-specific antibodies have shown that N-terminal 
(residues 590-609) and central domain (residues 2442-2477) regions undergo domain- 
domain interaction (Kobayashi et al. 2004). Additionally, using a peptide probe approach, 
Ikemoto and colleagues demonstrated that the N-terminal and central domains of the RyR 
(in both cardiac and skeletal muscle isoforms) are closely associated in the inactive channel 
state and in fact stabilise the closed conformation, while loosening of this interaction 
(‘unzipping’) by mutation and/or competitive binding of a peptide produced the active 
conformational state (El-Hayek et al. 1999; Yamamoto et al. 2000). These peptide probe 
approaches will be discussed in more detail in Section 1.5.
1.3.8 The RyR21-Domain
We recently identified a region involved in the critical regulation inter-domain interactions - 
the RyR2 l-Domain (interacting domain, aa 3722-4610). This is a surface-accessible, hinge­
like region of RyR2 that is the location for 32% of all reported CPVT-linked mutations (Figure
1.13), and is critically involved in the intrinsic regulation of the channel by transducing 
regulatory cytoplasmic events to the Ca2* pore-forming domain (George et al. 2004, 2006).
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Figure 1.13. CPVT-linked mutations located to the RyR2 l-Domain
The l-Domain contains 23 of the 71 CPVT-linked mutations so far identified in RyR2. Residues 3722- 
4353 has been found to be sufficient for interdomain interaction to occur, while residues 4353-4610 
markedly enhanced the functional impact of this interaction, indicating that interaction between 
discrete regions of single l-Domains result in the mediation of interaction between the cytoplasmic and 
TM regions of RyR2. Interestingly, no mutations have been identified in the region 4353-4499 
(termed ID8, see Chapter 3) implying that this region may be vital for viable channel function.
The l-Domain was initially identified using Fluorescence Resonance Energy Transfer 
(FRET) analysis, by demonstrating a specific association between RyR2 cytoplasmic 
domains and the membrane-localised TM region, which resulted in inhibitory (suppressed 
resting intracellular [Ca2+]) and excitatory (restored caffeine sensitivity) modulation of RyR 
Ca2+ channel functionality. By successive amino-terminal extension, the region mediating 
interaction between RyR2 TM and cytoplasmic domains was mapped to amino-acid residues 
3722-4610, which we termed the l-Domain. Because the determinants of inter-subunit 
interaction involved in RyR tetramerisation are located in regions distinct from the l-Domain 
(Stewart et al. 2003), it was suggested that the l-Domain mediated interaction within, and not 
between, RyR2 subunits in the intact tetramer. It was found that amino acid residues 3722- 
4353 were sufficient for interdomain interaction to occur, while residues 4353-4610 markedly
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enhanced the functional impact of this interaction (Figure 1.13). This indicated that 
interaction occurs between discrete regions of single l-Domains, thereby resulting in the 
modulation of interaction between the cytoplasmic and TM assemblies of RyR2 (Figure
1.14).
Sarcoplasm
SR lumen
Closed
l-domain
Interacting region 
(3722-4353aa)
Modulator/ region 
(4353-4499aa)
Figure 1.14. The RyR2 l-Domain intrinsically controls RyR2 opening through conformational 
rearrangement
Schematic diagram, showing that conformational re-ordering within the l-domain is associated with 
RyR2 channel opening and closing, based on data obtained from fluorescence resonance energy 
transfer (FRET) studies of cytoplasmic (light grey) and transmembrane domain (dark grey) 
interactions (George et al. 2004, 2006). Functionally distinct sub-regions within the l-Domain are 
predicted from experimental data and computational analysis (George et al. 2004; 2007b).
The l-Domain of RyR2 comprises two distinct domains, the interaction domain located at 
residues 3722-4353 and the modulatory domain, containing two putative TM domains 
located at residues 4353-4610 (George et al. 2004, 2006). Our data suggests that 
conformational rearrangements within the l-Domain can physically transduce the ‘sensing’ of 
cellular signals by cytoplasmic domains to regulate the TM Ca2+ pore-forming region, and
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that these events are perturbed following RyR2 mutation (George et al. 2004, 2006). 
Experimental and computational analysis have revealed that the l-Domain comprises sub- 
regions of distinct functionality, including the region responsible for interaction, a region that 
confers agonist sensitivity (modulatory region) and two predicted TM domains. This is 
supported by analysis of the putative locations of the CPVT domains on the three- 
dimensional RyR2 reconstruction indicates probable interactions between CPVT domains III 
and IV (which encompass the l-Domain), and it is likely that CPVT domains may assemble 
into two pairs of physically distinct interacting loci within RyR2. This concept is consistent 
with data from our laboratory suggesting that the precise mode of RyR2 mutation-linked 
conformational instability associated with CPVT is predicted by the mutational loci (George 
et al. 2006; Thomas et al. 2004)
1.4 RyR2 and pathology
The structural and functional complexity of RyR and its critical physiological role in Ca2* 
regulation discussed above, predicts that defects in any of the numerous facets of RyR 
regulation or function would be pathogenic. Mutations in RyR1 are known to cause the 
skeletal muscle pathologies malignant hyperthermia (MH) and central core disease (CCD). 
Mutations in corresponding regions of RyR2 are associated with catecholaminergic 
polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular 
cardiomyopathy type 2 (ARVC2) (Figure 1.15), and acquired or genetic defects in RyR2 that 
result in defective Ca2* release have been shown to underlie an increased propensity for 
ventricular arrhythmias. The discovery of these RyR2 mutation-related arrhythmia 
syndromes has triggered a large upsurge of interest in elucidating the molecular 
mechanisms underlying mutant channel dysfunction, since this represents a pre-requisite for 
the design of new therapeutic strategies based on detailed structure-function analysis, but 
may also provide fundamental insights into the mechanisms of arrhythmogenic RyR2 
dysfunction commonly occurring in HF.
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Figure 1.15. Schematic of the reported mutation sites RyR1 and RyR2.
The three hotspot regions and the RyR mutations found in these regions are indicated. The regions 
encompass the amino acid residues as indicated: N-terminal domain, amino-acids 0-600; central 
domain, amino-acids 2,100-2,500; channel region, amino-acids 4,100-5,000 (Yano 2008).
1.4.1.1 RyR2 in Heart Failure
Traditionally, RyR2 has not been considered to have a direct role in the pathogenesis of 
HF which has been attributed more to defects in SR Ca2+ loading. However there is now 
substantial evidence that RyR2 dysfunction is pivotal in cardiac deterioration and HF. 
Expression levels of functional RyR2 channels in HF, as measured by ryanodine binding 
have shown conflicting results. These measurements have shown the levels of RyR2 to be 
unchanged (Nimer et al. 1995), increased (Sainte Beuve et al. 1997) and decreased (Vatner 
et al. 1994) in a variety of animal HF models. Other studies suggest that the number of 
RyR2s relative to LTCCs is reduced, causing a functional uncoupling of the two channels, 
resulting in reduced SR Ca2+ release (Milnes & MacLeod 2001).
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Work by Yamamoto et al. (1999) implied that RyR2 activity is increased to compensate 
for the reduced SR load and Ca2+ release seen in HF. This compensatory modulation of 
RyR2 may come as the result of catecholaminergic stimulation whereby decreased cardiac 
output activates the compensatory effects of the sympathetic nervous system and HF is 
described as a hyper-catecholaminergic state (Scoote & Williams 2002). Several studies 
have shown a close correlation between levels of circulating catecholamines and prognosis 
of HF (Cohn et al. 1984, 1995). In response to this, the function of various EC coupling 
components, including the RyR2 is augmented by (3-adrenergic dependent increases in 
phosphorylation (Marx et al. 2000; Scoote & Williams 2004).
RyR2 phosphorylation is regarded as an extremely important physiological regulatory 
mechanism and has been implicated in HF and arrhythmogenesis, but the role of 
phosphorylation in channel dysfunction remains highly controversial (Bers et al. 2003, 2006; 
Lehnart et al. 2004; Marks 2003; Wehrens et al. 2005). A model in which abnormal cAMP- 
dependent protein kinase (PKA)-mediated ‘hyper-phosphorylation’ of RyR2 at Ser2808 
abolished the interaction between RyR2 and FKBP12.6, an accessory co-protein, and 
resulted in arrhythmogenic diastolic Ca2* leak, was proposed by Marx et al. as the primary 
causative basis of RyR2 dysfunction in HF (Marx et al. 2000). Additionally, decreased PP1 
and PP2A levels have been implicated in HF as a potential explanation for the PKA 
hyperphosphorylation of the RyR2 channel (Marx et al. 2000).
In a series of confirmatory experiments, this mechanism was extrapolated to other cardiac 
and skeletal muscle pathologies including CPVT (Marks 2003; Reiken et al. 2003; Wehrens 
et al. 2003), and in further support, the substitution of Ser2808 with alanine, thereby 
preventing PKA-mediated phosphorylation at this residue, protected RyR2 channels from 
PKA-induced defects (Lehnart et al. 2005a; Wehrens et al. 2003). This mechanism has 
attracted huge interest as it provides a feasible and attractive ‘unifying’ mechanism of RyR2 
dysfunction in cardiopathology. However, despite being extensively tested in numerous 
experimental models, this mechanism has been corroborated in only one other laboratory 
(Yano et al. 2003, 2005b), and many recent studies have highlighted fundamental
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inconsistencies relating to key tenets of this model.
Li et al. (2002) showed that a maintained increase in global and local SR Ca2* release in 
response to enhanced phosphorylation was due to phosphorylation of PLB, and this was 
consistent with the finding that changes in RyR2 phosphorylation associated with HF had no 
effect on cardiac function (Jiang et al. 2002a). Furthermore, the improved synchronisation of 
Ca2+ sparks in failing myocytes following (3-AR stimulation is contrary to what may have been 
expected if PKA-mediated phosphorylation was the major cause of the impaired Ca2+ 
handling dynamics (Litwin 2006). In contrast to studies in which enhanced RyR2 
phosphorylation promoted sudden death (Antos et al. 2001), and the demonstration that 
persistent channel phosphorylation in PDE4D3-deficient mice (a cAMP-specific 
phosphodiesterase) was linked to age-related cardiomyopathy (Lehnart et al. 2005b), 
prolonged RyR2 phosphorylation via inhibition of PP1 was cardioprotective (Yamada et al. 
2006). This finding supported previous reports that PKA-mediated RyR2 phosphorylation 
reduced channel functionality (Valdivia et al. 1995), and also that dephosphorylation 
stimulated channel activity in cardiac myocytes (Terentyev et al. 2003b). Additionally, Carter 
et al. (2006) showed that Ser2808 exhibited basal phosphorylation levels of -75% and 
proposed that this represented the lowest activation state of RyR2, whereby increased or 
decreased phosphorylation (by PKA or PP1, respectively) activated the channel via distinct 
mechanisms.
Although the importance of RyR2 phosphorylation under normal physiological conditions 
remains controversial, it may still play a role in generating triggered arrhythmias, which are 
thought to occur during SR Ca2+ overload. Pogwizd et al. (2001) showed that the residual |3- 
adrenergic receptor responsiveness was sufficient to load the SR with enough Ca2* to reach 
the threshold needed to initiate spontaneous Ca2* release. Since NCX is upregulated in HF, 
for every given SR Ca2* release there is a greater efflux of Ca2* via NCX and an inward 
arrhythmogenic Na* current, which could cause DADs.
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1.4.1.2 ARVC2/CPVT
CPVT is a highly malignant form of arrhythmogenic disorder characterised by exercise- or 
emotionally-induced polymorphic tachycardia in the absence of any detectable structural 
heart disease (Liu et al. 2008). CPVT was first reported as a bidirectional VT precipitated by 
effort and emotional stress testing of a 6-year old girl with no evidence of any structural 
abnormality in the heart (Reid et al. 1975). Later a series of cases in familial as well as in 
sporadic forms were reported, and the term CPVT to refer to a disease characterised by 
adrenergically mediated bidirectional and/or polymorphic ventricular tachycardia (VT) in the 
absence of cardiac pathology (Leenhardt et al. 1995a). In 2001 independent groups led by 
Priori and Lahat identified mutations in RyR2 and cardiac calsequestrin (CASQ2) underlying 
autosomal dominant and autosomal recessive forms of CPVT (Lahat et al. 2001; Priori et al. 
2001). The prevalence of CPVT in the population is not known, but has been estimated 
around 1:10,000. CPVT is now acknowledged as one of the most severe of the inherited 
arrhythmogenic disorder because in some cases the first event is lethal and it is a significant 
cause of sudden death at young age. The severity of the phenotype underscores the 
importance of its early diagnosis and prophylactic treatment.
In 1999, Swan et al. studied two CPVT families and assigned the CPVT locus to 
chromosome 1q42-q43 (Swan et al. 1999). Subsequently, Priori et al. demonstrated that the 
gene for CPVT encodes RyR2, and identified RyR2 mutations in four families with the typical 
pattern of CPVT and autosomal dominant pattern of inheritance (Priori et al. 2001). Shortly 
after, Lahat et al. mapped a recessively inherited CPVT locus to chromosome 1 p13-21 and 
identified a missense mutation in a highly conserved region of CASQ2, the major Ca2+ 
reservoir within the SR of cardiac myocytes, suggesting that CASQ2 mutations cause the 
autosomal recessive form of CPVT (Lahat et al. 2001).
ARVC2 was first described by Nava et al. (1988) and is distinct from the other forms of 
ventricular dysplasia because it is associated with exercise/stress-induced VT and SCD. 
Unlike CPVT, ARVC2 is characterised by fibro-fatty infiltrates in the myocardium and
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dysplasia of the right ventricle. Despite the morphological differences, CPVT and ARVC2 are 
allelic -  they are caused by mutation of the same gene and share a common pre-disposition 
to effort induced VT, suggesting that they could belong to a single clinical entity with a broad 
range of phenotypic variability influenced by other genetic or epigenetic factors.
1.4.1.3 The 'hot-spot’ nature of RyR2 mutational loci
As discussed in Section 1.3.7.2, RyR2 is organised as a complex series of discrete 
domains, which interact to modulate channel function. Almost every region of the RyR2 
protein contributes to channel modulation (George et al. 2005), but arrhythmogenic 
mutations cluster in four discrete regions, presently termed domains I, II, III and IV (Figure 
1.16). These ‘hot-spots’ are well conserved across species and RyR isoforms, and there are 
no reported mutations in three regions of sequence divergence (DR1-3) that are proposed to 
underscore the functional differences between RyR isoforms. The finding that ‘total exon’ 
screening has only detected mutations occurring within these hot-spots emphasises that 
mutational clustering is not an artefact of genetic screening but is likely to be a 
pathophysiological feature of CPVT. The functional significance of mutation clustering 
remains unclear, but structure-function analysis suggests that CPVT domains I—IV are 
predominantly associated with intra-RyR2 domain interactions and cytoplasmic Ca2+- 
dependent channel modulation (George et al. 2007a), and accordingly the l-Domain 
coincides with CPVT domain INI.
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Figure 1.16. Clustering of mutational loci in RyR2
The 71 CPVT-linked mutations cluster into four discrete regions of RyR2 (CPVT-I, 77-466; CPVT-II, 
2246-2534; CPVT-III, 3778-4201; CPVT-IV, 4497-4959). The assignation of four discrete clusters 
considers the non-Ca2+ pore-forming channel part of the carboxyl-terminal (domain III) distinct from 
those occurring in the vicinity of the Ca2+ pore-forming region (domain IV), a delineation that has not 
been considered in previous domain nomenclature. The predominant functional characteristics of 
these domains are Ca2+-dependent channel modulation and involvement in interdomain interactions 
(George et al. 2007a).
1.5 Defective inter-domain interactions and channel destabilisation in mutation- 
linked RyR2 dysfunction
Analysis of mutational loci in the context of RyR2 structure and function, reveals that 
mutations alter the ability of RyR2 to sense intracellular environment. Furthermore, the 
structural and functional complexity of RyR2 predicts that arrhythmogenic mutation-linked 
defects occur in diverse aspects of channel functionality.
RyR open-to-closed transitions are associated with long-range conformational reordering 
(Orlova et al. 1996; Sharma et al. 2000) and many regions of RyR participate in
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intramolecular interactions that are likely to stabilise channel conformation. Therefore, 
physical destabilisation of the RyR2 channel resulting from either chronic acquired defects 
(HF) or genetic mutations (CPVT), has emerged as a new mode of channel dysfunction in 
cardiac pathology (George et al. 2006; Oda et al. 2005; Okuda et al. 2005). CPVT-linked 
mutations (clustered in discrete domains termed CPVT l-IV, Figure 1.16) or other pathogenic 
stimuli have been proposed to weaken these innate structural interactions by so-called 
‘domain unzipping’ (George et al. 2005, 2007a; Oda et al. 2005; Yamamoto & Ikemoto 2002; 
Yano et al. 2005b). The clustering of CPVT-linked mutations in ‘hot-spots’ implies that these 
regions may be involved in vital channel regulation, such that their disruption results in 
cardiac arrhythmia.
Based on this notion, Ikemoto and colleagues proposed a ‘domain-switch’ model that 
involves inter-domain interactions between the N-terminal and central domains of RyR 
serving as a key mechanism for Ca2+ channel regulation (Ikemoto & Yamamoto 2000, 2002). 
The model assumes that in the resting or non-activated state, the N-terminal and central 
domains make close contact at several sub-domains, which have yet to be determined. The 
conformational constraints imparted by the ‘zipped’ configuration of these two domains 
stabilise the closed state of the Ca2+ channel. Under normal stimulating conditions, such as 
during EC coupling, the inter-domain contacts are weakened, resulting in an ‘unzipped’ 
configuration which leads to channel opening. According to this model, a mutation occurring 
within one of the sub-domains involved in maintaining the ‘zipped’ configuration would lead 
to weakened inter-domain contacts at that point. This results in a ‘partially unzipped’ 
configuration, which is more readily activated by stimuli than the correct fully ‘zipped’ 
channel, and manifests as the hyper-sensitisation and/or hyper-activation effects seen in 
channels containing disease-linked mutations, in both skeletal and cardiac RyR channels, 
implicating a structural basis for mutation-linked Ca2+ release dysfunction (George et al. 
2006).
This proposed model has been tested by examining the effects of a family of synthetic 
peptides corresponding to the putative critical domains of RyR (designated domain peptides,
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DP) on several aspects of channel function (Hamada et al. 2007a; Kobayashi et al. 2004; 
Oda et al. 2005; Yamamoto et al. 2000; Yang et al. 2006). The underlying assumption in 
rationalising the use of synthetic DPs as functional probes, is that these short peptides can 
mimic the native conformation of these epitopes in the folded channel architecture. The 
peptide probe strategy is summarised in Figure 1.17, and has been successful in identifying 
a number of interacting sub-domains in the N-terminal and central domains of RyR.
W!fd-typ® mtef-domaln 
interaction stabilizes channel 
in closed state
a .  activation
central domain mutation 
domains partially 
'unzipped* inducing channel 
instability/ tiyperactrvabon'
peptide containing 
central domain rrvulalton; 
does not compete at 
wild-type binding sites.
peptide containing 
wid-type sequence 
competes for N-terminal 
binding site, inducing 
instability/ 'hyperactivation'
dunng physiological activation, 
domain unzipping is recognised 
as a ClCR activation signal 
Hence, partial unzipping 
(by mutation or peptide) 
facilitates unzipping by Ca‘‘ 
activation
Figure 1.17. Schematic diagram summarising the peptide probe approach to the investigation 
of domain unzipping
The proposed interaction between the N-terminal and central domains, showing the postulated 
domain unzipping caused either by a mutation or a competitive interaction with the peptide probe 
(Yang et al. 2006).
1.6 Treating cardiac arrhythmias
Despite the global prevalence and mortality associated with cardiac arrhythmias, effective 
anti-arrhythmic strategies are lacking, with the majority of therapies sub-optimal and in some 
cases actually pro-arrhythmic. Although device-based therapies, such as implantable 
cardioverter devices (ICD), have revolutionised the treatment of highly symptomatic
COOH
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arrhythmias, their widespread use is limited by the high costs associated with this treatment 
strategy, and therefore, for the majority of individuals with increased arrhythmia 
susceptibility, the primary treatment option is drug-based therapy (George et al. 2008a). 
However, existing pharmacological strategies do not address the causal mechanisms of 
arrhythmia and have varying degrees of efficacy.
As discussed above, a vast number of ions, receptors and pathways are involved in 
maintaining normal cardiac rhythm, and consequently provide numerous potential 
therapeutic targets. Advances in cellular and molecular technologies are central to the 
detailed understanding of the mechanistic basis of arrhythmia. However, due to the complex 
and interdependent nature of cardiac EC coupling, specific modulation of a single target, 
may prove pro-arrhythmic, in the absence of a compensatory or adaptive change. Thus 
despite the many theoretical targets, in practice there may be relatively few targets that can 
be successfully modulated to prevent arrhythmia (George et al. 2008a) and for this reason, 
(3-blockers are widely used to treat cardiac arrhythmias -  they are safe and have a broad 
range of functional consequences, rather than being effective perse.
Despite the complexity of arrhythmias, their central mechanistic paradigm is simple -  any 
perturbation in N a\ K+ or Ca2+ ions with cardiomyocytes or across their surface is potentially 
arrhythmogenic. Therefore, it is possible that phenotypically similar arrhythmias can occur 
due to distinct acquired or genetically-linked cardiac disorders, and that the underlying 
mechanisms of ion dysfunction at the molecular level will impact the efficacy and tolerability 
of specific therapeutic strategies. Consequently, a key consideration in new anti-arrhythmic 
development is that the potential efficacy and/or pro-arrhythmic risk of a particular drug is 
largely dictated by the precise cardiac status of the individual.
1.6.1 Intracellular targets for anti-arrhythmics
Altered ionic fluxes through surface membrane ion channels, pumps and exchangers 
ultimately mediate cardiac electrical dysfunction, and therefore are targets of most anti-
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arrhythmic approaches. However, as the role of the SR is now emerging as an intracellular 
substrate for arrhythmogenesis, intracellular regulators are becoming attractive therapeutic 
targets. In particular, RyR2 and CaMKII, are the focus of current anti-arrhythmic strategies.
K201 (also termed JTV-519 or ICP-Calstan 100) (Kaneko 1994) is a mixed-action ion- 
channel modulator (Hachida et al. 1999; Kimura et al. 1999; Nakaya et al. 2000), and is a 
novel anti-arrhythmic aimed at normalising RyR2 Ca2+ handling dysfunction via restoration of 
the macromolecular signalling complex (Bers 2004; Marks et al. 2002). K201 appears to 
have profoundly beneficial effects in the context of HF, which although primarily attributable 
to its stabilising effects on RyR2, it is acknowledged that K201 interacts with many 
components of the cardiac EC coupling machinery, including LTCC, NCX and SERCA (Bers 
2004; Marks et al. 2002). Therefore, it may be that the beneficial effects of K201 may be a 
consequence of its lack of target specificity (George et al. 2008a). Despite its success in the 
normalisation of Ca2+ handling in HF (Hunt et al. 2007), K201 has recently proved completely 
ineffective in preventing malignant arrhythmias in a mouse model of RyR mutation-linked 
CPVT (Liu et al. 2006), which supports the theory that no unifying mechanism underlying 
RyR2 dysfunction in HF and CPVT exists (George & Lai 2007b). Clearly, the molecular 
pharmacology of K201 needs to be unequivocally resolved and its clinical utility in rescuing 
cardiac function needs to be demonstrated in clinical trials, which are currently taking place 
and the results of which are keenly anticipated.
1.6.1.1 Targeting the RyR21-Domain
An attractive and feasible route for the pharmacological modulation of RyR2 may include 
the use of recombinant proteins or small synthetic peptides that target specific functional 
epitopes within RyR2 to stabilise the channel (Ikemoto & Yamamoto 2002; Yamamoto & 
Ikemoto 2002). Since this approach confers sequence-specific interaction, and thus can be 
tailored to numerous intra-RyR2 targets, it offers the potential ability to modulate discrete 
aspects of RyR2 function. However, it is vital in this approach that the targeted RyR2
76
Chapter 1
epitopes must be spatially accessible to permit their modification by exogenous peptides. A 
potential target for this type of approach is the l-Domain (3722-4610) (Figure 1.14), which, 
according to cryo-EM studies is a surface-accessible region and is therefore amenable to 
stabilisation. Furthermore, this hinge-like region of RyR2 is the location for 32% of all 
reported CPVT-linked mutations (Figure 1.13) and is critically involved in the intrinsic 
regulation of the channel (George et al. 2004, 2006), making it an attractive target for future 
peptide-based therapeutic approaches.
1.7 Aims of this thesis
Interdomain interactions within the complex three-dimensional architecture of the cardiac 
RyR (RyR2) are pivotal in channel regulation. Acquired or genetic abnormalities that perturb 
these stabilising intra-molecular interactions are pathogenic. The interacting- or l-Domain of 
human RyR2 has been found to mediate the interaction between the cytoplasmic and 
transmembrane (TM) assemblies, and the general aim of this thesis is to further elucidate 
the precise roles of functional motifs within the l-Domain, and their effect on cellular Ca2+ 
cycling using a peptide probe-based approach. The intention of this approach was to gain 
an insight into the mechanism by which disruption of interdomain interactions via the I- 
Domain could result in abnormal Ca2+ handling, and whether targeting this region could 
normalise this interaction. It is anticipated that this investigation could provide clues to 
developing future epitope-targeting strategies for the therapeutic normalisation of Ca2+ 
cycling in cardiac disease.
1.8 General Hypothesis
This thesis will investigate the hypothesis that the l-Domain region of RyR2 modulates 
Ca2+ handling in living mammalian cells. Specifically, work will be presented that will 
evaluate the phenotypic consequences of recombinant l-Domain sequences on RyR2-
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dependent Ca2+ events in mouse cardiac cells (HL-1 cells) and human embryonic kidney 
(HEK) cells.
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Materials and Methods
Chapter 2
2.1 General Materials and Methods
All reagents and chemicals were of analytical grade and were obtained from Sigma or 
Calbiochem, unless otherwise stated. All reagents and equipment for polyacrylamide gel 
electrophoresis were obtained from Biorad and Hoefer respectively, unless otherwise stated. 
All reagents were dissolved in deionised water (dH20 ) and stored at room temperature 
unless otherwise stated. All filter sterilisation was through 0.2 pM filters (Sartorius).
General molecular biology, biochemical and cell culture techniques were based on 
procedures outlined in Short Protocols in Molecular Biology (Ausubel et al. 2002) and 
Molecular Cloning: a Laboratory Manual (Sambrook & Russell 2001) as described below, 
and on published methods optimised in this laboratory.
2.2 Molecular Biology
All growth media and antibiotics were obtained from Sigma. Sterile plasticware and 
glassware were obtained from Greiner and Fisher. All non-sterile glassware was washed in 
detergent-free water and autoclaved (135<C, 4 bars, 90 minutes). Growth media were 
autoclaved under the same conditions prior to the addition of antibiotics. Aseptic technique 
was employed throughout all protocols, and surfaces were swabbed with 70% (v/v) ethanol 
before and after use.
2.2.1 Molecular biology reagents
• NZY medium: 16 g/L NZ, 5 g/L yeast extract. Autoclaved.
• LB medium: 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCI, 15 g/L agar (for plates only). 
Autoclaved, and allowed to cool to ~ 50*0 before ad ding the appropriate antibiotic.
• Kanamycin, 30 mg/ml stock: filter sterilised and stored at -20<C. Used at a working 
concentration of 30 pg/ml. Kanamycin works as a bactericidal agent that binds to 70S 
ribosomes and causes misreading of mRNA, and thereby terminates protein synthesis.
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Transformed bacteria will contain the kanamycin resistance gene, which encodes 
aminoglycoside phosphotransferase that modifies the antibiotic and prevents its 
interaction with the ribosomes.
• Freezing down medium: 50% (v/v) LB medium, 50% (v/v) glycerol. Autoclaved.
• Resuspension solution: 50 mM Tris, 10mM EDTA, 100|jg/ml RNase A; pH adjusted to 7.5 
with HCI. Filter sterilised.
• Lysis solution: 0.2 M NaOH, 1 % (w/v) SDS. Filter sterilised.
• Neutralisation solution: 4.09 M guanidine-HCI, 0.759 M CH3COOK; pH adjusted to 4.2 
with glacial CH3COOH. Filter sterilised.
• Ethanol, 80% (v/v): a stock solution was prepared and filter sterilised.
• Tris, 2 M: a stock solution was prepared and the pH was adjusted to 8.0 with HCI.
• DNA modifying and restriction enzymes: all enzymes and appropriate buffers were 
obtained from New England Biolabs, Roche and Promega.
• TAE, 50x stock: 2 M Tris, 2 M acetic acid, 50 mM EDTA.
• DNA Loading buffer, 2x stock: 2x TAE, 50% (v/v) glycerol, 0.25% (w/v) orange G.
• Molecular weight DNA markers: 1 kb Plus ladder obtained from Invitrogen.
• Column equilibration buffer (QBT): 750 mM NaCI; 50 mM MOPS, pH7.0; 15% (v/v) 
isopropanol, 0.15% (v/v) Triton® X-100.
• Medium salt column buffer (QC): 1 M NaCI; 50 mM MOPS, pH 7.0; 15% (v/v) isopropanol.
• Column elution buffer (QF): 1.25 M NaCI; 50 mM Tris, pH 8.5; 15% (v/v) isopropanol.
• Sequencing kit: BigDye terminator v5, obtained from Applied Biosystems.
2.2.2 Oligonucleotides
Custom oligonucleotide primers were ordered from Sigma-Genosys, and were obtained
as lyophilised pellets. Pellets were resuspended in an appropriate volume of sterile dH20  to
give a stock concentration of -  250 pM, according to the manufacturer’s instructions. Primer
concentration was confirmed by spectrophotometric quantification of a 1:100 dilution (in
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duplicate), by measuring the absorbance at 260 nm (A26o) in a quartz cuvette using a 
spectrophotometer (MBA2000, Perkin-Elmer). Using the nucleotide sequence, the 
molecular weight and the melting temperature of the oligonucleotides, the concentration was 
calculated (given that A260 = 1 corresponds to ~20-39 pg/ml of ssDNA depending on the 
base composition, with ~ 33 pg/ml taken on assumption of an equal mixture of the four 
bases). Working concentrations (20pM for PCR amplification; 3.2pM for DNA sequencing) 
were prepared and primers were stored at -20*0. A list of the primers used in this study is 
given in Appendix I.
2.2.3 Propagation of recombinant DNA constructs
Epicuhan coli ultracompetent XL-10 Gold cells (Stratagene) have been shown to 
consistently propagate bona fide RyR2 plasmid (George et al. 2003a, 2003b) and were 
consequently used for the propagation of recombinant DNA constructs. This strain of E. coli 
contains the recA1 gene locus which minimises host rearrangement of recombinant DNA, 
and has been specifically optimised for increased transformation efficiency and stability of 
larger fragile templates such as hRyR2. Bacteria were cultured at 37*0 under aseptic 
conditions in LB medium, either on solid medium on LB-agar plates (Hereaus) or in 
suspension with shaking at 225 rpm (Innova 4300 shaker, New Brunswick). The LB medium 
contained kanamycin at 30 pg/ml for selective growth of bacteria containing the plasmid.
XL-10 Gold cells were transformed as follows: The ultracompetent cells (25pl) were 
thawed on ice and treated with 1pl 0.5 M (3-mercaptoethanol for 10 minutes, before the 
addition of DNA (50 ng for transformation of a ligation mix, or 10 ng for re-transformation of a 
plasmid). Cells were incubated for a further 30 minutes on ice, before heat-shock treatment 
at 42*0 for exactly 30 seconds then immediate trans fer to ice for 3 minutes. NZY medium 
(900pl) pre-warmed to RT was added and the suspension was incubated at 37*C for 1 hour 
with continuous shaking (225 rpm). Following this incubation time, the suspension was 
plated on LB-Agar medium containing kanamycin (30 pg/ml), which was incubated at 30*C
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until the appearance of discrete colonies (typically after 16-18 hours incubation). From these 
colonies, any larger colonies (diameter >1mm) were disregarded, and only the smallest 
colonies were selected for screening.
2.2.4 Generating frozen stocks of bacterial cells
For long-term storage of transformed bacteria, frozen glycerol stocks were made from 
750pl of liquid culture grown in the presence of antibiotic for 16 h mixed with sterile glycerol 
in a 1:1 ratio. The glycerol stocks were snap-frozen on dry ice and stored at -80*0 in cryo- 
vials. Bacteria from this frozen stock were cultured by streaking 10p I of the stock onto LB- 
agar plates containing antibiotic.
2.2.5 Small-scale plasmid DNA isolation (‘mini-prep’)
Colonies were screened for the presence of recombinant plasmid using the Wizard SV 
mini-prep plasmid purification kit (Promega), which employs the SDS-alkaline denaturation 
method for plasmid DNA isolation. Single colonies were inoculated into 5ml LB medium 
containing kanamycin (30 pg/ml) and incubated overnight at 370  with continuous shaking 
(225rpm). A proportion (3ml) of each culture was subsequently pelleted at 13,000 xg for 2 
minutes (Microfuge R, Beckman). The pellets were resuspended in 250pl resuspension 
solution containing RNase A to ensure that any contaminating RNA which could affect 
downstream applications is digested, and subsequently lysed in 250pl lysis solution 
containing SDS and NaOH. The SDS solubilises phospholipid and protein components of 
the cell membrane leading to the release of the cell contents, while the NaOH denatures the 
chromosomal DNA and plasmid DNA as well as proteins. The lysate was then neutralised 
by addition of 350pl neutralisation solution containing acidic potassium acetate. The rapid 
neutralisation with high salt concentration results in precipitation of potassium dodecyl 
sulphate (KDS) and causes chromosomal DNA to base-pair in an intra-strand manner,
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forming an insoluble aggregate that precipitates out of solution. Denatured proteins, 
chromosomal DNA, and cellular debris are co-precipitated in insoluble salt-detergent 
complexes, and were removed by centrifugation at 13,000 xg for 10 minutes. The circular 
covalently closed plasmid DNA renatures correctly by inter-strand hybridisation and remains 
in solution. The cleared lysate containing the plasmid DNA was then applied to a spin 
column containing a silica-gel DNA binding membrane, and centrifuged for a further 1 minute 
at 13,000 xg. The membrane was washed twice with an 80% ethanol buffer, and the DNA 
was eluted off the membrane in 50pl 10 mM Tris pH 8.
After purification, recombinant plasmids were verified by restriction endonuclease 
mapping; typically with two separate enzyme digest reactions, each producing a distinct 
band pattern. DNA fragments were then analysed by agarose gel electrophoresis (Section 
2.2.6) before being prepared on a larger scale (Section 2.2.7).
2.2.6 Agarose gel electrophoresis
DNA fragments were separated on an agarose gel and using a 1 kb DNA molecular 
weight marker (Invitrogen) for size calibration. All gels contained 1% agarose (ultra-pure, 
Eurogentec), and were prepared by dissolving the agarose (1% w/v) in 1x TAE buffer. The 
solution was heated in a microwave until boiling, then left to cool to below 50*0 before 
addition of ethidium bromide (0.1 pg/ml), and poured into a gel casting tray which was 
assembled according to the manufacturer’s instructions (BioRad). Once the gel was set, 
DNA samples in 1x DNA loading buffer were loaded onto the gel alongside the 1 kb 
molecular weight marker. The DNA loading buffer contains Orange G for visualisation, 
which co-migrates with DNA fragments at -200 bp. Electrophoresis was carried out by 
submerging the gel in 1x TAE and subjecting it to a constant voltage of 5 V per cm, until the 
dye front had travelled approximately two thirds the length of the gel. Gels were visualised 
with UV transillumination and imaged using a gel documentation system (BioRad) with a 
Hamamatsu camera and Quantity One Software (BioRad).
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2.2.7 Large-scale plasmid isolation (‘maxi-prep’)
Cultures which produced plasmid DNA giving the correct endonuclease digest pattern, 
with negligible evidence of degradation were selected for large-scale maxi-prep culture. 
Restriction-digest verified mini-prep culture (1ml) was inoculated in 5ml LB broth for 1-2 
hours, before being transferred to 250ml LB broth containing kanamycin (30pl/ml) and 
incubated for 16-18 hours at 37*0 with continuous s haking (225rpm).
The bacterial suspension was pelleted by centrifugation (8000 xg, 20 minutes, 4<C; Avanti 
J-25, Beckman) and plasmid extraction was performed using the QIAGEN PlasmidMaxi Kit, 
following the manufacturer’s instructions. This protocol is based on a modified alkaline lysis 
procedure, followed by binding of plasmid DNA to QIAGEN Anion-Exchange Resin, which is 
positively charged with diethylaminoethyl (DEAE) groups, under optimised low-salt and pH 
conditions. The pellets underwent bacterial lysis using the same reagents as previously 
described (Section 2.2.5). Samples were then incubated on ice for 20 minutes, before 
insoluble cell matter was removed by centrifugation (20 000 xg, 30 minutes, 4<C). The 
supernatant was applied to a QIAGEN-tip 500 pre-equilibrated with column equilibration 
buffer (QBT). The plasmid DNA was then washed twice with a medium-salt column wash 
buffer (QC) to remove impurities such as RNA and proteins. The plasmid DNA was then 
eluted off the column with a high-salt elution buffer QF. Plasmid DNA was precipitated using 
isopropanol (0.7 volumes) overnight at -20*0. Following centrifugation, (15 000 xg, 30 
minutes, 4*C) the DNA pellet was washed in 5ml 70% ethanol and further centrifuged 
(15,000 xg, 10 minutes, 4*C). The pellet was then incubated with 500pl Tris (pH 8, 10 mM) 
at 37*0 for 5 minutes to resuspend the plasmid DNA. Tris (10 mM, pH 8) was used instead 
of dH20, as DNA is more readily soluble under alkaline conditions and does not interfere in 
downstream applications.
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2.2.8 Spectrophotometric DNA quantification
DNA exhibits peak light absorption at 260 nm, and DNA concentration was determined by 
spectrophotometric quantification of a 1:50 dilution sample (in duplicate) at this wavelength. 
The concentration was calculated taking into account that an A260 of 1 corresponds to 
50pg/ml of double stranded DNA. Any contaminating proteins present will have a peak light 
absorbance at 280 nm, therefore plasmid purity can be quantified by using the ratio of 
A260/A280- Values £ 1.8 indicate plasmid preparations of high purity.
2.2.9 DNA Sequencing
All recombinant plasmids were confirmed by automated DNA sequencing using the 
BigDye Terminator cycle sequencing kit (ABI Prism) and ABI Prism 377 sequencer (Applied 
Biosystems) according to the manufacturer’s protocol using 3.2 pmol sense sequencing 
primer and 500 ng plasmid DNA. Automated sequencing is based on the incorporation of 
fluorescent dyes into fragments of DNA, which are optimised for detection with an argon 
laser. The fluorescent terminator dyes contain a fluorescein donor dye (6-FAM), conjugated 
to one of four dichlororhodamin (dRhodamine) acceptor dyes. The fluorescein donor 
determines the excitation maximum of each dye, while the emission spectrum is dependent 
on the dRhodamine acceptor. The fluorescently labelled DNA fragments are then separated 
by capillary array electrophoresis, and are passed through a laser beam as they enter the 
detection cell. The laser excites the fluorescent dyes, and the resulting fluorescence is 
converted into electronic form which is analysed by the sequencing software and visualised 
as a sequence electropherogram.
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2.2.10 PCR amplification of DNA
PCR reactions were carried out using a Perkin-Elmer GeneAmp system 2400 thermal 
cycler. Phusion™ High-Fidelity DNA Polymerase (Finnzymes) was used for the generation 
of high fidelity products suitable for cloning. This enzyme, possessing 3’->5’ exonuclease 
“proofreading" activity, exhibits low error rate and high efficiency. The reaction mixture 
components and thermal cycling conditions are shown in Table 2.1 and Table 2.2. PCR 
products were verified by agarose gel electrophoresis (Section 2.2.6) and purified using the 
QIAquick PCR purification kit (Qiagen) as described in Section 2.2.11.
Table 2.1. Typical PCR reaction mixture
Reagent Final Concentration Volume
DNA Template 50 ng 0.5pl of 200 ng/pl stock
Forward Primer 20 pmol 1 pi of 20 pM stock
Reverse primer 20 pmol 1pl of 20 pM stock
HF buffer (with 1.5 mM MgCI2) 1x 5pl of 10x stock
dNTP mix 0.2 mM 0.5pl of 20 mM stock
DNA polymerase 1 U 0.5pl of 2 U/pl stock
Nuclease-free dH20 Up to 50pl 41.5pl
Table 2.2. Typical thermal cycling conditions
Step Temperature Time Number of cycles
Initial denaturation 98*0 2 minutes 1
Denatu ration 98*C 10 seconds
Annealing* 60*C 30 seconds 28
Extension 72X1 60 seconds
Final Extension 72*C 5 minutes 1
Storage 4*C Indefinite 1
^Annealing temperature is dictated by the Tm of the primer, but is typically 58-60C
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2.2.11 Cloning of DNA fragments
Plasmid DNA (1 pg) was digested with suitable restriction enzymes (5-10 U per 20pl 
reaction) for 2 hours at 37*0, before separation on an agarose gel to confirm correct 
fragment size. The required band was excised from the gel using a sterile scalpel under 
ultra-violet light (A) and purified using QIAEX II gel extraction kit (Qiagen). Briefly, this 
agarose gel slice was dissolved in a high-salt buffer containing DNA-binding beads for 5 
minutes at 50*0. The high-salt buffer containing 4 M chaotropic guanidium salt disrupts the 
hydrogen bonds present in the agarose gel and allows the DNA to bind to the silica beads. 
The beads were then sedimented by centrifugation at 14,000 xg for 30 seconds, and then 
washed once with high salt buffer, followed by a further two times with a 70% ethanol buffer. 
DNA was eluted from the beads in 30pl 10 mM Tris pH 8.5.
PCR products were digested in the same way, and 10% of the reaction was analysed by 
gel electrophoresis. The remainder of the reaction was purified with the QIAquick PCR 
Purification Kit (QIAGEN), which employs a DNA-binding ‘spin’ column. The PCR products 
were added to the column and centrifuged at 14,000 xg for 1 minute before washing twice 
with an 80% ethanol buffer. The DNA was then eluted in 30pl nuclease-free water.
The DNA fragments were ligated into pET-29(b) plasmid vector (Novagen), a kanamycin 
resistant translation vector, with protein expression driven by a T7 phage ribosome binding 
site. pET-29(b) carries two fusion tags; an N-terminal S-Tag/thrombin configuration plus a 
C-terminal polyHis sequence (Figure 2.1). This combination of fusion tags was chosen due 
to their small size, and they also facilitate detection by immunoblot analysis (Section 2.3.6) 
as well as affinity purification with the corresponding resin and buffers (Sections 2.3.7 and 
2.3.8).
Prior to ligation, the linearised pET-29(b) vector was treated with 1pl Shrimp Alkaline 
Phosphatase (SAP, Promega) for 30 minutes at 37*C. SAP treatment removes the 5’- 
phosphate group from the linearised vector, and reduces the possibility of self-ligation. The 
SAP was then inactivated by heat denaturation at 65*0 for 15 minute.
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Ligation was carried out using the Rapid DNA Ligation Kit (Roche), according to the 
manufacturer’s guidelines. The insert to be ligated was mixed with the appropriately 
digested plasmid vector (50 ng) in a 3:1 molar ratio, along with a ligase buffer and T4 DNA 
ligase. To calculate the appropriate amount of insert to include in the ligation reaction, the 
following equation was used:
no of vector x kb size of insert x inse rt: vector molar ratio = ng of insert DNA 
kb size of vector
The ligation mixture was then incubated at 413 for 16 hours before being used to 
transform competent bacteria.
pET-29b sequence landmarks
T7 terminator 
la d  coding sequence 
pBR322 origin 
Kan coding sequence 
f1 origin
26-72
774-1853
3287
3996-4808
4904-5359
N c o  1(211) 
K p n  1(237) 
B g l 11(240) 
N s p  V (2 6 7 )  
N d e  1(294)
^  F1 origin
pet29b
5370 bp
T7 promoter 
T7 transcription start 
S*Tag coding sequence 
Multiple cloning sites 
(A/co I - Xho I)
His*Tag coding sequence 140-157
367-383
366
248-292
158-216
X h o  1(158) 
N o t  1 (166) 
E a g  1(166) 
H in d  111(173) 
S a l 1(179 ) 
S a c  1(190) 
E c o R  1(192) 
B a m H  1(198) 
E c o R  V (2 0 5 )  
Figure 2.1. pET-29(b) expression vector
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2.3 Protein Biochemistry
2.3.1 Protein biochemistry reagents
• Ammonium persulphate: 10% (w/v); always freshly prepared and kept on ice.
• Tris, 0.5 M: a 0.5 M solution was prepared, and pH adjusted to 6.8 with HCI. Stored at
4*0.
• Tris, 1.5 M: a 1.5 M solution was prepared, and pH adjusted to 8.8 with HCI. Stored at 
4 0 .
• Running buffer, 1x: 25 mM Tris, 250 mM glycine, 0.1 % (w/v) SDS.
• SDS-gel loading buffer, 2x: 100 mM Tris pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 10%
(v/v) 3-mercaptoethanol, 0.2% (w/v) bromophenol blue. Filter sterilised and always 
freshly prepared
• Molecular weight markers: prestained Kaleidoscope protein markers, obtained from Bio­
Rad.
• Protein stain: Imperial protein stain or SilverSnap silver staining kit, both from Pierce.
• Transfer buffer (for semi-dry transfers): 48 mM Tris, 39 mM glycine, 0.037% (w/v) SDS, 
20% (v/v) methanol, pH 8.3.
• Tris-buffered saline (TBS), 1x: 20 mM Tris, 137 mM NaCI; pH adjusted to 7.6 with HCI.
• TBS-T, 1x: 1x TBS, 0.1% (v/v) Tween-20.
• Blocking solution: 5% (w/v) non-fat dried milk dissolved in 1x TBS-T
2.3.2 Antibodies
• Ab-6xHis: a purified murine monoclonal 6-His antibody obtained from Covance Research
Products, raised against a recombinant protein containing the sequence HHHHHH. 
Used at 1:5000 dilution for western blotting.
• pAb-1093: rabbit anticlonal antiserum, raised against residues 4515-4564 of the cardiac
ryanodine receptor (EDKGKQKLRQLHTHRYGEPEC). The antibody was purified using
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MelonGel IgG Purification kit (Pierce) and subsequently used at 1:500 dilution for 
Western blotting.
• S-protein HRP Conjugate: a 104 aa S-protein, which binds with high affinity and 
specificity to the 15 aa S-Tag fusion tag expressed from the pET-29(b) protein 
expression vector. Obtained from Novagen, and used at 1:7500 dilution for Western 
blotting.
2.3.3 SDS-Polyacrylamide gel electrophoresis (SDS-PA GE)
Protein profiles were visualised by SDS-PAGE on 140 x 160 x 1.5 mm gels (SE600, 
Hoefer). A separating gel of appropriate acrylamide concentration was prepared as 
described in Table 2.3. The acrylamide/bisacrylamide forms a cross-linked polymer network 
in the presence of ammonium persulphate, and the size of pores created in the gel is 
inversely related to the amount of acrylamide used. Large proteins were resolved on gels 
with a low concentration of acrylamide, and vice versa. The separating gel was poured into 
the gel casting system, which was assembled according to the manufacturer’s instructions, 
and covered with a thin layer of water. The gel was left to set for -  2 hours, before carefully 
removing the water layer with filter paper. The stacking gel (4% (w/v) acrylamide) was then 
prepared as the separating gel, but using 0.5 M Tris pH 8 buffer. This was then poured on 
top of the separating gel, and a 15-lane comb was inserted to form the wells. The stacking 
gel has a larger pore size and a lower pH than the separating gel, making the proteins in 
each sample condense into a tight band before entering the separating gel. Once the 
stacking gel was set, protein samples were incubated at 500  for 10 minutes in 2x or 5x 
Laemmli buffer containing SDS, a strong anionic detergent which denatures non-covalent 
bonds in the secondary and tertiary structures and applies a uniform negative charge density 
to each protein to allow the proteins to separate according to mass. The samples were then 
loaded onto the gel alongside Kaleidoscope prestained protein molecular weight markers 
(BioRad) which consist of seven uniquely coloured proteins with molecular weight range of
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approximately 200 -  6.5 kDa. Electrophoresis was carried out at a constant current 
(typically 10-15 mA overnight at 4*C) until the bro mophenol blue dye-front had nearly run off 
the gel. Protein separation was visualised by protein staining of the gel (Section 2.3.4), or 
gels were then transferred to membrane and analysed by immunoblotting (Sections 2.3.5 
and 2.3.6).
Table 2.3. Separating acrylamide gel composition
Reagent Final
Acrylamide/bis-acrylamide (37.5:1), 40% X*
Tris, 1.5 M, pH 8.8 25% (v/v)
SDS, 20% (w/v) 0.5% (v/v)
Ammonium persulphate, 10% (w/v) 0.5% (v/v)
TEMED 0.05% (v/v)
dH20 Up to 30ml
* Where X is dependent on the % of acrylamide required, according to the sizes of the proteins 
separated
2.3.4 Staining proteins on an SDS-PAGE gel
Proteins were visualised on an SDS-PAGE gel by staining with Imperial Protein Stain 
(Pierce) or SilverSnap Stain (Pierce), before being scanned and dried onto filter paper in a 
vacuum gel dryer.
Imperial Protein Stain is a Coomassie R-250 dye-based reagent, claimed by the 
manufacturer to be sensitive to as little as 3 ng protein. After electrophoresis, gels were 
washed with dH20  three times for 5 minutes, then left overnight at RT in Imperial Protein 
Stain on a rocking platform. After this time, the stain was discarded and the gel was 
destained in dH20  on a rocking platform at RT overnight.
SilverSnap Stain is an ultrasensitive silver stain system, and can detect £ 0.25 ng protein. 
After electrophoresis, gels were washed twice with dH20  for 5 minutes, then fixed in 30% 
ethanol: 10% acetic acid for 2 x 15 minutes on a rocking platform. The fixing solution was
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discarded, and the gel washed in 10% ethanol for 2 x 5 minutes, then in dH20  for 2 x 5 
minutes. The gel was subsequently sensitised for exactly 1 minute in Sensitizer Working 
Solution (1:500 SilverSnap Sensitizer: dH20 ) before being washed for 2 x 1 minute in dH20. 
The gel was then incubated in Stain Working Solution (1:50 SilverSnap Enhancer : 
SilverSnap Stain) for 30 minutes at RT on a rocking platform. After this time the gel was 
washed briefly in dH20  for 2 x 20 seconds, then incubated in Developer Working Solution 
(1:50 SilverSnap Enhancer : SilverSnap Developer) for 2-3 minutes at RT on a rocking 
platform, until protein bands began to appear. The reaction was stopped by transferring the 
gel to 5% (v/v) acetic acid.
2.3.5 Electro-transfer of proteins onto a membrane
Proteins from SDS-PAGE gels were transferred onto polyvinylidene difluoride (PVDF) 
membrane with a pore size of 0.45 pm (Immobilon-P, Millipore) using a semi-dry transfer 
system (Hoefer). The PVDF membrane was prepared, according to the manufacturer’s 
guidelines, by soaking in methanol for 10-30 seconds then in semi-dry transfer buffer for 30 
minutes. Protein transfer was carried out at RT for 3 hours at 250 mA, with voltage limited to 
25 V.
2.3.6 Immunoblot analysis
Following protein transfer, non-specific binding sites were blocked by incubating the 
PVDF in membrane blocking buffer for 90 minutes at RT or overnight at 4*0. Primary 
antibody was added in the appropriate dilution (Section 2.3.2) in membrane blocking buffer 
for 90 minutes at RT or overnight at 4*C. The memb rane was then washed with TBS-T (5x 
10 minutes, 2x 5 minutes) to remove surplus non-bound primary antibody. A suitable HRP- 
conjugated secondary antibody was then added in membrane blocking buffer (1:10,000 
dilution) for 90 minutes at RT. The membrane was washed as before in TBS-T. The
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immunoreactive protein bands were visualised using enhanced chemiluminescence (ECL) 
reagent (GE Healthcare), a highly sensitive detection method which can detect as little as 1 
pg of antigen, dependent on the quantities of labelled secondary antibody present. 
Chemiluminescence systems generate light by oxidation of luminol in the presence of 
hydrogen peroxide (H20 2) and HRP under alkaline conditions. Immediately following 
oxidation, the luminol is in an excited state which then decays to ground state via a light 
emitting pathway. The ECL system enhances the emitted light signal by the oxidation of 
luminol by the HRP in the presence of phenol, which has the effect of increasing the light 
output approximately 1000-fold and extending the time of light emission. The light produced 
by this enhanced chemiluminescent reaction peaks after 5-20 minutes and decays slowly 
thereafter with a half life of approximately 60 minutes. The maximum light emission is at a 
wavelength of 428 nm which can be detected after a short exposure to high performance 
chemiluminescence film (Hyperfilm, GE Healthcare) and developed using an automated 
image developer.
2.3.7 Purification of histidine-tagged proteins using a Ni2* affinity technique
There are many commercially available systems for the nickel-affinity purification of His- 
tagged proteins. For the purposes of this study, His GraviTrap™ (GE Healthcare) was used 
due to the speed and ease of the purification of large volumes of bacterial culture. His 
GraviTrap™ is a prepacked, single-use gravity-flow Ni Sepharose™ 6 Fast Flow column for 
purification of histidine-tagged proteins by immobilised metal-affinity chromatography 
(IMAC). This system allows the purification of large sample volumes, and the histidine- 
tagged protein is effectively eluted in a small volume.
Purification of histidine-tagged proteins on His GraviTrap can be divided into four stages: 
equilibration, sample application, washing, and elution (Figure 2.2). The column was first 
equilibrated with 20 mM imidazole washing/binding buffer (10ml). The sample is then loaded 
and allowed to flow through the column, before washing with 20 mM imidazole buffer (10ml).
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His-tagged protein was then eluted in 10ml 500 mM imidazole elution buffer (2 x 3ml).
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Figure 2.2. Schematic of Ni2+ affinity purification of histidine-tagged proteins
Four-stage purification of HexaHis-tagged proteins. First, the column is equilibrated. The sample is 
then loaded and washed to remove contaminants. Purified protein is then eluted with 500 mM 
imidazole.
2.3.8 Purification of S-tagged proteins by S-protein affinity
The S-tag Thrombin Purification Kit (Novagen) was used for affinity purification of S-tag 
using S-protein agarose which specifically retains S-tag fusion proteins. In this strategy, the 
protein was released from the S-protein agarose by thrombin digestion which occurs at the 
thrombin cleavage site located between the S-tag sequence and the cloning region.
The protein was first incubated with the S-protein Agarose (2ml) and incubated on an 
orbital shaker (30 mins, RT). This was then centrifuged (10 mins, 500 xg) and the 
supernatant decanted, the resultant agarose pellet containing the target protein was 
resuspended in 1x bind/wash buffer (5ml). The centrifugation and washing steps were 
repeated twice more. After the washing steps, the pellet was resuspended in 1x thrombin
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cleavage buffer (5ml) supplemented with biotinylated thrombin (25 U), and incubated on an 
orbital shaker (3 hr, RT). After this incubation time, streptavidin agarose (800pl) was added 
to the slurry and incubated on an orbital shaker (10 min, RT). The mixture was then 
transferred to a spin filter and centrifuged (5 mins, 500 xg), and the flow-through collected. 
A further 1.25ml of thrombin cleavage buffer was added to the spin filter and then 
centrifugation was repeated, in order to elute any target protein remaining on the filter.
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Figure 2.3. Schematic of protein purification by S-protein affinity and thrombin cleavage
The S-tagged protein is captured by S-protein agarose and washed to remove contaminants, before 
being S-tag is cleaved off by thrombin digestion.
2.3.9 Densitometric analysis
Densitometric quantification of the density of stained protein bands is a technique widely 
used to compare the amounts of different MW proteins present in one or more samples, and 
was carried out using QuantityOne imaging software (BioRad).
Images were obtained by scanning the SDS-PAGE gel or exposed chemiluminescence 
film. Densitometry was subsequently carried out by defining an equal area around the
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bands of interest and quantifying its optical density (OD/mm2). Densitometry is only valid at 
sub-saturating levels of signal development. QuantityOne has an in-built feature that 
determines whether the signal is within 256 shades of gray (i.e. sub-saturation) of 
background signal levels.
2.3.10 Determination of protein concentration
Protein concentration was determined using BCA assay kit (Pierce) per the 
manufacturer’s guidelines. This assay is based on a colorimetric change produced by the 
reduction of Cu2+ to Cu* by protein in alkaline solution, and subsequent chelation of the Cu+ 
ion by bicinchoninic acid (BCA) to produce a purple coloured reaction product. The assay 
was performed in a 96-well plate and the absorbance read at 560 nm in a Multiscan EX 
(Labsystems) plate reader using the Genesis software (Labsystems). All readings were 
done in triplicate, and compared to a standard curve produced by measurement of known 
concentrations of bovine serum albumin (BSA) (0 -  2000 pg/ml) using the same method.
2.4 Mammalian cell culture
All growth media and reagents were supplied by Invitrogen and all chemicals were 
obtained from Sigma unless otherwise stated. Sterile culture flasks and bottles were 
supplied by Nunc (Fisher) or Greiner. Class II cell culture containment hoods (Microflow 
biological safety cabinets) were employed for all procedures.
2.4.1 Mammalian cell culture reagents
• Dulbecco’s Modified Eagle Medium (DMEM): supplemented with 10% (v/v) foetal calf 
serum, 2 mM glutamine and 100 pg/ml penicillin/streptomycin (all filter sterilised). Stored 
at 4*C.
• Cell fixing solution: 4% (w/v) paraformaldehyde in PBS, always freshly prepared.
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• Poly-L-lysine, 0.1% solution: used to coat coverslips (150pl/coverslip). Stored at 4<C.
• Saline solution: 0.9% (w/v) supplied by Baxter Medical Supplies.
• Trypsin-EDTA: 1x in HBS without Ca2+ or Mg2+, stored at -  20tC.
• Freeze-down medium: 10% (v/v) dimethyl sulphoxide (DMSO) in foetal calf serum, filter 
sterilised and stored at 4*0.
• Phosphate buffered saline (PBS): 137 mM NaCI, 2.7 mM KCI, 4.3 mM Na2HP04> 1.4 mM 
KH2P04, pH adjusted to 7.4 using HCI, filter sterilised.
• Gelatin fibronectin (GFN): 1.25% (v/v) fibronectin, 0.002% (w/v) gelatin in dH20 , filter 
sterilised.
• Norepinephrine, 10 mM: made up in 30 mM ascorbic acid solution.
• Claycomb medium: supplemented with 10% (v/v) foetal calf serum, 2 mM glutamine, 100 
pg/ml penicillin/streptomycin and 100 pM norepinephrine (all filter sterilised).
2.4.2 Mammalian cell lines
• HL-1 cells: cardiac cell line derived from the AT-1 mouse atrial cardiomyocyte tumour 
lineage (Claycomb etal. 1998). This cell line is described in detail in Chapter 4.
• HEK293: cells derived from human embryonic kidney cells immortalised by adenovirus 5 
DNA infection (Graham et al. 1977).
2.4.3 Culture of Human Embryonic Kidney (HEK) 293 cells
HEK293 cells were cultured in DMEM containing 4.5 g/L glucose (Invitrogen) 
supplemented with foetal calf serum (10% v/v), and penicillin/streptomycin/glutamine (1% 
v/v) (Invitrogen) in an incubator at 37*0, 5% CO 2 and -80% humidity (Heraeus) using 150ml 
flasks (Nunc). Cells were maintained in 75 cm2 flasks containing 20ml medium, and these 
were harvested, and passaged when 70% confluency was reached, as shown in Figure 2.4. 
They were harvested by brief trypsinisation (2ml) at 37*C before being pelleted (1100 rpm, 3
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min). The resulting pellet was resuspended in 5ml of medium, and 1ml was used to seed a 
new culture flask. The remainder was discarded or preserved in liquid nitrogen (see Section 
2.4.5).
2.4.4 Culture of HL-1 cardiomyocytes
HL-1 cells were cultured in Claycomb medium (SAFC) supplemented with foetal calf 
serum (10% v/v), and penicillin/streptomycin/glutamine (1% v/v) (Invitrogen) in an incubator 
at 37*0, 5% CO 2 and ~80% humidity (Heraeus) using 150ml flasks (Invitrogen). Cells were 
maintained in GFN-coated 25 cm2 flasks containing 7ml medium, and these were harvested, 
split and re-seeded at a ratio of 1 in 3 when superconfluency was reached (Figure 2.4). 
Cells were harvested by trypsinisation for 2 mins at 37*C and washed with dH 20  to remove 
any cells that were not strongly adhered to the GFN matrix. Non-adherence directly to the 
GFN matrix is the primary cause of dedifferentiation from the cardiac cell phenotype in this 
cell population. This was followed by a second trypsinisation step at 37*C until all of the 
cells were released from the matrix, before being pelleted (1100 rpm, 3 min). The resulting 
pellet was resuspended in 6ml of medium, and 2ml was used to seed a new culture flask. 
The remainder was discarded or preserved in liquid nitrogen (see Section 2.4.5).
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Figure 2.4. Phase microscopy images of healthy HEK and HL-1 cells
Panels A and B show a phase image of healthy HEK cells at -70% confluency; 20x and 40x 
magnification respectively. Panel C shows a phase image of healthy non-confluent HL-1 cells with 
20x magnification. Panel D shows healthy HL-1 cells at ‘superconfluency’, which are ready to be 
harvested and split. At ‘superconfluency’ HL-1 cell boundaries in the myocyte monolayer are difficult 
to determine. All images taken on a Zeiss Axiovert 200 microscope
2.4.5 Generating frozen stocks of mammalian cell lines
Cells were harvested and pelleted as above and the cell pellet was resuspended in 1 ml of 
freeze-down medium using a wide-bore syringe and transferred to labelled cryo-vials 
(NUNC). Vials were wrapped in several layers of tissue paper to prevent rapid freezing and 
stored for 24h at -800. Once fully frozen, the in sulating tissue was removed and vials were 
transferred into liquid nitrogen storage.
To establish cultures from stocks, cells were rapidly thawed by hand warming and the 
DMSO was removed by pelleting the cells at 500 g for 2 min. Cells were resuspended in the 
appropriate supplemented media and re-seeded as above.
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2.5 Computer software and data analysis
Numerical data were stored in spreadsheets and plotted in graphical form using Excel 
(Microsoft) or GraphPad Prism. Western blots were scanned at 300dpi using a densitometer 
(GS-700, Bio-Rad), and image processing was undertaken using Photoshop (Adobe) and 
PowerPoint (Microsoft). Densitometric analysis was performed on ‘raw data’ images using 
Quantity One software (Bio-Rad). All measurements were calibrated against an area of the 
blot that did not contain protein.
DNA and protein sequence analysis was done using software contained within the 
Genetic Computing Group package (GCG, University of Wisconsin, USA) or JEMBOSS, 
both of which can be accessed via the MRC website (http://www.hgmp.mrc.ac.uk) or using 
software available at the NCBI website (http://www.ncbi.nlm.nih.gov).
Calcium imaging data were analysed by SALVO for HL-1 myocytes (see Chapter 4) or in 
Microsoft Excel for HEK 293 cells, and all statistical analysis was performed using an 
unpaired Student’s t-test after testing the data sets for normality and equality of variance 
(GraphPad Prism). In all cases, datasets containing equal number of experimental 
measurements were compared. It is important to note that in Figures 4.8 and 4.9, a paired t- 
test would have been an appropriate method to compare HL-1 WT and experimental data 
sets as the measurments are taken from the same populations, before and after 
microinjection. However, in order to allow all statistical observations to be compared fairly, 
an unpaired t-test was used in all cases. All statistical outputs were validated using different 
software packages (Microsoft Excel, Minitab, and Graphpad Prism), all of which returned the 
same conclusions. Unless otherwise stated, all data are presented as the mean ± standard 
error of the mean (SEM), and a p value of <0.05 was considered to be significant.
2.6 Health and Safety
All reagents were handled and stored as recommended by manufacturer’s safety sheets. 
All experiments were carried out in accordance with COSHH regulations and local college
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regulations. All genetic manipulation was registered and carried out in accordance with local 
GMAG guidelines. All bacteria, yeast and mammalian cell culture waste were disinfected 
with Actichlor (Adams) at 1000ppm available chlorine (1 tablet per litre of waste) prior to 
disposal.
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In vitro expression and purification
of 1-Domain proteins
Chapter 3
3.1 Introduction
3.1.1 The RyR21-Domain
The l-Domain of RyR2 comprises two distinct domains, the interaction domain located at 
residues 3722-4353 and the modulatory domain located at residues 4353-4610 (George et 
al. 2004, 2006). As discussed in Chapter 1, the l-Domain contains approximately 30% of all 
known VT-linked RyR2 mutations, and functions to critically regulate the interaction between 
the regulatory cytoplasmic region and the transmembrane (TM) Ca2+-pore-forming domain 
(George et al. 2004).
Since the functionality of the l-Domain may be predominantly conferred by the precise 
primary amino-acid sequence of this region, a bioinformatic approach was used to yield 
greater insight into the mechanistic basis of RyR2 regulation by the l-Domain. A 
comparatively simple bioinformatic strategy revealed striking structural homology between 
sub-fragments of the RyR2 l-Domain and l-Domain-like regions of inositol 1,4,5- 
trisphosphate receptors (IP3R), despite the absence of any notable primary sequence 
homology between these two Ca2+ release channels (Appendix II) and the lack of homology 
between the entire RyR2 l-Domain and corresponding regions of IP3R. Based on this 
structural homology modelling, the l-Domain was divided into the three sub-fragments used 
throughout this study (Figure 3.1). This chapter will describe the generation of expression 
cassettes encoding recombinant l-Domain fragments, and the optimisation of expression 
and purification strategies linked to an in vitro cell-free expression system.
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Figure 3.1. Schematic representation of the truncated l-Domain constructs
Residues 3722-4353 are important for intramolecular interaction while having limited functional 
importance, whereas residues 4353-4610 are functionally important, yet had little effect on interaction. 
Two TM domains (4499-4519 and 4572-4593) are predicted in the region 4499-4610, which may also 
contribute to the functionality of this region of the molecule (George 2004).
3.1.2 Cell-free protein expression
Integral membrane proteins and receptors play key roles in numerous human diseases 
and they currently represent important drug targets (Klammt et al. 2006). However, they can 
be problematic to synthesise in mammalian or bacterial cell systems as their production can 
be toxic to the cells, and typically in vivo expression in eukaryotic or prokaryotic cells does 
not successfully generate sufficient membrane proteins for subsequent study. As a result of 
this, in vitro cell-free expression systems are emerging as important tools in the synthesis of 
membrane proteins, toxins, and other proteins whose expression is detrimental to cell 
physiology (Schwarz et al. 2007).
In vitro translation systems are largely based on the pioneering studies of Nirenberg and 
Matthaei (1961) who first showed that cell integrity was not required for protein synthesis to 
occur. Now commonly used, cell-free protein synthesis is a valuable tool for studying the 
mechanisms of protein synthesis separate from the complexities of other mammalian or
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bacterial cellular processes (Katzen et al. 2005). Cell-free expression systems exploit the 
cellular protein synthesis machinery to direct protein synthesis using exogenous messenger 
RNA (mRNA) or DNA as template. This has been achieved by combining a crude lysate 
from growing cells, which contains all the necessary machinery for protein synthesis 
including ribosomes, tRNAs, aminoacyl-tRNA synthetases, with the exogenous supply of 
essential amino acids, nucleotides, salts and energy-generating factors (Jackson et al. 
2004). In vitro protein expression offers several advantages over traditional cell-based 
expression methods (Schwarz et al. 2007) including:
• the relative speed of protein synthesis and ease of interpreting the results
• the ease of synthesising radiolabelled proteins for detection by autoradiography
• the specific labelling of recombinant proteins for monitoring and isolation.
• the capacity to synthesise toxic, proteolytically sensitive or unstable gene products
Cell-free protein synthesis systems have been developed from several organisms, but the 
most widely used systems are derived from E. coli, and wheat germ (WG) extracts and 
rabbit reticulocyte lysates (RRL). Cell-free systems can be utilised either in a ‘coupled’ 
mode, where DNA is used as template, or as an ‘uncoupled’ system, which requires mRNA 
template produced from native sources or by in vitro transcription. The DNA template may 
be a circular or linear fragment, but must contain a promoter (e.g. T7) and a translation 
initiation signal such as the Kozak sequence (CCCGCCGCCACCATGG) (Kozak 1987). To 
increase the expression level, a transcription and translation termination signal (TGA) is also 
required.
The choice of a cell-free system for protein synthesis is generally determined by the origin 
of the proteins to be expressed and their downstream applications (Summarised in Table
3.1). The commonly used E. coli S30 extract, WG extract and RRL systems are 
commercially available in both coupled and uncoupled formats. Coupled systems are 
generally simpler and more efficient; they also avoid problems associated with mRNA
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degradation and mRNA secondary structure (Alimov et al. 2000). E. coli based systems 
provide higher yields and more homogenous samples suitable for structural studies, 
however their applicability is generally limited to expressing only those proteins which can 
successfully be expressed by intact E. coli (Torizawa et al. 2004; Vinarov et al. 2006). 
Eukaryotic-based systems, although typically yielding less product, synthesise proteins that 
are better suited for use in functional studies. In light of this, only coupled eukaryotic 
systems have been considered for the purposes of this study.
Table 3.1. Choice of cell-free protein synthesis systems
E. coli extract RRL WG extract
Productivity per ml 6 mg 6 |jg 4 mg
Synthesised protein Many incomplete polypeptides Mainly full length Mainly full length
Post-translational
modifications No Yes Yes
Recommended 
template source Bacteria
Animal, plant, 
bacteria, 
mammalian virus 
and plant virus
Animal, plant, 
bacteria, and plant 
virus
3.1.3 Objectives of this chapter
This chapter describes the optimisation of a reliable in vitro protein expression and 
purification strategy for the production of the l-Domain and truncated l-Domain proteins. The 
purified proteins will be used for microinjection into mammalian cells to investigate their 
effect on cellular Ca2+ handling and phenotype.
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3.2 Methods
3.2.1 Preparation of hRyR2 l-Domain expression plasmids
The vector containing the l-Domain of human RyR2 (hRyR2), obtained from Dr. Chris 
George, was generated as follows: a cDNA fragment encoding the l-Domain of hRyR2 
(11288-13950 bp; aa 3722-4610) was generated by PCR amplification using Phusion 
polymerase (Finnzymes) (see Chapter 2) and oligonucleotides designed to incorporate 5’ 
EcoRI and 3’ Xhol restriction sites (Appendix I). Following restriction enzyme ligation, the 
amplified fragment was ligated into EcoRI/Xhol-digested pET-29(b) vector (Novagen), 
generating the l-Domain expression cassette fused in-frame with the S-tag (C-terminus) and 
His-tag (N-terminus) (Figure 3.2, A). Additional truncated l-Domain expression cassettes 
were produced by the same strategy using the oligonucleotide primers shown in Appendix I 
(Figure 3.2, B).
Recombinant vectors were transformed into Epicurian coli XL-10 ultracompetent cells 
(Stratagene), before selected colonies underwent small-scale alkaline lysis plasmid 
purification and restriction enzyme mapping using agarose gel electrophoresis (see Chapter 
2). The restriction fragments were visualised using ethidium bromide fluorescence and UV 
transillumination before colonies displaying the correct restriction profile were selected for 
large-scale plasmid isolation and verification by DNA sequencing.
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Thrombin cleavage site 
A  \  /  Xhol
S-TAG P D L G T M A I S D P N S E l-DOMAIN LE 6 X HIS
L
T7 P rom ote r \
'  20 aa linker sequence
B
l-DOMAIN 888 aa
IDA 631 aa
7 ipB 146 aa 1 1
7 |  IDC 257 aa ||~
Figure 3.2. Schematic representation of the l-Domain expression cassettes
Panel A. Each recombinant protein consists of l-Domain fragments fused to a 15 aa 
(KETAAAKFERQHMDS) N-terminal S-tag fusion, a 20 aa linker containing a thrombin cleavage site 
for S-tag removal following purification, and a dipeptide linker encoding the Xhol restriction site and 
six histidine residues as described above. This expression cassette will permit bimodal 
detection/purification of the recombinant proteins. Panel B. The expression cassettes represented 
with relative size-based scaling of the tags and linker sequences.
3.2.2 Cell-free protein expression
As discussed above, both WG (TNT Coupled Wheat Germ Extract System, Promega) 
and RRL (TNT Quick Coupled Transcription/Translation System, Promega) cell-free systems 
were employed in this study.
The TNT coupled WG extract is advantageous because it has low background 
incorporation due to its low level of endogenous mRNA, and typically produces a protein 
yield which can be up to two orders of magnitude higher than the RRL system (Anderson et 
al. 1976; Endo & Sawasaki 2006; Jackson et al. 2004; Katzen et al. 2005). In this system, 
protein expression can only take place if the DNA template is linear, hence the plasmid DNA 
was linearised by Sma\ digestion (37XZ, 2 hours). Reactions were carried out in 50pl 
volumes as outlined in Table 3.2. Reaction samples were incubated in a 30G water bath for 
90 minutes, and terminated by placing on ice.
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Table 3.2. Typical WG extract reaction mixture
Component
TNT WG extract 25pl
TNT reaction buffer 2pl
TNT RNAT7 Polymerase 1 pi
Amino Acid mixture, minus methionine, 1 mM 1pl
[35S]-labelled methionine (or unlabelled methionine, 1 mM) 0.5 MBq (or 1 pi) 
RNasin ribonuclease inhibitor (40 U/pl) 1 pi
Linearised plasmid DNA template 1 pg
Nuclease-free dH20  Up to 50pl
The TNT Quick Coupled Transcription/Translation System is based on RRL in which 
recombinant proteins are synthesised from either linear or circular DNA templates using a T7 
promoter. Reactions were carried out in 50pl volumes, as summarised in Table 3.3, by
adding plasmid DNA and [^®S]-labelled methionine (obtained as Pro-mix (92.5 MBq), GE 
Healthcare) or unlabelled methionine to the provided TNT Master Mix (containing T7 RNA 
polymerase, nucleotides, amino acids (minus Methionine), salts and ribonuclease inhibitor). 
Reaction samples were incubated in a 30*0 water bat h for 90 minutes, and terminated by 
placing on ice.
Table 3.3. Typical quick coupled transcription/translation reaction mixture
Component
TNT T7 Quick MasterMix 40pl
[35S]-labelled methionine (or unlabelled methionine, 1mM) 0.5 MBq (or 1 pi)
Linearised plasmid DNA template 1 pg
Nuclease-free dH2Q Up to 50pl
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Proteins synthesised by both systems were purified by magnetic bead affinity purification 
(Section 3.2.5). The radiolabelled proteins were subsequently visualised by autoradiography 
(Section 3.2.3) following SDS-PAGE, while the non-labelled proteins intended for 
microinjection into cells were visualised by Western blotting (Section 2.3.6).
3.2.3 Autoradiography
SDS-PAGE gels (Section 2.3.3) containing radiolabelled proteins were washed in fixing 
buffer for 1 hour, then soaked in dH20  for 1 hour to rehydrate them. To enhance 
radiographic detection, the gel was washed with ~ 50ml Amplify™ Fluorographic Reagent 
(GE Healthcare) for a further hour, before being dried onto filter paper (Whatman) using a 
vacuum gel dryer. The dried gel was then exposed to high performance chemiluminescence 
film (Hyperfilm, GE Healthcare) and developed using an automated image developer in 
order to visualise the protein bands.
3.2.4 Antibody purification using affinity strategies
The Melon Gel IgG purification system (Pierce) purifies antibodies from serum by 
removing contaminating proteins often present in high abundance, and was used according 
to the manufacturer’s guidelines which are summarised in Figure 3.3. Briefly, 500pl of the 
supplied binding gel is placed in a spin tube and centrifuged (2000 xg, 1 min, RT) to prepare 
the support matrix. This is then equilibrated by washing twice with the supplied purification 
buffer followed by centrifugation (2000 xg, 10 secs, RT). The serum antibody is diluted with 
the purification buffer (1:10) and applied to purification support matrix which binds non­
antibody serum proteins, such as albumin and transferrin. The serum is incubated with the 
purification support matrix for 5 mins at RT with continuous end-over-end mixing. 
Subsequently, the purified antibody is eluted off the matrix by centrifugation (2000 xg, 1 min, 
RT).
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Collection Tube
1. Add 500 mI of gel to the column 
and centrifuge
2. Wash gel twice with 300 pi 3. Dilute serum in Purification Buffer, 
of Purification Buffer
•  • • • •
•  • • • •
4. Place bottom cap on column, add 5. Mix column end-over-end
the antibody-containing solution and for 5 minutes,
place top cap on column
6. Remove bottom cap and 
centrifuge to collect purified 
antibody in a collection tube.
Figure 3.3. Summary of Melon Gel IgG purification strategy
Taken from http://www.piercenet.com
3.2.5 Zn2*-affinity purification of recombinant proteins
The MagZ protein purification system (Promega) was used for the isolation of the I- 
Domain proteins, and was carried out according to the manufacturer’s guidelines. Briefly, 
the entire protein synthesis reaction (50|jI) was diluted in the supplied binding/wash buffer 
(containing 20 mM sodium phosphate and 500 mM NaCI). This was then incubated with 
MagZ particle slurry (60pl) for 15 mins at RT on an orbital rotator. The MagZ particles were 
then washed four times with the binding/wash buffer and the purified proteins were 
subsequently eluted using 0.6 M imidazole (pH 7.5).
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3.3 Results
3.3.1 Generation o f truncated l-D om ain constructs
Fragments of hRyR2 l-Domain were successfully amplified by PCR using the conditions 
and oligonucleotide primers described in Chapter 2 and Appendix I (Figure 3.4). Plasmid 
pET-29(b) encoding the truncated l-Domain fragments were generated and restriction 
enzyme mapping was used to confirm the correct ligation of the fragments into the vector 
(Figure 3.5). DNA sequencing was used to verify the integrity of the l-Domain fragments and 
the restriction boundaries (Figure 3.6).
IDA ID B IDC
4072
3054
2036- ^  
1636- >
1018
506
396
Figure 3.4. hRyR2 l-Domain cDNA fragments were successfully amplified by PCR.
Agarose gel electrophoresis (1 % (w/v)) showing amplification of discrete l-Domain cDNA fragments 
of the correct size (IDA, 1892 bp; ID8, 436 bp; ID0, 770 bp) from the full-length l-Domain template. 
Numbers indicate DNA marker sizes in base pairs (bp).
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pet29b / 
IDA
5845
436
pet29b / 
IDB
5400
6108—>  
5090->  
4072 ->  
3 0 5 4 ^
2036
1 6 3 6 ^
1018~>
< 5845
< 1477
1018 —^  
506
396 - >
< 5400
< 436
797
pet29b / 
4353-4610
5288
2036 ->  
1636“ >
1018—>
506 " >  
396 - >
< 5288
< 797
Figure 3.5. Verification of pET-29(b)-cloned l-Domain expression cassettes by restriction 
mapping.
Restriction maps of pET-29(b) containing l-Domain or truncated l-Domain digested with the enzymes 
shown, and verified by agarose gel electrophoresis. Numbers indicate fragment sizes in base pairs 
(bp).
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Figure 3.6. Verification of constructs by sequencing
Electropherograms showing the sequences obtained by sequencing pET-29(b)-cloned fragments in 
the forward direction using the T7 priming site. Confirms the presence of the S-tag, thrombin 
cleavage site, and EcoRI restriction site. The start of the l-Domain fragment is indicated by the 
arrowhead. Also verified by reverse sequencing (not shown).
3.3.2 In vitro expression o f l-Dom ain fusion proteins
3.3.2.1 Selection o f an appropriate cell-free expression system
The l-Domain and truncated l-Domain constructs were expressed in WG and RRL 
systems according to the protocols described above, and the resultant proteins were 
visualised on an SDS-PAGE gel by Imperial protein staining as described in Section 2.3.4. It 
can be seen in Figure 3.7 (Panel A) that WG extract comprises a less complex protein 
mixture than the RRL and it was anticipated that this lower background of protein would be 
advantageous in downstream applications such as detection and purification of the target 
proteins. In both systems, the proteins expressed were below the levels of detection of 
Imperial protein stain, indicating that the high protein yields reported in some studies (Table
3.1) could be achieved for l-Domain proteins.
Next, the l-Domain and truncated l-Domain constructs were expressed and radiolabelled 
with 35S-methionine using WG and RRL as previously described. Autoradiography showed 
that both WG and RRL expressed proteins of the anticipated molecular weight. However,
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there was consistently elevated levels of protein produced from RRL (using circular or linear 
template) when compared with the WG system which conspicuously failed to produce ID and 
ID8 (Figure 3.7, Panel B). As a result of this, the RRL system was selected for the 
expression of the l-Domain proteins, and the following sections describe the detection and 
purification of the target proteins from this cell-free system using a circular plasmid template.
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A RRL WG
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42 kDa —^  
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B  Expression System 
Template
71 k D a -* -
42 kDa —>•
3 1 kDa —>
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Figure 3.7. Comparison of RRL and WG extract protein expression systems
Panel A: Imperial protein stain of 25pl RRL and WG expressing full-length and truncated l-Domain 
proteins. The right-hand lane of each gel shows 25pl of the RRL or WG containing no DNA template, 
and shows no noticeable difference in protein profile to those containing the target proteins. Panel B: 
Expression of radiolabelled l-Domain proteins from 25pl of RRL or WG, using circular and linear DNA 
templates. MW of the fragments are ID -  106.3 kDa, IDA -  76.7 kDa, ID8 -  21.8 kDa, IDC -  34.4 kDa. 
The differences in band intensity between the constructs is dependent on the number of radiolabelled 
residues present in each construct, and will be discussed in the next section.
RRL RRL WG
circular linear linear
<  CD o
9  9  9  9 < m o9 9 9 9
< CD o
9 9  9 9
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3.3.2.2 Quantification of protein expression in RRL
The relative expression levels of the l-Domain and truncated l-Domain constructs in the 
RRL system were compared by virtue of 35S-methionine labelling the synthesised proteins. 
For a given specific activity of the 35S-methionine label, the density of the non-saturated 
autoradiographic signal is absolutely dependent upon the number of labelled residues in the 
protein. It is important to note that densitometry can only be accurately carried out on non­
saturating exposures, hence the weaker signals observed in Figure 3.8 (Panel A), compared 
with in Figure 3.7 (Panel B) section 3.3.2.1. Densitometric analysis confirmed the direct 
proportionality of the relationship between the number of radioactive residues present and 
signal density (Figure 3.8, B). This linear relationship (r2 = 0.9951) clearly shows that 
variation in signal density reflects the number of labelled residues per protein and not the 
level of expression (Figure 3.8, C), and that the four proteins exhibited comparable levels of 
expression.
B
r2 = 0.99511 .0 -
g 0.9- 0)
<0g 0.8-
0 10 20 30 40 50
No. radioactive residues
Construct MW
(M>.)
No. of 
radioactive 
residues
Signal
Density/
mm*
Relative Signal 
Density
ID 106.3 42 63.1 1.000
ID * 76.7 35 59.2 0 .932
ID" 34.4 2 42.5 0 .724
IDC 21.8 7 44.8 0 .746
Figure 3.8. Autoradiography of 35S-labelled l-Domain proteins
Panel A: SDS-PAGE (10% (v/v)) analysis of 25pl RRL protein expressing radiolabelled l-Domain 
proteins. All proteins were expressed successfully and consistent with the predicted MW, 
summarised in panel C. The final lane showed no non-specific incorporation of radiolabelled 
methionine in RRL (25pl) not supplemented with DNA template. Panel B: Densitometric analysis of 
35S-labelled l-Domain proteins shows a linear correlation between the number of labelled methionine 
residues and signal density (n=5), indicating that all constructs were expressed at comparable levels.
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3.3.3 Detection of l-Domain proteins
l-Domain proteins expressed using the RRL were successfully detected by S-protein HRP 
conjugate, anti-RyR ab1093 and anti-His tag antibodies as described in Chapter 2.
3.3.3.1 Detection of l-Domain proteins by S-protein HRP
The S-tag / S-protein HRP protein detection system is based on the strong interaction 
between the 15aa S-tag and 103aa S-protein, both of which are derived from RNase A. The 
15aa S-tag protein fused to the N-terminus of the l-Domain proteins displays a very strong 
and highly specific affinity to S-protein and thus proteins fused to the S-tag can be directly 
detected with S-protein conjugated with HRP.
Detection by S-protein HRP does not require a secondary antibody, and as a result the 
signal density is directly proportional to the level of protein expression (Figure 3.9). The four 
ID proteins were successfully detected by S-protein HRP, exhibiting protein bands at the 
correct molecular weight. Densitometric analysis of the S-protein HRP signal showed that all 
l-Domain proteins were expressed at equivalent levels in RRL, which corroborated the 
observations from the radiolabelled proteins (Figure 3.8).
119
Chapter 3
protein
1 ^ 4
l-Domain Protein 6xHis
B
< m o <d
q  g  9  g  >
16 kDa
C
5000
|4 0 0 0
>3000
w
§2000
1000
ID ID* ID8 IDC
MW
(kDa)
Signal Density/ 
mm2
ID 106.3 5.40 x 1 0 3
IDA 76.7 5.22 x 103
IDB 21.8 5.23 x 1 0 3
IDC 34.4 5.20 x 1 0 3
Figure 3.9. Detection by S-protein HRP conjugate
Panel A: Schematic representing the detection strategy using the S-protein affinity to the N-terminal 
S-tag. Panel B: A representative SDS-PAGE (10% (v/v)) with 25pl RRL expressing correctly sized 
full-length and truncated l-Domain proteins. The final lane contains 25pl RRL without exogenous 
DNA template, and shows negligible background S-protein detection. Panel C: Densitometric 
analysis of the S-protein HRP signals (n=5) for each l-Domain protein clearly shows that all constructs 
are expressed at the comparable levels in RRL.
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3.3.3.2 Detection of l-Domain proteins by anti-RyR2 antibody (ab1093)
In addition to the fusion tags at either end of the l-Domain protein, we also used ab1093, 
a polyclonal anti-RyR antibody produced in our laboratory for immunodetection of most of 
the recombinant fragments. The epitope for ab1093 is located downstream of TM1 (Tunwell 
et al. 1996) at residues 4454-4474 of hRyR2, and is present in the truncated l-Domain 
proteins, with the exception of IDA.
Immunodetection of l-Domain fragments using ab1093 serum was successful but 
displayed a high level of background signal (Figure 3.10, C) that lower dilutions of antibody, 
longer incubation of the PVDF membrane with blocking buffer, and reduced incubation with 
the primary and secondary antibodies failed to eliminate.
To negate these issues, the antibody was then purified using the Melon Gel IgG 
purification kit (Pierce) as described in Section 3.2.4. Purification by this technique 
profoundly reduced the amount of protein present in the antibody serum by removing non- 
relevant proteins such as albumin and transferrin (Figure 3.10, B).
Immunodetection of the l-Domain proteins was repeated using the purified ab1093 
antibody and resulted in markedly cleaner blots with very little background signal (Figure 
3.10, C). The improved blots clearly show that, as anticipated, full length ID, ID8 and IDC are 
detected by ab1093 and show the correct molecular weights. Unlike 35S labelling and S-tag 
detection, the signals obtained by ab1093 immunodetection are not linear due to the use of a 
secondary antibody. As predicted, IDA is not detected by this antibody, as the epitope is not 
present in this protein.
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Figure 3.10. Immunodetection by anti-RyR2 ab1093
Panel A: Schematic illustrating the location of ab1093 epitope at residues 4454-4474, and the 
detection strategy using ab1093. Panel B: SDS-PAGE analysis of ab1093 (5pl) before (Lane 1) and 
after (Lane 2) IgG purification. Panel C: Immunoblot analysis of RRL (25pl) synthesised full-length 
and truncated l-Domain proteins using ab1093 before (left) and after (right) IgG purification.
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3.3.3.3 Detection of l-Domain proteins by anti-His antibody
The C-terminal hexa-his fusion tag was detected using an anti-His polyclonal antibody. 
Initially, an anti-His (H-3) antibody from Santa Cruz was used for 1-Domain protein detection. 
This antibody was chosen as it is widely used in our laboratory and has proven successful 
for detection of other hexa-his tagged proteins. However, when used for the detection of the 
1-Domain proteins, this antibody produced poor blots with very high levels of background 
signal and non-specific binding (Figure 3.11, B) that was not reduced by lowering the 
dilutions of antibody, longer incubations of the PVDF membrane with blocking buffer, and 
shorter incubation times with the primary and secondary antibodies. As a result, a different 
anti-His antibody obtained from Covance was investigated. This clonally-derived antibody is 
entirely distinct from other commercially available anti-His antibodies, and its use resulted in 
strikingly clearer blots with very little background and much higher signal-to-noise levels 
(Figure 3.11, B). This approach further corroborates the reliable in vitro synthesis of 
recombinant proteins of the anticipated molecular size. The large non-specific band at -20  
kDa, visible in all the samples and which obscures the signal for IDB, is thought to be due to 
the high levels of haemoglobin present in RRL. It was anticipated that this would be 
eliminated once the l-Domain proteins were purified from the RRL reaction mixture (Section 
3.3.4). Taken together, the successful detection of l-Domain fragments by N-terminal S-tag, 
anti-RyR2 and anti-His-tag strategies verifies the use of the RRL in vitro system to robustly 
produce bona fide recombinant proteins for use in downstream applications.
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Figure 3.11. Detection by anti-His antibodies
Panel A: Schematic representing the detection strategy using the C-terminal hexa-His epitope. Panel 
B: Immunoblot analysis of RRL (25pl) expressing the l-Domain and truncated l-Domain proteins using 
anti-His antibody from Santa Cruz (Left) and Covance (Right).
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3.3.4 Purification of l-Domain proteins
The fusion of tags to either end of an expressed protein facilitates not only the detection 
of target proteins, but also their isolation from the complex mix of background proteins 
present in the RRL expression system. The presence of two tags, one on either end of the I- 
Domain proteins provides two possible strategies for purification -  the first using the Hexa- 
His tag and an immobilised metal affinity chromatography (IMAC) approach using Ni2+ 
sepharose, and the second via affinity purification of S-tag fusion protein using the S-protein 
conjugated to an inert carrier such as agarose. In order to determine the relative merits of 
these purification strategies, it was decided to initially concentrate on pursuing the 
optimisation of both IMAC and S-tag approaches using only the full-length l-Domain. Both of 
IMAC and S-tag techniques were employed in the purification of the full-length l-Domain 
from RRL according to the protocols described in Sections 2.3.7 and 2.3.8. The resultant 
eluate from each system was visualised by SDS-PAGE analysis followed by Imperial protein 
staining (Figure 3.12), and equivalent gels were transferred onto PVDF membrane and 
blotted with the three antibodies described above. As expected, proteins purified by the S- 
tag strategy were not detected by S-protein HRP as the S-tag is cleaved off the l-Domain 
protein by thrombin digestion during the last stage of purification. However, western blotting 
(not shown) and protein staining (Figure 3.12) failed to detect any l-Domain protein in the 
eluates from either purification strategies. To eliminate the possibility that the protein was 
present in levels below the threshold for immunodetection, 500pl of each eluate (equivalent 
to 25pl of original RRL reaction mixture) was concentrated using a Microcon centrifugal filter 
device (Millipore, 50,000 NMWL) and analysed in the same way (Figure 3.12). Once again, 
no l-Domain protein was detected by protein staining (Figure 3.12) or western blot (not 
shown) and it was concluded neither of these strategies were suitable for the isolation of I- 
Domain protein from RRL.
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106.3  kDa
Figure 3.12. Unsuccessful purification of ID protein from the RRL expression system using 
column-based systems
Eluates (100|jI) from the Ni2+ affinity and S-protein affinity systems before microcon concentration (left 
and middle panels, respectively) were separated by SDS-PAGE (10% (v/v)), and visualised with 
Imperial protein stain. Eluates resulting from these strategies (500pl) were concentrated in a 
centrifugal filter device and were compared with 20pl RRL expressing ID (right panel). All of these 
systems failed to produce any detectable ID protein staining (shown above), and immunoblot analysis 
also failed to detect the ID protein (not shown).
Given the failures of a Ni2+-based IMAC approach and S-tag affinity purification systems 
to purify recombinant l-Domain protein from RRL, an alternative purification strategy was 
necessary. A new development in IMAC technology has been the MagZ protein purification 
system (Promega) which uses zinc paramagnetic beads (Section 3.2.5) rather than the Ni2+- 
based chemistries to selectively bind the C-terminal hexa-His tag, which was developed to 
overcome the problems associated with the co-purification of haemoglobin using traditional
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Ni2+-affinity techniques. Initially, this technique was optimised for purification of 35S- 
methionine labelled full-length l-Domain using imidazole-based elution protocols. Figure 
3.13 (Panel A) shows that from a 50pl RRL reaction expressing ID, very little protein is lost 
during the binding (lane 2) and washing (lanes 3-6) process, when compared with Lane 1 
that contains 2pl of ‘unpurified’ RRL. Importantly, after the first two washes, the colour of the 
reaction mixture changed from bright red to clear, indicating that the high levels of 
haemoglobin in RRL are eliminated by this purification method. This was not seen by the 
Ni2+ affinity method described above; implying that the high levels of haemoglobin in RRL 
may have adversely affected the efficacy of this purification system. In order to optimise the 
elution conditions, protein was sequentially eluted off the beads using increasing 
concentrations of imidazole in the elution buffer (lanes 7-14). This showed that l-Domain 
protein was successfully isolated by this technique, and 0.6 M imidazole was sufficient to 
elute ~80% of the target protein from the beads (Figure 3.13, A). It was decided that, 
despite sacrificing a small amount of protein, 0.6M imidazole represented the optimal 
conditions for protein elution since it would minimise potential adverse effects caused by 
higher imidazole concentrations (e.g. 1M) in downstream applications. Given the apparent 
success of this technique in enriching full-length l-Domain protein, this approach was 
extended to enriching the other truncated using similar conditions to those described above 
(Figure 3.13, B).
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Figure 3.13. Purification of radiolabelled l-Domain proteins using a zinc-affinity approach.
Panel A. Optimisation of ID protein purification from 50pl RRL using zinc paramagnetic beads. Lane 
1 shows 2pl of unpurified RRL expressing ID. Lane 2 shows the unbound product (100pl) following 
incubation with the Zn2+ slurry. Lanes 3-6 show the loss following sequential wash-steps (100pl). 
Lanes 7-14 show the ID protein eluted with increasing concentrations of imidazole. Panel B. 
Purification of ID and truncated ID proteins using optimised Zn2+-affinity strategy from RRL (50pl). 
Lane 1 shows the unbound product (100pl) following incubation with the Zn2+ slurry; lanes 2-5 show 
the losses following 4 sequential wash steps. Lane 6 shows the resultant protein eluted with 0.6 M 
imidazole.
The efficacy of this system was quantified by densitometric analysis of purified and non­
purified RRL expressing the l-Domain and truncated l-Domain proteins. Silver staining was 
used to visualise the proteins remaining after Zn2+-based purification, as the amount of 
protein was below the detection threshold of Imperial protein stain (Section 2.3.4). The silver 
stained protein profiles were plotted and the area under each curve was calculated by 
integration, which showed that the MagZ purification system removed -95%  of all 
background protein (Figure 3.14), thereby enriching the l-Domain proteins.
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Figure 3.14. Quantification of the efficacy of the MagZ Zn2+-affinity purification system by densitometry
Panel A: Silver staining reveals the protein profiles of MagZ-treated RRL (50pl) in which ID proteins had been synthesised 
(left) or 2pl of non-purified RRL expressing ID proteins (right). Panel B: Densitometric analysis of the protein profiles in 
MagZ-treated (blue line) and untreated (black line) samples were determined using Quantity one analysis of band density 
through the lane profile. Panel C: The area under each trace, which can be considered as a robust index of protein quantity 
was obtained by mathematical integration. These figures show that MagZ processing removes > 95% of background proteins. 
For example, MagZ treatment removes haemoglobin, indicated by <.
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Next, immunoblot analysis of recombinant l-Domain proteins was performed using S- 
protein HRP, anti-RyR ab1093, and anti-His tag approaches as previously described. In 
contrast to the failures of Ni2+ and S-tag strategies to yield immunodetectable levels of I- 
Domain proteins, Figure 3.15 clearly shows that all the l-Domain proteins were successfully 
purified from RRL by the MagZ strategy, at levels sufficient for immunodetection. All the 
antibodies detected clear, clean protein bands at the correct MW, although the proteins were 
detected at different levels indicating that enrichment may not have been equivalent for all 
the l-Domain fragments. Detection by the anti-His antibody showed that the majority of the 
non-specific binding observed in non-purified RRL had been eliminated, which was 
consistent with the removal of haemoglobin by zinc affinity purification.
< 0 Q U  <  CO o  <  DO o
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S-tag ab1093 His
Figure 3.15. Successful immunodetection of MagZ purified l-Domain proteins in RRL
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3.4 Discussion
3.4.1 Successfui propagation of i-Domain expression cassettes
Propagation and isolation of the pET-29(b) expression cassettes containing truncated I- 
Domain templates was successful, when carried out under the conditions optimised for the 
propagation of hRyR2 DNA that avoid spontaneous recombination or plasmid DNA 
degradation (George et al. 2005). These conditions included a low propagative temperature 
(typically 30°C), short durations in culture (<18 hours), the use of a specific strain of bacteria 
adapted for viable transformation with large plasmids, and resin-based DNA purification 
systems that do not shear the isolated plasmid (George et al. 2003a, 2003b).
3.4.2 Successful expression of l-Domain proteins in vitro
Cell-free protein expression is emerging as an important tool for studying eukaryotic in 
vitro protein synthesis, particularly for the expression of integral membrane proteins which 
have proven problematic to synthesise in mammalian or bacterial cell systems as their 
production can be detrimental to the physiology of the cells (Endo & Sawasaki 2006; 
Jackson et al. 2004; Junge et al. 2008; Katzen et al. 2005; Klammt et al. 2006). The I- 
Domain contains two putative TM domains (Tunwell et al. 1996) that may make it difficult to 
express in non-in vitro systems, therefore this study made extensive use of a cell-free 
system for recombinant protein. Furthermore, bioinformatic analysis of the full-length I- 
Domain and the three truncated l-Domain fragments revealed differences in the properties of 
these proteins, including hydrophobicity, which could affect the way they are expressed in 
bacterial or mammalian systems. As demonstrated above, cell-free protein expression 
largely overcomes this problem and the data shows that the bona fide l-Domain proteins 
were consistently synthesised regardless of size, secondary structure, or hydrophobicity. 
Densitometric analysis of radiolabelled proteins showed that the four l-Domain proteins were 
successfully expressed, regardless of their size, hydrophathy or secondary structure. This
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was further supported by detection using S-protein HRP conjugate, which gave comparable 
signals for ail proteins, indicating broadly equivalent levels of expression.
l-Domain proteins were successfully expressed in a RRL cell free system, and 
immunodetection using the fusion protein epitopes at either end the protein expression 
cassette confirmed that full-length recombinant proteins had been produced. Interestingly, 
expression of the l-Domain proteins in the WG extract was not successful. Only two of the 
truncated proteins (IDA and IDC) were expressed by WG extract albeit in lower levels than by 
RRL, while ID and ID8 were not expressed at all. This was unexpected, as WG was 
anticipated to yield proteins in the range of two orders of magnitude higher than those 
produced in RRL ( Alimov et al. 2000; Endo & Sawasaki 2006; Hino et al. 2008; Jermutus et 
al. 1998; Katzen et al. 2005; Vinarov et al. 2006; Zhao et al. 2007).
3.4.3 The C-terminal hexa-His epitope can be used for isolating l-Domain proteins
Purification of l-Domain proteins from RRL using the S-tag affinity system and the Ni2+ 
affinity column proved unsuccessful. It is likely that in both cases, this was due to the small 
volumes of RRL used and the low levels of expression of the l-Domain proteins which may 
have been below the effective thresholds of these systems.
The l-Domain proteins were, however, effectively isolated from RRL using a newer 
strategy based on magnetic zinc beads with a high affinity to poly-His-tagged proteins but 
not to haem groups, thus allowing the purification of the target protein without co-purification 
of haemoglobin present in the RRL. This strategy resulted in the removal of 95% of 
contaminating background proteins, and permitted enrichment of the l-Domain proteins that 
could be unequivocally identified using immunoblotting techniques.
This chapter has described the robust applicability of cell-free protein synthesis coupled 
to Zn2+-based purification strategies to yield bona fide full-length and truncated l-Domain 
proteins. Ultimately, the aim of this project was to investigate the effects of these fragments 
on the Ca2+ handling and phenotype of mammalian cells, and the following chapter
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describes the optimisation of microinjection techniques for introducing these recombinant 
proteins into HL-1 cardiac myocytes.
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Optimisation of microinjection strategies
Chapter 4
4.1 Introduction
4.1.1 HL-1 cells: an immortalised cardiac cell line
HL-1 cardiomyocytes are the only cardiac cell line that can be serially passaged, while 
retaining full contractility and differentiated cardiac morphology, biochemical, and 
electrophysical properties (Claycomb et al. 1998; White et al. 2004). They are also, to the 
best of our knowledge, the only cell type that can be cultured into confluent electrically- 
coupled monolayers that form the basis for the experiments described later in this chapter. 
The HL-1 cell line was derived from AT-1 cardiac myocytes, which are atrial cardiac muscle 
cells obtained from transgenic mice in which expression of the SV40 large T antigen was 
under the control of the atrial natriuretic factor (ANF) promoter (Field 1988). Although AT-1 
cells maintain cardiac cell phenotype and contract spontaneously in culture, they cannot be 
serially passaged in vitro or recovered from frozen stocks. AT-1 cells can only be 
maintained as a subcutaneous tumour lineage in syngenic mice, and myocytes must be 
prepared from these tumours as primary cells (Delcarpio et al. 1991) and thus the utility of 
the AT-1 cell type is limited. The HL-1 lineage, a derivative of AT-1 cells that could be 
serially passaged while maintaining a differentiated phenotype, was isolated by Claycomb 
after more than 100 separate preparations and attempts to passage AT-1 cells under 
carefully controlled conditions (Claycomb et al. 1998). The HL-1 cell line can be serially 
propagated in culture with an apparently unlimited life span, and retain the ability to contract 
for at least 240 passages. These characteristics are retained by cells that have been 
recovered from stocks frozen in liquid nitrogen. In order for HL-1 cells to be passaged 
repeatedly while maintaining a highly proliferative and differentiated contractile cardiac 
phenotype, they require a gelatin-fibronectin (GFN) matrix and a specially formulated growth 
medium containing components such as retinoic acid, norepinephrine, insulin, and essential 
lipids in addition to factors found in normal foetal calf serum (FCS) (Claycomb et al. 1998; 
White et al. 2004).
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4.1.2 Phenotypic characteristics of HL-1 cells
HL-1 cardiomyocytes have been extensively characterised using microscopic, 
immunohistochemical, electrophysiological and pharmacological methods to demonstrate 
that HL-1 cells exhibit properties similar to primary cardiomyocytes in situ (Claycomb et al. 
1998; White et al. 2004) as summarised in Figure 4.1.
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Figure 4.1. Phenotypic characteristic features of a typical HL-1 cardiomyocyte
Panel A. Shows a phase-contrast image of two HL-1 cardiomyocytes that have just completed 
cytokinesis adjacent to a contracting myocyte. Panel B. A schematic representation of the phenotypic 
and protein expression characteristics of an HL-1 myocyte. Abbreviations: Cx -  connexin; iNOS -  
inducible nitric oxide synthase; MAPK -  mitogen-activated protein kinase; ERK -  extracellular signal- 
regulated kinase; MEK -  MAPK/ERK kinase; JNK -  Jun kinase; MHC -  myosin heavy chain; MLC -  
myosin light chain; GLUT -  glucose transporter; RyR -  ryanodine receptor; FKBP -  FK506 binding 
protein; /f -  pacemaking current; /Ca -  calcium current; /Na -  sodium current; /« -  potassium current; 
Wca -  sodium-calcium exchange current. The following genes expressed in HL-1 cells are shown 
under the current with which they are associated in vivo: the hyperpolarisation, cyclic nucleotide-gated 
channels (HCN), the voltage-gated L-type Ca2+ channel (LTCC), the voltage-gated sodium channel 
(Scn5a), modulatory |3-subunit for the inward rectifier potassium current (minK), and the 
sodium/calcium exchanger (NCX). Adapted from White et al. (2004).
According to both microscopic and immunohistochemical studies, HL-1 cells do not have 
a classical T-tubular organisation, yet they contain highly organised sarcomeres necessary 
for mediating contraction and intracellular ANF granules characteristic of atrial myocytes. 
Morphological characterisation revealed that HL-1 cells resemble AT-1 cells (Moses & 
Claycomb 1984) and immature mitotic mouse atrial cardiomyocytes in situ (Delcarpio et al.
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1991). As is characteristic of healthy mitotically active cardiomyocytes, the cytoplasm of HL- 
1 cells contains nascent myofibrils and glycogen-rich areas. The majority of HL-1 cells 
contain a single centrally-positioned nucleus surrounded by a ring of contracting myofibrils. 
HL-1 cells also possess perinuclear ANF-containing granules, cardiac-specific myosin, and 
muscle-specific desmin intermediate filaments. Myofibrillogenesis, a characteristic typical of 
normal myofibril development in mitotic cardiomyocytes in the developing heart, was also 
observed in cells undergoing cellular reorganisation following cell passage or cytokinesis 
(Claycomb et al. 1998). During mitosis, HL-1 cells remained attached to adjacent cells via 
intercalated discs, another characteristic common to mitotically active atrial cardiomyocytes 
in situ (Claycomb et al. 1998).
Analysis of gene expression in HL-1 cells reveals that they exhibit an adult 
cardiomyocyte-like gene expression profile, based on contractile protein isoform expression 
which is a well established index of the developmental and differentiated state of 
cardiomyocytes (Claycomb et al. 1998). For example, HL-1 cells expressed the adult 
isoform of MHC (a-MHC) as well as a-cardiac actin, ANF and connexin43, similar to adult 
mouse ventricular cells.
HL-1 cells spontaneously depolarise and express the necessary ion channels required for 
generating APs characteristic of primary cardiomyocytes. After several days in culture, HL-1 
cells exhibited spontaneous APs and synchronous beating in super-confluent cultures. The 
contractile cells displayed electrophysiological characteristics consistent with those seen in 
cardiomyocytes in situ, including the presence of several voltage-dependent currents typical 
of a cardiac myocyte phenotype.
Pharmacological studies show that HL-1 cells respond appropriately to inotropic and 
chronotropic agonists, indicating the expression of functional receptors and intracellular 
signalling proteins required for these signalling pathways (Claycomb etal. 1998).
Overall, the HL-1 cell line represents a hybrid between an embryonic and an adult 
myocyte. HL-1 cells retain a pattern of gene expression typical of normal adult mouse 
myocytes, and express genes encoding adult protein isoforms despite the fact that they are
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actively dividing. However, as a consequence of their ability to continuously divide in 
culture, they possess a less differentiated and less organised ultrastructure, which is similar 
to that of actively dividing embryonic cardiomyocytes (White et al. 2004).
4.1.3 HL-1 cells as a model system
HL-1 cardiomyocytes are unique in their capacity to proliferate and be serially passaged 
without reverting to an embryonic phenotype (Claycomb et al. 1998; White et al. 2004). 
Furthermore, HL-1 cells are the only cultured cell line of cardiac origin which can form 
synchronously coupled beating monolayers suitable for imaging experiments. These 
properties make them attractive for studies that require expression of adult-specific genes 
and for studies of cardiomyocyte function, as well as for assessing the activity of 
pharmacological agents such as modulators of cardiac ion channels.
HL-1 cells have proven useful for studying many aspects of cardiac biology in vitro, 
including hypoxia (Cormier-Regard et al. 1998; Nguyen and Claycomb 1999), 
hyperglycaemia (Collier et al. 2002), cellular signalling (McWhinney et al. 2000; Kitta et al. 
2001; Suzuki 2003), electrophysiology (Akhavan et al. 2003; Claycomb et al. 1998), cell 
cycle regulation (Lanson et al. 2000; Zandstra et al. 2003), apoptosis (George et al. 2007c) 
and calcium handling (George et al. 2003a, 2006).
Our laboratory routinely uses HL-1 cardiomyocytes to study the effects of altered 
intracellular Ca2+ handling in a cardiac cell environment (George et al. 2003a). HL-1s also 
represent a robust system for investigating the effects of ouabain, a pharmacological 
arrhythmogen which mechanistically mimics the events frequently leading to human 
arrhythmias (Barberini-Jammaers et al. 2008).
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4.1.4 Microinjection
Single cell microinjection (Ml) has been successfully utilised to deliver exogenous 
proteins, cDNA constructs, peptides, drugs and particles into transfection-challenged cells. 
Since it permits the precise control of the amount and timing of delivery, this technique has 
been used in many studies of primary cultured cells, transgenic animal production, and in 
vitro fertilisation.
Transductions of exogenous cDNAs, proteins, peptides, and drugs are widely used in 
modern cellular and molecular biology by a variety of different techniques. Chemical 
transfection of foreign DNAs into the cytosol of mammalian cells is routinely achieved by 
calcium phosphate or liposome-mediated reagents (Colosimo et al. 2000; Zhang & Yu 
2008). Viral infection transfers genes of interest through packaging them into a replication- 
defective viral vector encapsulated within a viral envelope enhancing gene transfer 
efficiency. Both chemical transfection and viral infection can achieve high levels if 
transduction once the experimental conditions have been optimised. As an alternative to 
chemical and viral transduction methods, other more physical methods are available, such 
as electroporation. Electroporation can directly deliver non-permeable exogenous 
substances into cells (Orlowski & Mir 1993). During electroporation, a rapid high-voltage 
electrical pulse results in temporary pore formation in the cell membrane, through which 
foreign proteins or DNA can enter the cell. Because electroporation eliminates the 
cytotoxicity caused by chemical transfection or viral infection, it has been widely used to 
deliver large molecules such as proteins, antibodies, and dextrans. However, 
electroporation requires relatively large amounts of protein preparation for a single 
transduction, and has a relatively low efficiency (Orlowski & Mir 1993; Tompers & Labosky 
2004). A novel system for protein delivery uses a cationic lipid mixture as a vehicle for the 
proteins, and releases them into the cell by fusing with the cell membrane. This method is 
faster and more efficient than the transfection methods discussed above, but has the same 
limitations with regards to the precise control of timing and the amount of sample being
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delivered into the cell. However, none of these methods described above are suited to the 
experimental approaches described in this thesis since none permit the precise control of 
timing and amounts of exogenous material introduced into the cells (Zhang & Yu 2008).
A robust mechanical delivery method, Ml of single cells, achieves high transduction 
efficiency in the majority of cell types, including cultured primary cells and oocytes. The 
greatest advantage of this method is the ability to precisely control the dosage, timing, and 
location of delivery. Considering a recent study in our laboratory that showed that the effect 
of l-Domain proteins on cell phenotype occurs less than one day after their recombinant 
expression in HEK cells (Fry 2008), the technique of Ml, that allows control over delivery 
time, location and amount of exogenous material, is the only feasible way to study the acute 
effects of these proteins.
In an optimised and well-controlled Ml strategy, the exogenous injected material is the 
only independent variable and therefore the effect of the injected substance can be 
unequivocally determined. Modern air pressure driven microinjectors allow the fine-tuning of 
injection pressure, compensation pressure and injection time, which together manipulate the 
injection volume. The successful application of Ml to experiments involving HL-1 myocytes 
has been demonstrated by Clarke et al. (2006) to investigate peptide-based manipulation of 
gap junction-mediated intercellular communication.
4.1.5 Objectives of this chapter
This chapter describes the optimisation of a robust Ml strategy for the delivery of I- 
Domain proteins into HL-1 myocytes, while preserving cell viability and ultrastructure. 
Recent studies in our laboratory (Fry 2008) established that recombinant expression of some 
l-Domain subfragments IDA and IDC were profoundly cytotoxic and induced apoptosis in HEK 
cells after 1 day. In light of these observations, together with the bioinformatics analysis 
discussed in Chapter 3 and Appendix II, this chapter will focus on investigating the effects of 
ID8 on spatio-temporal Ca2+ handling in HL-1 myocytes.
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4.1.6 Specific Hypothesis
Here, we tested the hypothesis that microinjection of recombinant fragments would 
enable the phenotypic consequences of ID subfragment, ID8 to be determined. This chapter 
describes the characterisation of Ml as an appropriate technique for this purpose.
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4.2 Methods
4.2.1 Preparation of HL-1 ceils for Ml
HL-1 cardiomyocytes were cultured and harvested as described in Chapter 2. The 
harvested cell pellet was resuspended in supplemented Claycomb media before plating onto 
glass chambers (14 mm diameter, 0.1 mm thickness, MatTek), which had been coated 
overnight with a GFN substrate, at a density of 5 x 105 cells/chamber. The cells were initially 
applied to the GFN-coated chambers in a 200pl meniscus, and allowed to adhere to the 
glass for between 4 and 6 h before the chamber was flooded with an additional 1800pl of 
supplemented Claycomb media. These were then left to grow for 48 h (37°C, 5% C 02, 
-80% humidity) with the growth media being replaced daily in order to maintain the cells in a 
healthy contractile state, before being used for Ml experiments.
4.2.2 Ml apparatus and techniques
All Ml experiments were carried out using an Eppendorf NI2 system which provides a 
reliable and reproducible system for Ml of mammalian cells. The system consists of two 
basic units: the InjectMan NI2 micromanipulator, which electronically controls movement of 
the microcapillary and the FemtoJet microinjector, which regulates injection parameters. 
The InjectMan NI2 micromanipulator is controlled by the operator through a joystick and is 
capable of smooth, coarse, or fine movement, in the x-, y-, and z-axes. Cells were injected 
by Femtotip microcapillaries (Eppendorf) with a needle diameter of 0.5 pm ± 0.2 pm, using 
the axial mode in which the microcapillary penetrates the cells at an angle of 45° (Green et 
al. 2007).
The FemtoJet is programmable and communicates with the micromanipulator to execute 
standardised injection routines. The injection parameters which can be optimised are 
injection pressure (Pi), injection time (Ti), and compensation pressure (Pc). The Pi is the 
pressure which is needed to drive the fluid from the capillary into the cells, and together with
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the Ti determines the volume of sample injected. It is vital to use an optimal Pi; using a high 
Pi risks damaging the internal structure of the cell while lower Pi values may result in 
inefficient injection. The Pc maintains a low positive pressure inside the capillary to prevent 
back filling of the needle, and will depend on the viscosity of the sample (Bartoli & Claycomb 
1997).
Using defined parameters across different experiments permits the controlled injection of 
reproducible volumes of injection sample into cells. Once the injection parameters have 
been set on the FemtoJet microinjector, the capillary is lowered to the focal plane just above 
the cells. The injection level is then determined by setting the z-limit on the 
micromanipulator -  this is the position on the z-axis at which the microcapillary will enter the 
cell. The choice of an appropriate z-limit is a critical parameter for successful Ml. If set too 
low it will penetrate through the whole cell and risk breaking the needle, or if positioned too 
high the needle will not penetrate the cell at all, in both cases resulting in unsuccessful Ml. 
The capillary is then brought back to a focal plane above the cell, and by activating the 
joystick key, the semi-automatic injection (Figure 4.2, A, B) starts with an axial movement to 
penetrate the cells. When the capillary has reached the injection level, the microinjector 
automatically switches from compensation pressure to injection pressure. The injection 
pressure is applied to the capillary according to the preset injection time. After injection has 
taken place, the pressure is switched back to the compensation pressure and the capillary 
returns along the same path (Figure 4.2, C) to its starting position.
All Ml experiments were carried out using the set-up described above. The glass culture 
chambers containing the adherent cells were placed on a heated microscope stage pre­
warmed to 37*0, onto which the micromanipulator was mounted.
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Microcapillary
Search level
Injection level
Figure 4.2. Schematic depicting semi-automated Ml into adherent cells
A, B, and C represent the axial movement of the microcapillary during an injection. Search level is the 
focal plane above the cell monolayer, and the injection level is the point on the z-axis at which the 
microcapillary enters the cell (Image reproduced from http://www.eppendorf.com)
4.2.3 O ptim isation o f M l param eters
Optimisation of Ml parameters was carried out using a Zeiss Axiovert 200 fluorescence 
microscope. All cDNAs, dyes or peptides to be microinjected were centrifuged at 17,000 xg 
for 1 h at 4 0  prior to loading the Ml needle, to remove any small particles which may block 
its tip. While loading the needle, great care was taken to avoid air bubbles which would 
prohibit successful injection. Ml into the adherent cells was carried out under phase contrast 
microscopy, initially using ranges of Pi (50-150 hPa), Pc (20-120 hPa) and Ti (0.1-0.5 secs).
Determinination of the most suitable Ml conditions was carried out in two stages. Firstly, 
propidium iodide was used as a marker of successful injection, using a range of times and 
pressures to find the optimal Pi, Pc and Ti parameters that did not cause cell damage such 
as bursting or prolonged deformation. Propidium iodide was injected into the cytoplasm of 
the cells under phase microscopy, and viewed immediately after Ml using fluorescence filters 
546nm/580-590nm (Zeiss Axiovert). Once the optimal Ml parameters had been identified,
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cDNA encoding enhanced green fluorescent protein (eGFP, Clontech) (250 pg/ml in 3M Tris, 
0.3M EDTA) was injected into the nuclei of HL-1 cells to verify that, under the Ml conditions 
determined above, the cells remained viable and expression-competent for sufficient time to 
express recombinant eGFP. Following Ml, the medium was replaced with fresh 
supplemented Claycomb media pre-warmed to 37*0, and the cells were viewed after 48 
hours using fluorescence filters 345-440nm/460-470nm (Zeiss Axiovert).
4.2.4 Ml of recombinant protein and cellular Ca2* imaging
Cells were prepared for Ml as described above (Section 4.2.1), before loading with Fluo- 
4AM (10 pM in 20% (w/v) pluronic acid F-127 dissolved in DMSO) in non-supplemented 
Claycomb medium pre-warmed to 37*C. The dye-contai ning solution was added to each 
chamber as a 200pl meniscus and incubated for 60 minutes (37^, 5% C 0 2, ~80% 
humidity). The cells were then immersed in a further 1800pl pre-warmed non-supplemented 
medium prior to Ca2+ imaging. Ca2+ dependent Fluo-4AM fluorescence was imaged using a 
Leica RS2 confocal microscope with an oil immersion 40x objective lens, using an 
Argon/Krypton laser (excitation at 488nm, and the fluorescence emission detected at 
500nm). 8-bit scaled data were acquired every 200 ms (5 Hz) in a field of view at 512 x 209 
pixel resolution. Resting cells were imaged for 1 minute (300 frames) prior to Ml in order to 
obtain a measurement of basal fluorescence levels.
Proteins synthesised and purified as described in Chapter 3 were injected into 
superconfluent ‘beating’ HL-1 cells using the optimal conditions determined above. The 
MagZ purified protein in injection buffer (100 mM potassium chloride, 5 mM potassium 
phosphate, pH 7.4; using chelex-treated dH20  (5g chelex /100ml dH20)), was co-injected 
with Alexa-647 dye conjugated to a 10,000 MW dextran (1 pg/ml stock) as a non- 
transferable cellular marker of injection that enables the identification of microinjected cells, 
in a protein:buffer:dye of 1:2:1 (v/v) ratio. The injection buffer has similar ionic and osmotic 
properties to those displayed by the intracellular environment, and facilitates complete cell
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recovery after Ml (Bartoli & Claycomb 1997). Approximately twenty cells per field of view 
were injected within a time frame of < 2 minutes, and allowed to recover for 5 minutes prior 
to imaging the cells for a further 60 seconds (300 frames). In every microinjection 
experiment RRL without l-Domain protein, yet processed using Zn2+-affinity purification 
under exactly the same conditions as the RRL samples in which the l-Domain protein was 
synthesised, was used as a control.
Data were acquired from regions of interest (ROIs) representing global Ca2+ 
environments, typically approximately 50 pm2 in area (~ 200 pixels). These were collected 
and analysed using Leica confocal software (Leica Microsystems, Heidelberg, Germany). 
Further analysis was carried out using the SALVO program in Matlab (Section 4.2.5).
Cells imaged
a  c m ; „ .  fo r lm in■ 60 m ins ^  ■ ■ 15 mins ^  . .
J 37°C / 5% CO. V ~ 7 37°C 15% CO, " V -°  /  ,
Immersed cells in a further 
1800 ill warm media
Ex 488 nm Em 500 nm
Cells loaded with Fluo-4 
under a 200 pi meniscus  pi r  i
Cells imaged 
for 1 min
\-J - t —  LCeils a ||0weci to '
i
I
Cells microinjected with 
RRL +/- IDB, under phase 
microscopy
recover from 
microinjection 
Ex 488 nm Em 500 nm
Figure 4.3. Summary of Ml and Ca2+ imaging protocol
4.2.5 Analysis of spatio-temporal Ca2+ handling in HL-1 myocytes
Spatio-temporal Ca2+ handling in coupled monolayers of fluo-4 loaded HL-1 myocytes 
was recorded at 5 Hz as described above (Section 4.2.4). Multi-parametric data analysis 
from 20 ROIs per field of view was performed using the Synchronicity-Amplitude-Length- 
Variability of Oscillation (SALVO) program (Barberini-Jammaers et al. 2008); an analytical 
platform for decoding intracellular Ca2+ handling using high-resolution confocal imaging of 
spontaneously-beating, coupled HL-1 monolayers. SALVO was programmed in Matlab 
(The Mathworks Inc.) based on Uhlen’s concepts of ‘peaks and valleys’ (Uhlen 2004) and
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enables the robust deciphering of the Ca2+ handling parameters outlined in Figure 4.4. 
SALVO provides a quantitative analysis of the release and sequestration processes 
underlying Ca2+ fluxes in HL-1 myocytes. By simultaneously measuring a number of 
inherently inter-linked parameters, it allows a holistic approach to considering the data and 
provides an indication of the cellular processes that may be involved in shaping Ca2+ fluxes.
For the purposes of this study, SALVO was used to quantitatively measure ten different 
parameters of Ca2+ handling, each of which can be related to specific processes in a cellular 
context, as summarized below (Table 4.1).
Frequency
H  H Control
Amplitude
Kinetics
sequestration)Kinetics
(release)
BaselineAreaLength
Cell 1
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
t  U  H  M  i
Synchronicity
Cell 2
‘Arrhythmic’
Inter-transient ‘noise’
Figure 4.4. Deciphering intracellular Ca2+ signalling in HL-1 cardiac cell monolayers
Schematic diagram illustrating SALVO analysis parameters (Barberini-Jammaers etal. 2008).
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SALVO parameter Description
Total noise 
(arbitrary units)
This parameter calculates the temporally-resolved Ca2+ 
fluctuations throughout the entire trace, both within and between 
the Ca2+ transients. This is an index of how cellular processes 
regulate Ca2+ release and sequestration.
Inter-transient Noise 
(arbitrary units)
This parameter calculates all sub-threshold fluctuations in Ca2+, 
that are distinct from clearly resolved amplitude and temporal 
characteristics of Ca2+ “transients” (where a transient is defined as 
an event exhibiting an amplitude more than 2-fold higher than the 
mean background signal noise).
Total: Inter-tansient 
Noise
Ratio of noise in the entire trace versus the inter-transient noise. 
An increased ratio is suggestive of a reduced inter-transient noise 
(defined above), indicating either (i) a reduced inter-transient 
noise, or (ii) reduced time between the transients.
Amplitude 
(fluorescence units)
The amplitude of the transient is calculated from the mean 
baseline of the trace, to the peak of each transient. The amplitude 
of the transient reflects the amount of Ca2+ released with every 
oscillation, and is therefore dependent on the amount of Ca2+ 
available in the SR Ca2+ stores.
Transient Length 
(s)
The transient length is calculated, in seconds, from the moment 
the transient exceeds the mean baseline until the moment it 
returns to the mean baseline level. This is related, to both the 
amplitude of the transient (i.e. the amount of Ca2+ available for 
release from intracellular stores) and to the rate of Ca2+ 
sequestration and reuptake into the stores, as reflected by the 
length to decay. The length of the transient is governed by a 
number of factors including (i) SERCA, (ii) mitochondrial uptake 
and (iii) plasma membrane extrusion, although the precise 
contribution of each of these remains unknown.
Area
(arbitrary units)
The area under the transient is calculated by integration. Since 
this parameter is dictated by both the transient length and 
amplitude, it serves to highlight any putative compensatory 
mechanisms exhibited by the cell, in response to changes in either 
the transient length or amplitude.
Rate Up 
(Fs1)
The transient rate up is the rate of Ca2+ release from the 
intracellular stores into the cell, and is calculated using the 
amplitude, and the length of time it takes for the transient to 
exceed the mean baseline level until it peaks.
Length to Decay 
(s)
The length to decay of the transient is the time taken from the 
peak of the transient, until it returns to baseline levels.
Rate of Oscillation 
(Hz)
Rate of oscillation is the rate at which the HL-1 myocytes produce 
transients per minute.
Synchronicity
(%)
Synchronicity calculated as a percentage of Ca2+ transients 
occurring simultaneously within the 20 ROIs being analysed. A 
value of synchronicity at 100% would show that all transients seen 
in these regions are occurring simultaneously, all of the time.
Table 4.1. Explanation of SALVO parameters
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In the beating syncytium, the most striking phenotype of cellular integrity and intercellular 
functionality is synchrony. Synchrony is a powerful indicator of intra- and inter-cellular Ca2+ 
handling, and was used in this context throughout this thesis. Considering that ID fragments 
were predicted to functionally modify RyR2/IP3R signalling, the phenotypic endpoint of such 
modulation would logically be expected to be changes in synchrony. The utility of the multi- 
parametric nature of SALVO allows the user to interrogate the mechanisms underlying 
alterations in synchrony. Alternatively, in the absence of changes in synchrony, SALVO 
analysis may resolve cellular mechanisms of plasticity in Ca2+ handling.
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4.3 Results
4.3.1 Optimised parameters for Ml
Following extensive evaluation of specific Ml protocols, optimal conditions for Ml 
efficiency and cell viability were determined at injection pressure (Pi) of 90 hPa, 
compensation pressure (Pc) of 80 hPa and an injection time (Ti) of 0.3 sec. These 
conditions gave a Ml efficiency of -95%  as observed by injection of propidium iodide, and 
-75% of the cells remained viable and able to express recombinant eGFP for at least 48 h 
(Figure 4.5).
A
B
Figure 4.5. Optimal Ml parameters confer efficient injection and cell viability.
Panel A: HL-1 cells injected with propidium iodide visualised by fluorescence microscopy (right) and a 
phase contrast image of the same field of view (left). Panel B: Fluorescence (left) and phase contrast 
microscopy (right) of HL-1 cells 48h after Ml with eGFP cDNA. Scale bar: 100pm
:-  •„ v
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4.3.2 Ml of recombinant proteins and markers into HL-1 myocytes
l-Domain proteins synthesised and purified as described in Chapter 3, were successfully 
microinjected into HL-1 myocytes, using the parameters described above. The use of a 647- 
alexa conjugated dye enabled the easy visual detection of microinjected cells (Figure 4.6, E). 
Importantly cell phenotype and Fluo-4 fluorescence appeared to be unaltered by Ml, 
indicating that Ml conditions were minimally invasive (Figure 4.6, B and D respectively). 
However, it can also be seen that the intensity of the Alexa 647 signal is not homogenous in 
all microinjected cells. The differences in signal intensity could be an artefact of the 
heterogeneity of cell size and shape, but it is also possible that it is an indicator of the 
amount of sample injected into each of the cells. Nevertheless, similar heterogeneity is 
evident in all experiments and thus should be normalised by the very large number of cells 
imaged (15-20 cells per experiment, n = 6-10).
Fluo-4 Alexa 647
Figure 4.6. Ml of proteins into HL-1 cells
Panel A. Phase contrast image of the field of view, the arrowhead shows the tip of the microcapillary 
moved to a focal plane above the cells. Panels B & C. Fluorescent signals prior to Ml. Panels D & 
E: the same field of view 5 minutes after Ml with Alexa 647 dextran. The Fluo-4 loaded cells appear 
unchanged (D) while the microinjected cells are clearly identifiable (E). Scale bar: 25 pm
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4.3.3 Ml of RRL affects some aspects of cell Ca2*-handling phenotype
Although the Fluo-4 data presented above suggested that, under optimised conditions, Ml 
was well tolerated by the cells, the Ml procedure itself may modulate some aspects of 
cellular phenotype and signalling. Consequently, rigorous control experiments were 
performed to evaluate whether any changes in Ca2+ handling were attributable to Ml. As 
described above (Section 4.2.4), Zn2+ affinity processed RRL that had not been used for 
producing 1-Domain protein was microinjected since this sample contains identical 
‘background’ proteins to samples in which the 1-Domain protein was synthesised. Control 
injections of ‘naive’ RRL were performed in all Ml experiments described in this thesis.
SALVO analysis (Figure 4.7) showed that injection of RRL into beating HL-1 myocytes did 
not alter the amplitude, length or area of Ca2+ transients (panels D, E and F respectively). 
There was also no significant change in the kinetics of Ca2+ handling (G and H). However, 
RRL-injected cells were characterised by significantly increased inter-transient noise (B), 
and the frequency of spontaneous Ca2+ transients was decreased from 0.74 ± 0.01 Hz in 
non-microinjected HL-1 cells to 0.58 ± 0.02 Hz in RRL-injected cells (I) (illustrated in Figure 
4.8). As anticipated, increased inter-transient noise (B) significantly augmented the ratio of 
total signal noise to inter-transient noise (C). Importantly, the overall synchronicity of the 
coupled monolayer, a direct index of the synchronisation of Ca2+ oscillations between 
neighbouring cells, was not affected by Ml (Figure 4.9).
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Figure 4.7. SALVO analysis of the effects of Ml on HL-1 myocyte monolayers
Spatio-temporal Ca2+ handling parameters in HL-1 myocytes injected with RRL controls (black) 
compared with non-injected W T HL-1 myocytes (grey), plotted from SALVO analysis of Ca2+- 
dependent Fluo-4 fluorescence (mean ± SEM, n = 7, 15-20 cells per experiment. The total number of 
cells is indicated in brackets). *  represents p<0.05 when compared with WT HL-1.
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5 F.U.
10 sec
k
RRL
Figure 4.8. Representative traces of WT and RRL-injected HL-1 myocytes
Traces show an increased level of inter-transient noise and a lower rate of oscillation in the RRL- 
injected HL-1 myocytes, compared with W T HL-1 cells. F.U. denotes arbitrary fluorescence units 
measured in defined regions of interest.
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Synchronicity
W THL-1 RRL
Figure 4.9. Synchronicity in WT HL-1 cells compared with RRL injected cells
Synchronicity within HL-1 myocytes monolayers injected with RRL controls (black) compared with 
non-injected WT HL-1 myocytes (grey), plotted from SALVO analysis of Ca2+-dependent Fluo-4 
fluorescence (mean ± SEM, n = 7, 15-20 cells per experiment. The total number of cells is indicated 
in brackets). No significant difference between RRL-injected and WT HL-1 was observed.
4.3.4 Ml of ID8 into HL-1 myocytes
Following the detailed assessment of the changes in HL-1 Ca2+ phenotype induced by Ml 
of RRL proteins (Figure 4.7 and Figure 4.9), it was possible to determine the specific effects 
of ID8 on Ca2+ handling in HL-1 cardiomyocytes. Figure 4.10 revealed that ID8 is associated 
with a decrease in total signal noise (A) -  from 585 ± 23.29 in RRL-injected cells to 446.6 ± 
9.067 in cells injected with ID8 -  which as predicted, was mirrored by an increase in the 
totahinter-transient noise ratio (C, 0.3412 ± 0.0117 with RRL to 0.3875 ± 0.0135 with ID8). In 
addition, ID8 injection was linked to a significant decrease in the average rate of Ca2+ release 
from 12.96 ± 0.6656 in the RRL-injected control cells to 8.003 ± 0.2215 in ID8-injected cells
(G). These ID8-mediated changes did not cause alterations in Ca2+ transient amplitude (D), 
length (E), area (F), decay time (H) and frequency of oscillation (I) which remained 
unchanged. Corroborating the data presented in Figure 4.9 above, cellular synchronicity 
was not affected (Figure 4.12).
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Figure 4.10. SALVO analysis of the effects of ID on HL-1 myocyte monolayers
Spatio-temporal Ca2+ handling parameters In HL-1 myocytes Injected with ID8 protein (white) 
compared with RRL-injected controls (black), plotted from SALVO analysis of Ca2+-dependent Fluo-4 
fluorescence (mean ± SEM, n = 7-9, 15-20 cells per experiment). *  represents p<0.05 when 
compared with RRL-injected control cells.
156
Chapter 4
RRL
5 F.U.
10 sec
Figure 4.11. Representative traces of HL-1 myocytes injected with RRL and ID6
Traces show an increased noise in HL-1 myocytes injected with ID8, compared with the RRL-injected 
controls. ID8 -injected cells also displayeda lower mean transient rate-up. F.U. denotes arbitrary 
fluorescence units measured in defined regions of interest.
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Figure 4.12. Ml of IDB does not alter synchronicity
Synchronicity within HL-1 myocytes monolayers injected with ID6 protein (white) compared with RRL- 
injected controls (black), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean 
± SEM, n = 7-9, 15-20 cells per experiment). No significant difference between HL-1 cells injected 
with RRL or ID8 protein was observed.
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4.4 Discussion
4.4.1 Conditions for successful Ml
This chapter describes the conditions necessary for the successful Ml of HL-1 myocytes 
while maintaining cellular function and viability. Using the optimised conditions, an injection 
efficiency of approximately 95% was achieved and more than 75% of cells remained viable 
for at least two days after Ml of cDNA into their nuclei. The successful expression of eGFP 
after Ml of the cDNA is fundamental in the success of this technique, because all gene 
expression is dependent on appropriately regulated Ca2+ signals, and shows that cells can 
tolerate the stress caused by Ml without disruption of the tightly regulated cellular Ca2+ 
handling. This provided a robust foundation for studying the effects of l-Domain proteins on 
Ca2+ handling in functionally- and electrically-coupled HL-1 myocytes and this will be 
considered in more detail in Chapters 5 and 6.
4.4.2 Ml affects some aspects of Ca2* handling in WT HL-1 myocytes
Like gene expression, synchronicity in contractile HL-1 myocytes is entirely dependent on 
co-ordinated Ca2+ fluxes. As discussed above, Ml did not alter overall cellular Ca2+ signalling 
over a 48 hour period. In a shorter time frame, Ml of RRL into HL-1 cells under the 
optimised conditions did not alter the synchronicity of the monolayer five minutes after 
injection, indicating that the regulation of Ca2+ fluxes was not sufficiently disrupted by Ml to 
result in asynchrony. In addition, Ml did not alter Ca2+ transient amplitude, length, and area. 
It did, however, have some effect on the inter-transient noise and transient rate. The 
increased ‘inter-transient noise’ which is a measurement of sub-threshold homeostatic Ca2+ 
fluctuations, that are distinct from the readily observed Ca2+ ‘transients’ (see Figure 4.8) was 
complemented by reduced frequency of Ca2+ transient oscillations. Whether the decrease in 
transient rate results in increased inter-transient noise, or vice versa remains to be 
determined. Interestingly, the increase in the ratio of totakinter-transient noise, along with
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the increase in inter-transient noise, suggest that there may be an increase in Ca2+ 
fluctuations within the transients themselves. This has also been observed in ongoing 
studies in our laboratory, though the underlying mechanism has not yet been established. 
These subtle changes in Ca2+ handling can only be detected using sophisticated approaches 
such as SALVO. Less detailed analyses would not distinguish such subtleties, which are 
well tolerated by the cell and result in no change to the synchronicity of the cell monolayer.
4.4.3 ID8 does not affect synchronicity in resting HL-1 myocytes
The data presented in this chapter emphasise that it is vital to have appropriate controls 
in order to unequivocally determine the effects of recombinant l-Domain proteins on cell 
function and phenotype. The findings above clearly show why all data derived from cells 
injected with l-Domain fragments must be compared with experiments in which the cells 
were microinjected with “naive” RRL.
Injection of ID8 appeared to have little effect in synchronous resting HL-1 cells and 
although subtle changes in some Ca2+ handling parameters, they did not manifest as 
alterations in synchronicity. Despite the small changes in noise and rate of Ca2+ release, 
which may imply some interaction with SERCA, the transient characteristics and 
synchronicity remained unchanged compared with the control cells. However, ID8 may have 
a more pronounced effect in HL-1 cells in an arrhythmic state, and this will be discussed in 
the next chapter.
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Chapter 5
5.1 Introduction
5.1.1 Cardiac glycosides
Cardiac glycosides are a class of plant-derived and animal-derived steroids used clinically 
to increase contractile force in patients with cardiac disorders (Hauptman et al. 1999a; 
McConkey et al. 2000). Their main effect is to inhibit the ubiquitous cell surface enzyme 
Na+/K+-ATPase, which transports Na+ ions out of cells and K+ ions into cells, thus 
maintaining the ion gradients between intracellular and extracellular compartments 
necessary for normal cell function. This results in increased intracellular Na+ and Ca2+, and 
decreased intracellular K+. The increased intracellular Ca2+ promotes muscle contraction 
and cardiac contractile force (i.e. a positive inotropic effect). Na+/K+-ATPase has two 
subunits, alpha and beta, with the extracellular domain of the alpha subunit containing a 
stereospecific-binding site for the cardiac glycosides and related steroids (Buckalew 2005).
Cardiac glycosides can be divided into subgroups including cardenolides, compounds 
identified originally in plants, and bufadienolides, identified in toad venom; both of which 
have also been found endogenously in humans (Nesher et al. 2007). They share a common 
general structure - a steroid nucleus with a lactone ring at C-17 and a hydroxyl group at C-14 
(Figure 5.1). The 5- and 6-membered lactone rings, in cardenolides and bufadienolides, 
respectively, are considered the most essential functional group of these substances.
The most widely studied cardenolides are digoxin and ouabain, which are derived from 
the plant genera Digitalis and Strophanthus respectively, and have also been purified from 
human plasma and the hypothalamus, and identified by mass spectroscopy (Goto et al. 
1990; Hamlyn et al. 1991; Mathews et al. 1991; Qazzaz et al. 2004).
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Figure 5.1. Structures of endogenous cardiac glycosides belonging to the cardenolide and 
bufadienolide groups.
Taken from Schoner & Scheiner-Bobis (2007)
5.1.1.1 Digoxln
The steroid glycoside digoxin was first isolated from Digitalis lanata in 1930, and since 
then this compound and other similar derivatives have been developed into drugs which are 
still used to treat HF and atrial fibrillation. The effects of digoxin have been widely studied, 
and it has a well characterised effect on RyR2. Digoxin is known to increase cardiomyocyte 
cytosolic [Ca2+] via its inhibitory action on the Na+/K+-ATPase (Reuter et al. 2002), whereby 
the resulting [Na+] increase is removed from the cell by the NCX, resulting in an inward Ca2+ 
flux. However, digoxin also directly activates RyR2, and therefore its inotropic effect may 
also reflect its direct effect on RyR2 (McGarry & Williams 1993; Sagawa et al. 2002).
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5.1.1.2 Ouabain
Ouabain is a cardiac glycoside chemically related to the digitalis compound found in 
foxgloves (Figure 5.1). It has been identified in mammalian tissues and, like other steroids, 
is synthesised in the adrenal glands, as well as locally produced in other tissues such as the 
hypothalamus (Kawamura et al. 1999, 2001; Schoner 2000, 2001). In humans, ouabain 
concentrations increase rapidly in blood during physical exercise and decline quickly after 
rest. About half of people of European descent with hypertension have abnormally high 
levels of ouabain, as do patients with congestive HF (Arnon et al. 2000; Schoner 2001).
Until recently, it was not known how ouabain directly affects heart function at a cellular 
level. Recent studies by Aizman et al. (2001) revealed a new pathway of ouabain signalling 
through receptors on the plasma membrane, which induce slow oscillations of intracellular 
Ca2+ levels and thereby activate the transcription factor NF-kB, a key regulator of cell 
activity. Aizman et al. showed that, at low concentrations which only partially inhibit Na^K*- 
ATPase, ouabain acts as a hormone and a signal transducer and activator for NF-kB. Slow 
Ca2+ oscillations are produced through the interactions of other proteins located on the 
plasma membrane, including store-operated Ca2+ channels (SOCCs) and L-type voltage- 
gated Ca2+ channels, and IP3 receptors on the ER/SR. This leads to the translocation of NF- 
kB into the nucleus where it regulates several genes involved in cardiac physiology.
5.1.2 Mechanisms underiying cardiac arrhythmias
Cardiac arrhythmias result from aberrant impulse initiation or impulse conduction or a 
combination of both. Abnormal impulse initiation is generally believed to originate from 
either automaticity or triggered activity (Wit & Rosen 1983). Automaticity refers to the ability 
of myocardial cells to initiate spontaneous depolarisation during the diastolic interval; 
however it is triggered activity which is thought to be most closely linked to Ca2+-mediated 
arrhythmogenesis. Studies using three-dimensional mapping suggest that most VT in non- 
ischaemic HF is initiated by such mechanisms (Janse 2004; Pogwizd et al. 1998, 2004).
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Triggered activity is so-called because, unlike the spontaneous depolarisations of 
automaticity, the impulse can only occur if it follows a previous AP i.e. it is triggered by the 
previous impulse. Triggered impulses are caused by sub-threshold membrane 
depolarisations, termed afterdepolarisations. These are second depolarisations that occur 
either during repolarisation of the previous AP (EADs) or after repolarisation is complete 
(DADs) as shown in Figure 5.2 (Scoote & Williams 2002).
DADs result from a transient inward current evoked by spontaneous Ca2+ release from 
the SR under conditions that favour accumulation of cellular Ca2+. If this inward current is 
sufficient to cause a DAD with an amplitude exceeding the threshold potential, depolarisation 
will occur. The abnormal impulse generated from this can cause a triggered arrhythmia if 
surrounding polarised cells propagate the wave, and this is believed to be the underlying 
cause of bi-directional ventricular tachycardia (VT) (Wit & Rosen 1983; Scoote & Williams 
2002). Several factors can increase the amplitude of DADs, and therefore increasing the 
probability of triggered arrhythmias, including an increase in the rate of the triggering action 
due to an increased heart rate, and an increase in intracellular Ca2+ load.
Arrhythmias associated with RyR2-linked channelopathies such as CPVT (see Chapter 1) 
take the form of bi-directional and/or polymorphic VT, both of which are capable of 
degenerating into ventricular fibrillation and SCD (Leenhardt et al. 1995a; Priori et al. 2001, 
2002). Bi-directional VT is a rare type of arrhythmia, normally associated with intracellular 
Ca2+ overload caused by digoxin toxicity (Ma et al. 2001).
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Figure 5.2. Schematic representation of early and delayed afterdepolarisations with respect to 
the normal cardiac action potential.
A normal AP: (A) may be extended in duration (B) such that an EAD is generated (C) during the 
repolarisation phase. Dispersion of depolarisation time throughout ventricle promotes re-entrant 
arrhythmia generation. A DAD (D) only occurs after a normal AP (A) is completed and the cell has 
returned to the resting membrane potential. If the DAD is of sufficient magnitude to reach a 
depolarising threshold a new AP (E) can occur which itself can initiate a triggered arrhythmia. Taken 
from Scoote & Williams (2002).
5.1.3 Cardiac glycosides in arrhythmia
The mechanism by which cardiac glycosides, such as digoxin and ouabain, cause 
arrhythmia is known to be via Ca2+ overload and DAD generation within cardiomyocytes 
(Hauptman & Kelly 1999b; Rosen & Danilo 1980). This is supported by evidence from 
isoproterenol induction of arrhythmia in CPVT that DADs occur as a result of this stimulus 
and lead to the generation of bi-directional VT (Nakajima et al. 1997). Cardiac glycosides 
increase intracellular [Ca2+], and thereby create conditions which favour DAD generation. 
They inhibit the Na+/K* ATPase pump, causing excess cytosolic Na+ to be removed by 
sarcolemmal NCX in exchange for inward bursts of Ca2+. CPVT-linked mutations in RyR2 
are also associated with bi-directional VT, and this raises the possibility that the mechanism 
whereby glycosides bring about this arrhythmia is also linked to a direct action on RyR2 
(Scoote & Williams 2002). Studies have shown that cardiac glycosides do indeed have a 
direct action on RyR2 (McGarry & Williams 1993; Sagawa et al. 2002), and lead to an 
increase in channel open probability. It is possible that the bi-directional VT is a
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manifestation of DADs, brought about by an increased diastolic release of Ca2+, which itself 
is an indicator of abnormal RyR2 function.
5.1.4 Objectives of this chapter
The effect of ouabain on HL-1 myocytes has been studied previously in our laboratory 
(Barberini-Jammaers et al. 2008), and has been found to be a robust ‘arrhythmogen’ 
perturbing both Ca2+ handling and synchronous contractility. In this chapter, normal 
synchronous beating of HL-1 myocytes was disrupted using ouabain and the effects of ID8 
on ouabain-induced Ca2+ handling dysfunction and dyssynchrony was determined.
5.1.5 Specific Hypothesis
Following on from the work presented in the previous chapter, where ID8 was 
successfully delivered into HL-1 myocytes by microinjection, this chapter now specifically 
addresses the functional impact of recombinant ID8 on the Ca2+ handling phenotype of 
ouabain-treated HL-1 cardiomyocytes.
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5.2 Methods
The effect of ID6 on ouabain-induced intercellular dyssynchrony was investigated by two 
distinct approaches. The first strategy analysed the effects on ID6 on cells which had been 
treated with ouabain prior to Ml, and therefore had perturbed intracellular Ca2+ cycling and 
reduced intercellular synchrony. The second strategy looked at the effects of ID8 Ml prior to 
ouabain treatment of the cells.
5.2.1 Ml of cells before and after incubation in ouabain
Cells were prepared for Ml as described in section 4.2.1, before loading with Fluo-4AM 
(10 pM in 20% w/v pluronic acid F-12 / DMSO) in non-supplemented Claycomb media pre­
warmed to 3713. The dye-containing solution was added to each chamber as a 200pl 
meniscus and incubated for 60 minutes (3713, 5% CO 2, -80%  humidity).
For cells incubated in ouabain prior to Ml, the cells were then immersed in a further 
1800pl pre-warmed non-supplemented media containing 100 nM ouabain 40 mins prior to 
Ca2+ imaging, as summarised in Figure 5.3. The cells were imaged for 1 minute (300 
frames) as described in section 4.2.1 prior to Ml in order to obtain a measurement of basal 
fluorescence levels.
100 nM
ouabain Cells imaged
An for 1 min
60 m ins ^  . . 40 m ins ^   ^ ,
37°C I 5% CO, W  37°C I 5% CO, r  V~   ^
Cells loaded with Fluo-4 Immersed cells in a further
under a 200 Ml meniscus 1800 pi warm media ™  rT's%  _
Ex 488 nm Em 500 nm
I
Cells microinjected with 
RRL +/- IDB, under phase 
Cells imaged ^  microscopy
for 1 min
^  J  ^ 5 mins i
Cells allowed to ^  
recover from 
microinjection
Ex 488 nm Em 500 nm
Figure 5.3. Ml of HL-1 myocytes after incubation in ouabain
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For experiments where the cells where microinjected before incubation in 100 nM 
ouabain, the MagZ purified protein (Chapter 3) was co-injected with the Alexa-dextran 
conjugate in injection buffer. Twenty cells per field of view were injected within a time frame 
of < 2 minutes, and allowed to recover for 5 minutes before the addition of 100 nM ouabain. 
The injected cells were incubated in the ouabain-containing media for 40 mins, and were 
subsequently imaged for 60 seconds, as shown in Figure 5.4
Cells imaged
►  I  J  37oc 15% CO, ^
60 mins ^  , 15 mins for 1 min
37°C /5% C 02 ^  37°C / 5% C02
Cells loaded with Fluo-4 Immersed cells in a further
under a 200 pi meniscus 1800 pi warm media
Ex 488 nm Em 500 nm
I
A. Cells microinjected with 
100 nM I /  RRL+ /- IDB, under phase
ouabain | microscopy
Cells imaged 
for 1 min
^ _________ j  ^  40 mins ^ __________j  g 5 mins i /  i
37°C 15% C02 Cells allowed to
recover from
microinjection 
Ex 488 nm Em 500 nm
Figure 5.4. Ml of HL-1 myocytes prior to incubation in ouabain
As in previous experiments, MagZ-enriched ID6 protein (Chapter 3) was injected into 
superconfluent, spontaneously oscillating (0.74 ± 0.01 Hz) HL-1 cells using the optimal 
conditions determined in Chapter 4. The MagZ purified protein (Chapter 3) was co-injected 
with the Alexa-dextran conjugate in injection buffer. Approximately twenty cells per field of 
view were injected within a time frame of < 2 minutes, and allowed to recover for 5 minutes 
prior to imaging the cells for a further 60 seconds. As before, naive RRL not expressing any 
l-Domain protein and subjected to zinc-affinity purification under exactly the same conditions 
as the samples containing ID6 was used as negative control in all Ml experiments, and data 
were acquired and analysed as in Chapter 4.
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5.3 Results
5.3.1 Effect of ouabain on beating HL-1 myocytes
The concentration of ouabain used here (100 nM) was determined previously as robustly 
ablating intercellular Ca2+ synchrony in cardiac myocytes (George, unpublished). The extent 
of ouabain-induced disruption is so great, that it was noticeable by eye during confocal 
microscopy. SALVO analysis of spatio-temporal Ca2+ handling parameters in HL-1 cells 
subjected to 100 nM ouabain for 40 minutes showed a significant change in almost every 
aspect of Ca2+ handling compared with WT HL-1 cardiac myocytes (Figure 5.6). The total 
noise (A) remained the same in ouabain treated cells possibly implying the same level of 
Ca2+ ionic movement in both models despite the ouabain-evoked disruption of Ca2+ 
regulation. There were, however, significant increases in inter-transient noise (B) and the 
ratio of totahinter-transient noise (C). The shapes of the transients were also altered in 
ouabain-treated cells (Figure 5.5), displaying significantly increased amplitude, length and 
area (D, E and F respectively). Ouabain also affected the kinetics of Ca2+ release and 
sequestration, manifested as significantly increased rate up (G) and length to decay of 
transients (H), as well as a strikingly decreased transient rate (I). Together, the changes in 
these parameters have a marked affect on the synchronicity of the HL-1 monolayer, leading 
to a significant decrease in the percentage synchronicity observed (Figure 5.7), validating 
this as a model of Ca2+-induced dyssynchrony in coupled HL-1 cell monolayers.
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Figure 5.5. Representative traces of WT and ouabain treated HL-1 myocytes
Theses traces illustrate the differences in Ca2+ observed in WT HL-1 cellls, and HL-1 cells treated with 
ouabain. The ouabain-treated cells exhibit large slow Ca2+ oscillations, with a profound loss of 
synchrony compared with the synchronously coupled WT-HL-1 cells. F.U. denotes arbitrary 
fluorescence units measured in defined regions of interest.
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Figure 5.6. SALVO analysis of the effects of ouabain on HL-1 myocyte monolayers
Spatio-temporal Ca2+ handling parameters in HL-1 myocytes incubated with 100 nM ouabain for 40 
mins (dark grey) compared with WT HL-1 myocytes (light grey), plotted from SALVO analysis of Ca2+- 
dependent Fluo-4 fluorescence (mean ± SEM, n = 7, 15-20 cells per experiment. The total number of 
cells is indicated in brackets). *  represents p<0.05 when compared with WT HL-1.
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Figure 5.7. Synchronicity in WT HL-1 cells compared with RRL injected cells
Synchronicity within HL-1 myocytes monolayers incubated with 100 nM ouabain for 40 mins (dark 
grey) compared with WT HL-1 myocytes (light grey), plotted from SALVO analysis of Ca2+-dependent 
Fluo-4 fluorescence (mean ± SEM, n = 7, 15-20 cells per experiment. The total number of cells is 
indicated in brackets). *  represents p<0.05 when compared with WT HL-1.
5.3.2 Ml of HL-1 cells following pre-treatment with ouabain
5.3.2.1 Control experiments
As discussed in Chapter 4, Ml did affect some facets of Ca2+ handling in HL-1 myocytes 
and suitable controls must be in place in order to discriminate between the effects of Ml and 
the effects of ID6 in HL-1 myocytes. Throughout the following section, the negative control 
was HL-1 cells treated with 100 nM ouabain for 40 minutes prior to Ml with MagZ-purified 
naive RRL (i.e. RRL expressing no l-Domain protein).
Injection of RRL into ouabain-treated HL-1 cells caused an increase, from 813 ± 25.48 to
1374.4 ± 67.33, in total noise (Figure 5.8, A) but no significant change in inter-transient noise 
(B) or the ratio of totakinter-transient noise (C) when compared with WT HL-1 cells treated 
with ouabain. The size of the transients in ouabain-treated HL-1 myocytes was 
approximately 50% smaller than in WT HL-1 cells, with a decreased amplitude, length and 
area (D, E, and F respectively). Furthermore, there was a decrease in the length to decay
(H) and an increased transient rate (I).
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For some of the Ca2+-handing parameters, such as amplitude, length and area of the 
transients (D, E and F, respectively), injection of RRL into ouabain-treated cells caused 
these parameters to shift closer to the values observed in untreated WT HL-1 cells. 
However, it is important to note that despite these changes, there was no restoration of 
cellular synchrony by RRL in the ouabain-treated HL-1 monolayer (Figure 5.9).
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Figure 5.8. SALVO analysis of the effects of Ml on HL-1 myocyte monolayers pre-treated with 
100 nM ouabain
Spatio-temporal Ca2+ handling parameters in non-injected HL-1 myocytes incubated with 100 nM 
ouabain (oua, dark grey) compared with ouabain-treated HL-1 myocytes injected with RRL (oua+RRL, 
black), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 
15-20 cells per experiment. The total number of cells is indicated in brackets). *  represents p<0.05 
when compared with ouabain-treated HL-1 myocytes. Illustrative values for HL-1 WT cells (light grey) 
are from Figure 5.6, and were not included in statistical analyses with injected cells.
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Figure 5.9. The Ml technique does not restore synchrony in ouabain-treated myocytes
Synchronicity within HL-1 myocytes monolayers incubated with 100 nM ouabain (oua, dark grey) 
compared with ouabain-treated HL-1 myocytes injected with RRL (oua+RRL, black), plotted from 
SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 15-20 cells per 
experiment. The total number of cells is indicated in brackets). No significant difference between 
RRL-injected and non-injected ouabain-treated HL-1 cells was observed. Values for HL-1 WT cells 
(light grey) shown here are from Figure 5.7, and were not included in statistical analyses with injected 
cells.
5.3.2.2 Effect of ID8 on ouabain treated cells
Using ouabain-treated HL-1 cells injected with RRL as a negative control, the effect of ID8 
on ouabain-treated HL-1 myocytes was investigated (Figure 5.10). ID8 caused a significant 
decrease in total noise (A) and inter-transient noise (B), while the ratio of total:inter-transient 
noise (C) remained unchanged compared with the RRL-injected control cells. There was 
also a significant decrease in the amplitude (D) of the transients in cells injected with ID8. 
The rate up was also significantly decreased (G), while the length to decay was significantly 
higher (H) and the rate of the transients remained unchanged (I). Most strikingly, ID8 
partially restored the synchrony in the ouabain-treated monolayer, which increased 
significantly to 34.6% ± 2.4 in IDB-injected cells from 18.1% ± 0.94 in the RRL-injected 
control cells (Figure 5.11). Furthermore, as shown above, synchrony in WT HL-1 cells was 
49.4% ±4.19  and is comparable to the level of synchrony in ouabain-treated cells injected 
with ID8.
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Figure 5.10. SALVO analysis of the effects of ID on HL-1 myocyte monolayers pre-treated 
with 100 nM ouabain
Spatio-temporal Ca2+ handling parameters in RRL-injected ouabain-treated HL-1 controls (oua+RRL, 
black) compared with IDB-injected ouabain-treated HL-1 (oua+IDB, white), plotted from SALVO 
analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 15-20 cells per experiment. 
The total number of cells is indicated in brackets). *  represents p<0.05 when compared with RRL- 
injected ouabain-treated HL-1 controls. Values for HL-1 WT cells (light grey) shown here are from 
Figure 5.6, and were not included in statistical analyses with injected cells.
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Figure 5.11. IDB partially restores synchrony in dyssynchronous ouabain-treated HL-1 
myocytes.
Synchronicity within RRL-injected ouabain-treated HL-1 controls (oua+RRL, black) compared with IDB- 
injected ouabain-treated HL-1 (oua+IDB, white), plotted from SALVO analysis of Ca2+-dependent Fluo- 
4 fluorescence (mean ± SEM, n = 5-7, 15-20 cells per experiment. The total number of cells is 
indicated in brackets). *  represents p<0.05 when compared with RRL-injected ouabain-treated HL-1 
controls. Although Ml of ID restored synchrony to levels which were not statistically different from 
that in HL-1 WT cells (light grey), a direct statistical comparison between WT and microinjected cells 
is not valid.
5.3.3 Effect of ouabain on HL-1 myocytes following ID8 transduction
5.3.3.1 Controls
Next, the effect of ouabain on cells already microinjected with ID6 was investigated, to 
see whether the stabilising effects seen were maintained. Once again appropriate controls 
were set up. In this case, the controls cells were microinjected with MagZ-purified RRL 
containing no l-Domain protein, then subjected to 100 nM ouabain for 40 minutes.
When compared with ouabain-treated WT HL-1 cells, there was a significant difference in 
all the parameters analysed (Figure 5.12) in cells microinjected with RRL prior to the addition 
of ouabain. However, once again despite all of these changes, the synchrony within the 
monolayer remained virtually identical and RRL had no corrective effect on cellular 
dyssynchrony (Figure 5.13).
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Figure 5.12. SALVO analysis of the effects of Ml on HL-1 myocyte monolayers prior to 
incubation with 100 nM ouabain
Spatio-temporal Ca2+ handling parameters in ouabain-treated HL-1 controls (oua, dark grey) 
compared with HL-1 myocytes injected with RRL prior to incubation with ouabain (RRL+oua, hatched), 
plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 6-7, 15-20 
cells per experiment. The total number of cells is indicated in brackets). ★ represents p<0.05 when 
compared with ouabain-treated HL-1 controls.
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Figure 5.13. Ml before ouabain-treatment does not alter ouabain-induced dyssynchrony
Synchronicity within ouabain-treated HL-1 controls (oua, dark grey) compared with HL-1 myocytes 
injected with RRL prior to incubation with ouabain (RRL+oua, hatched), plotted from SALVO analysis 
of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 6-7, 15-20 cells per experiment. The total 
number of cells is indicated in brackets). No significant difference was found in RRL-injected ouabain- 
treated cells compared with ouabain-treated HL-1 controls. Values for HL-1 WT cells (light grey) 
shown here are from Figure 5.6, and were not included in statistical analyses with injected cells.
5.3.3.2 Effect of ouabain-treatment on HL-1 myocytes after Ml of IDB
Using the above cells as a negative control, the effect of ouabain-treatment on HL-1 
myocytes after Ml of ID8 was investigated (Figure 5.14). In this case, ID8 significantly 
increased the inter-transient noise (B) and the ratio of total:inter-transient noise (C). The 
amplitude of the transients (D) and the rate up (G) were also significantly increased in cells 
containing ID8, while the rate of transients (I) was significantly slower. The transient length 
(E), area (F) and length to decay (H) remained unchanged. Under these conditions, ID8 did 
not restore synchrony in the cell monolayer (Figure 5.15).
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Figure 5.14. SALVO analysis HL-1 myocytes treated with ouabain after Ml with ID8
Spatio-temporal Ca2+ handling parameters in HL-1 myocytes injected with ID8 prior to incubation with 
ouabain (IDB+oua, spotted) compared with injection of RRL prior to incubation with ouabain (RRL+oua, 
hatched), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 6-7, 
15-20 cells per experiment. The total number of cells is indicated in brackets). *  represents p<0.05 
when compared with RRL-injected ouabain-treated HL-1 controls.
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Figure 5.15. Ml of ID8 prior to ouabain-treatment does not prevent ouabain-induced 
dyssynchrony
Synchronicity within ouabain-treated HL-1 myocytes injected with ID8 prior to incubation with ouabain 
(IDB+oua, spotted) compared with injection of RRL prior to incubation with ouabain (RRL+oua, 
hatched), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 6-7, 
15-20 cells per experiment. The total number of cells is indicated in brackets). No significant 
difference was found between IDB-injected and RRL-injected ouabain-treated cells.
5.3.4 Bystander effect
During the analysis of the above data, in each field of view, non-microinjected cells 
exhibited some of the same characteristics as cells which had been microinjected (Figure 
5.16). This unexpected and intriguing finding was termed the ‘bystander effect’ and will be 
discussed below.
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Figure 5.16. Illustration of non-microinjected bystander cells
The three panels show confocal images of Fluo-4 loaded cells. Cells containing Alexa 647 have been 
microinjected. Overlay shows microinjected (black circle) and non-microinjected ‘bystander’ cells 
(white circles). Scale bar: 25 pm
5.3.4.1 Bystander effect in HL-1 cells microinjected following pre-treatment with
ouabain
Figure 5.17 shows SALVO analysis of ouabain-treated cells which have not been 
microinjected, compared to those in the same field of view which have been injected. In 
every case, there is no significant difference between the injected and non-injected cells. 
This is particularly noticeable in the parameters where there was a significant difference 
between the control RRL-injected cells and those injected with ID6 as discussed above 
(indicated on Figure 5.17 by * ) .  Most importantly, ouabain-induced dyssynchrony was 
eliminated both in cells which had been injected with ID6 and in cells in the same field of 
view which had not been microinjected (Figure 5.18).
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Figure 5.17. SALVO analysis shows a bystander effect in non-injected ouabain-treated HL-1 
myocytes
Non-injected HL-1 myocytes (RRL - and ID6 -) exhibit the same alterations in most spatio-temporal 
Ca2+ handling parameters as those injected with RRL or ID8 after incubation with 100 nM ouabain 
(RRL + and ID , respectively), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence 
(mean ± SEM, n = 5-7, 15-20 cells per experiment.). *  represents p<0.05 when compared with RRL- 
injected ouabain-treated HL-1 controls.
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Figure 5.18. Ouabain-treated HL-1 myocytes not injected with IDB showed a comparable level 
of synchrony as those containing IDB.
Non-injected bystander cells (ID8 -) showed the same restoration of cellular synchrony as those 
injected with ID8 in the same field of view, plotted from SALVO analysis of Ca2+-dependent Fluo-4 
fluorescence (mean ± SEM, n = 5-7, 15-20 cells per experiment). *  represents p<0.05 when 
compared with RRL-injected ouabain-treated HL-1 controls.
5.3.4.2 Bystander effect in HL-1 cells microinjected prior to treatment with ouabain
In HL-1 cells that were injected prior to the addition of ouabain, there was a significant 
difference in the length (E) and area (F) of the transient, and in the length to decay (H) 
between cells injected with RRL and those not injected (Figure 5.19, indicated by #). In the 
parameters where there was a significant difference between the control RRL-injected cells 
and those injected with ID8 as discussed above (indicated on Figure 5.19 by * ), no 
significant change was seen between IDB-injected cells and non-injected bystanders.
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Figure 5.19. SALVO analysis shows a bystander effect in non-injected ouabain-treated HL-1 
myocytes
Non-injected HL-1 myocytes (RRL - and ID6 -) exhibit the same alterations in some spatio-temporal 
Ca2+ handling parameters as those injected with RRL or ID8 after incubation with 100 nM ouabain 
(RRL + and ID , respectively), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence 
(mean ± SEM, n = 5-7, 15-20 cells per experiment). *  represents p<0.05 when compared with RRL- 
injected ouabain-treated HL-1 controls.
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Figure 5.20. Ml of ID8 prior to ouabain-treatment does not restore ouabain-induced 
dyssynchrony in injected or bystander cells.
Non-injected bystander cells (ID8 -) showed the same level of synchrony as those injected with ID8 in 
the same field of view, plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± 
SEM, n = 5-7, 15-20 cells per experiment). *  represents p<0.05 when compared with RRL-injected 
ouabain-treated HL-1 controls.
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5.4 Discussion
5.4.1 Alterations to some Ca2+ handling parameters do not manifest as altered 
intercellular synchrony
Results presented in this chapter corroborated those from Chapter 4 and showed that the 
Ml procedure perturbs some aspects of Ca2+ handling (summarised in Table 5.1). It has also 
been shown that despite these changes, the synchronicity of the myocyte monolayer is not 
altered as a result of these perturbations. This indicates that although precise Ca2+ 
regulation is vital for maintaining regular, synchronous contractions in cardiac cells, the cells 
are able to robustly compensate for a surprisingly large degree of disruption in Ca2+ and still 
maintain an overall regulated synchronously beating state.
Table 5.1 shows that it is not possible at this stage to pin-point one or a combination of 
parameters which determine whether or not intercellular synchrony in cardiac cells is 
perturbed, but further more detailed analyses of each of these parameters may give an 
insight into the mechanism underlying the regulation of synchronous contraction in cardiac 
myocytes. Since the experimental work presented in this thesis was completed, new studies 
are beginning to unravel the relationships between Ca2+ handling, rhythmicity and synchrony 
in coupled cardiac monolayers (Silvester et al. 2009).
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Table 5.1. Summary of alterations of spatio-temporal Ca2+ handling parameters
Total Noise
Intertransient
Noise
Totahlntertransent
Noise
Am
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Transient Length
>
00)
Rate 
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to 
Decay
Rate 
of O
scillation
S
ynchronicity
HL-1 + RRL
— X X X —
HL-1 + IDB X — X — — — X — — —
HL-1 + oua
— X X X X X X X X si/
HL-1 + oua +RRL X — — X X X — X X —
HL-1 + oua +IDB X X — X — — X X — *
HL-1 + RRL + oua X X X X X X X X X —
HL-1 + IDB + oua
— X X X — — X — X —
Table summarising the changes observed in microinjected cells compared with controls, as discussed 
above. (-) refers to an unchanged parameter; ( X )  indicates a significant change compared to the 
appropriate control; ( 'I') and (si/) indicate a significant increase or decrease in cellular synchronicity.
5.4.2 Effect of ID8 on arrhythmic HL-1 myocytes
Ouabain-dependent increase in [Ca2+] has been shown to occur in cardiac muscle cells 
(Santana et al. 1998), where ouabain binding to Na+/K+-ATPase is thought to mediate 
conformational transitions to adjacent Na+ channels, thereby allowing conduction of Ca2+ and 
a local increase in Ca2+ levels. In a model of ouabain-induced Ca2+-overload and 
intercellular dyssynchrony, which from a mechanistic perspective closely mimics the events 
underlying malignant human arrhythmia, ID6 reduced the total and inter-transient noise in the 
cell, which reflects a reduction in sub-threshold Ca2+ fluctuations. The most striking effect of 
ID6 is the restoration of synchrony in the ouabain treated cells, to a level which is
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comparable to that seen in WT HL-1 cells.
This effect of ID8 is corroborated by FRET reporter studies carried out by Dr Chris 
George, which also showed that ouabain-treated cells had significantly lower signal 
variability in the presence of ID8 (Figure 5.21).
Interestingly, the restoration of synchrony by ID8 was not observed in cells which were 
microinjected prior to the addition of ouabain, implying that the potential beneficial effects of 
ID8 on normalising cellular Ca2+ cycling may be restricted to those cells in which Ca2+ cycling 
is already perturbed. The mechanistic basis of this finding remains to be explored further.
This chapter has shown that MagZ-purified ID8 synthesised in a cell-free expression 
system has a ‘normalising’ effect on intercellular synchrony in ouabain-disrupted HL-1 
myocytes. Next, we investigated if this effect could be reproduced using ID8 protein 
expressed in other systems, and these findings will be presented in the following chapter.
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Figure 5.21. FRET reporter studies of the effect of ID8 on ouabain-treated HL-1 myocytes.
Kindly supplied by Dr Chris George. Panel A: Schematic showing the FRET linker inserted at the 
start of the l-Domain. Panel B: FAC sorted HL-1 cells expressing the FRET reporter. CFP (left 
panel) and YFP (right panel) show identical localisation. Scale bare represents 20pm. Panel C: 
Traces showing the ratio of CFP:YFP, where the magnitude of the ratio indicates resting CFP:YFP 
signal. Signal variability is interpreted as changes in channel stability. Panel D: Bar chart showing 
the quantification of SV (mean ± SEM). *  and # represent p<0.05 when compared to HL-1 WT and 
ouabain-treated HL-1 myocytes, respectively.
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5.4.3 Bystander effect
Section 5.3.4 described the observation that cells not subjected to Ml displayed the same 
alterations in Ca2+ handling as neighbouring cells which had been injected with RRL or ID8. 
This ‘bystander effect’, although not previously reported in cardiac cells, has been observed 
in other ongoing studies in our laboratory (Fry 2008), where cells transfected with ID8 show 
similar traits to neighbouring non-transfected cells.
The ‘bystander effect’ has been regularly reported in the study of immunology, and in 
cancer therapy after exposure to ionising radiation treatment in cancer therapy, whereby 
irradiated cells may also transmit damage signals to non-irradiated cells in a population, 
leading to the occurrence of the same genetic effects in these ‘bystander’ cells that 
themselves receive no radiation exposure (Morgan & Sowa 2007).
In the experiments described here, non-injected HL-1 cardiomyocytes exhibit similar 
changes in Ca2+ handling to cells which have been injected with ID8. The cause of the 
bystander effect is yet to be determined, and will be discussed in more detail in Chapter 8.
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Chapter 6
6.1 Introduction
6.1.1 E. coli as a system for protein expression
E. coli is one of the most successful vehicles for over-expression of both prokaryotic and 
eukaryotic proteins and remains the most efficient widely-used host for recombinant protein 
production (Miroux & Walker 1996; Saida et al. 2006). Well-known genetics, high 
transformation efficiency and inexpensiveness are the main factors that contribute to the 
selection of this host.
6.1.2 Factors affecting protein expression in E. coli
Expression of recombinant protein in E. coli can be achieved by inserting the target gene 
into a multi-copy plasmid vector under the transcriptional control of either a constitutive or 
inducible promoter. Constitutive promoter systems provide a simple means of over­
producing a foreign protein in a bacterial cell since the target protein is continually 
expressed. However, unregulated high level expression of a foreign protein causes a 
metabolic burden on the bacterial cells’ energy resources leading to a reduction or inhibition 
of cell growth (Glick & Whitney 1987; Bentley et al. 1990; Donovan et al. 1996). Since the 
overall yield of the target protein is a function of both the cell yield (number of cells per litre 
of culture) and the amount of recombinant product expressed per bacterium, the reduced 
cell growth that generally accompanies constitutive expression results in lower yields of the 
target protein compared to inducible promoter systems (Donovan et al. 1996).
Inducible promoter systems provide the ability to 'switch on' the expression of a foreign 
gene by varying an environmental factor such as temperature (Remaut et al. 1981; Whitney 
et al. 1989; Yabuta et al. 1995), or the concentration of a particular component in the growth 
medium (Carter et al. 1992; Neubauer et al. 1992). For example, the bacteriophage lambda 
pL and pR promoters in conjunction with a temperature sensitive repressor gene can be 
thermally induced when the temperature of the fermentation broth is raised from the growth-
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optimum temperature of 30-35*0 to 42*C (Murray et al. 1979; Whitney et al. 1989). The E. 
coli trp and phoA promoters are induced following depletion of tryptophan and phosphates, 
respectively, from the medium (Carter et al. 1992; Rockenbach et al. 1991), while the lac 
promoter is induced in the presence of lactose or isopropyl-3-D-thiogalactoside (IPTG) 
(Neubauer et al. 1992).
The ability to induce foreign gene expression allows for the separation of cell growth 
phase from the product synthesis or induction phase of the fermentation. After obtaining a 
high concentration of cells during an optimised growth phase, the foreign gene can then be 
induced resulting in higher total yields of the recombinant protein than otherwise could be 
achieved using constitutive expression. In some cases, the level of transcription of the 
foreign gene can be regulated by using an appropriate level of the inducing stimulus. This in 
turn can further improve yields by allowing the level of expression to be optimised during the 
induction phase (Donovan etal. 1996).
The lac promoter from the E. coli lactose operon is one of the most commonly used 
promoters for regulating the expression of recombinant genes in bacteria. It is the most 
widely studied of all bacterial promoters and has been extensively characterised at the 
molecular level (Donovan et al. 1996). This operon will be exclusively used to induce 
bacterial expression in the experimental system discussed in this chapter.
6.1.2.1 The effect of IPTG concentration
While a wide range of IPTG concentrations, ranging from 0.005 to 5 mM, have been used 
for successful protein expression (Chalmers et al. 1990; Pack et al. 1993; Winograd et al. 
1993), expression is commonly induced using 1 mM IPTG. It has been shown that high 
concentrations of inducer that are often used in an effort to fully induce the lac promoter do 
not necessarily lead to maximal expression of a target protein (Glick 1995), and optimal 
inducer concentration should be chosen to balance the decreasing yields of recombinant 
cells following induction with increasing cellular levels of target protein (Bentley et al. 1991).
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Studies have shown that high inducer concentrations (>3 mM IPTG) resulted in a severe 
reduction in growth rate, which led to an early onset of the stationary phase and cell death. 
At slightly lower concentrations (~2 mM IPTG), however, the cells partially recovered from 
the initial shock following induction and established a constant specific growth rate that was 
60% lower than pre-induction levels. Thus, the overall level of protein expression in batch 
culture is a trade-off between increasing product expression in the cell and decreasing cell 
yields resulting from a lower specific growth rate following induction with IPTG (Bentley et al. 
1991).
The optimal concentration of IPTG is thus entirely system-dependent and must be 
empirically determined. However, an intermediate IPTG concentration in the region of 0.5- 
1.0 mM IPTG usually balances the opposing phenomena of increasing target protein 
expression and decreasing cell yields to maximise the overall expression of the recombinant 
product (Donovan etal. 1996).
6.1.2.2 The effect of temperature
The maximum growth rate of E. coli occurs at a temperature of 37-390. Although this is 
also the temperature at which the lac promoter exhibits maximal activity, the use of sub- 
optimal growth temperatures can in some cases improve the yield and/or solubility of the 
target protein product (Donovan et al. 1996). Reducing the culture temperature from 370 to 
25-300 can also significantly reduce proteolytic d egradation and improve the stability of the 
target protein (Baneyx et al. 1991; Surek et al. 1991). Furthermore, studies have shown that 
ATP-dependent proteolytic activity can decrease more than 2.5-fold as the temperature was 
decreased from 4 2 0  to 30*0 (Kosinski & Bailey 1991 ). Since it has been suggested that 
ATP-dependent proteolysis of recombinant proteins may initiate further degradation by ATP- 
independent proteases, lower culture temperatures may minimise the activity of pathways 
that lead to product degradation (Kosinski & Bailey 1991). Increased proteolytic degradation 
of recombinant products above 30*0 may also result from conformational changes in the
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target protein which may expose sites for proteolytic cleavage (Chesshyre & Hipkiss 1989). 
Precipitation of over-expressed protein in the form of insoluble aggregates is also less 
prevalent at lower temperatures (Cabilly 1989).
As with reduced inducer concentrations, lower culture temperatures may enhance 
functional protein formation by reducing the rate at which the recombinant protein is formed 
(Donovan et al. 1996). Reduced expression rates reduce the concentration of the unfolded 
recombinant protein in the cell. At lower concentrations, reduced interaction between 
unfolded intermediates may allow the proteins to react via folding pathways rather than 
those leading to aggregation (Knappik et al. 1993). Improved folding at lower temperatures 
may also reduce the level of interaction between improperly folded recombinant product and 
the inner and outer membranes. Since long-term exposure to improperly folded proteins 
may substantially reduce membrane integrity (Skerra & Pluckthun 1991), this may explain 
why some studies have shown that outer membrane leakiness, cell lysis and death observed 
at 37*0 in response to expression of secreted prote ins was reduced or eliminated at 20- 
30*0 (Chalmers etal. 1990; Skerra & Pluckthun 1991; Somerville etal. 1994).
6.1.3 Objectives of this chapter
The previous chapter showed that in vitro-generated ID8 reversed the ouabain-induced 
intercellular dyssynchrony in HL-1 myocytic monolayers, and restored synchrony to levels 
comparable with those determined in untreated, natively coupled HL-1 cells. This chapter 
discusses the validity of these findings and utilises ID8 synthesised via a distinct mode of 
expression, namely using a bacterial expression system.
For reasons given above, an inducible system was used and the E. coli BL21 strain was 
chosen to initially optimise the expression of full-length l-Domain. It was anticipated that this 
would be the most challenging protein to express due to its size and hydrophobicity, and the 
conditions suitable for the expression of the l-Domain would also be amenable to successful 
expression of the truncated l-Domain fragments.
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This chapter discusses the optimisation of conditions for efficient expression and 
purification of 1-Domain proteins in a bacterial expression system. The resultant protein was 
used to further investigate the effect of ID8 on HL-1 myocytes.
6.1.4 Specific Hypothesis
Having demonstrated in the previous two chapters that in wfro-synthesised ID8 can be 
successfully microinjected into HL-1 myocytes, and that it restores synchrony in ouabain- 
treated cells, this chapter now investigates the hypothesis that these observations are 
independent of the source of the protein, and that microinjection of bacterially-produced ID8 
will produce entirely comparable results.
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6.2 Methods
6.2.1 Bacterial expression of recombinant 1-Domain proteins
BL21 competent cells are the most widely used E. coli strains for protein expression from 
the T7 promoter. These strains have been engineered to contain an inducible T7 RNA 
polymerase gene and contain a mutation in the ompT protease gene, which is implicated in 
the degradation of some recombinant proteins. BL21 cells are derivatives of E. coli B and 
naturally lack the Lon protease, which may affect the stability of some recombinant proteins. 
For the purposes of this study, E. coli Rosetta™ 2(DE3) competent cells (Novagen) were 
used for the expression of recombinant proteins. E. coli Rosetta™ 2(DE3) cells are BL21 
derivatives designed to enhance the expression of eukaryotic proteins that contain codons 
rarely used in E. coli. For transformation with recombinant plasmid DNA, Rosetta™ 2(DE3) 
cells (20pl) were thawed on ice before the addition of 5 ng cDNA and subsequent incubation 
on ice (5 mins), prior to ‘heat-shock’ treatment at 42*C for exactly 30 seconds then 
immediate return to ice for 3 minutes. SOC medium (80pl) pre-warmed to RT was added 
and the suspension was incubated at 37*0 for 1 hour with continuous shaking (225 rpm). 
Following this incubation time, the suspension was plated on LB-Agar medium containing 
kanamycin (30pg/ml) and chloramphenicol (40pg/ml), which was incubated at 37*C until the 
appearance of colonies (typically 16-20 hours).
6.2.2 Optimisation of culture conditions
6.2.2.1 IPTG-induction of bacterial protein expression
The optimal conditions for the induction of expression of full length l-Domain in E. coli 
Rosetta™ 2(DE3) were investigated using small scale cultures (200ml). In order to find the 
optimal conditions for protein expression a range of different IPTG concentrations, 
temperatures and induction times were tested. At each given temperature, four different 
IPTG concentrations, and four durations of induction were investigated (summarised in
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Table 6.1). A total of 39 conditions were tested, and cells not exposed to IPTG were used 
as a negative control.
Table 6.1. Summary of bacterial induction conditions
Temperature: 12°C, 30°C, 37°C
IPTG Concentration: 25pM, 100pM, 500pM, 1mM
Induction Time: At 12°C: 6, 24, 48 hrs; At 30°C & 37°C: 2, 6, 24 hrs
Negative Control: Uninduced cells
Isolated colonies from plates grown overnight (as described in Section 6.2.1), were 
inoculated in 10ml LB broth, containing kanamycin (30pg/ml) and chloramphenicol (40pg/ml) 
and left to grow overnight on a shaking platform (37*0, 250 rpm, 16-18 h). Following this 
incubation time, the inoculum was transferred to 190ml LB pre-warmed to 37*C and 
incubated under the same conditions until an O D 6oo was reached. At this stage, the bacterial 
cells were induced with 0.025, 0.1, 0.5, or 1 mM IPTG, and incubated at 12*0, 300  or 370  
as described in Table 6.1. After the induction time was complete, the bacterial suspension 
was pelleted by centrifugation and stored at -800  until needed for downstream application.
6.2.2.2 Protein expression by autoinduction
The Overnight Express™ Autoinduction System (Novagen) is optimised for high-level 
protein expression with IPTG-inducible pET bacterial expression systems without the need 
to monitor cell growth and induce protein expression. The method is based on media 
components that are metabolised differentially to promote growth to high density and 
automatically induce protein expression from lac promoters. In auto-induction media, 
cultures reliably grow ‘uninduced’ to relatively high density and then spontaneously induce 
high levels of target protein without the need to monitor cell density or add IPTG (Studier
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2005).
Isolated colonies from plates grown overnight (as described in Section 6.2.1), were 
inoculated in Overnight Express™ System medium, containing kanamycin (30 pg/ml). A 
multi-stage inoculation strategy was employed for larger cultures in order to minimise the 
shock-induced lag phase in growth caused by transfer of a small inoculum to a larger volume 
of fresh medium and diffusion of vitamins, minerals and cofactors from the cells (Studier 
2005). Inoculation of flask cultures greater than 30ml were inoculated in this way using 
several stages and flasks of increasing size filled with medium (10-20% of the flask volume), 
by generating a 5% (v/v) inoculum. Typically, the culture was initiated by single colony 
inoculation of 5ml Overnight Express™ System medium, which was incubated on a shaking 
platform (37*0, 250 rpm, -2  h) until an OD 6oo of approximately 0.5 was reached. This was 
then transferred into 95ml of pre-warmed Overnight Express™ System medium, and 
incubated under the same conditions for a further 2 h. Once this culture had reached an 
ODeoo of ~0.5, it was divided equally into four flasks, each containing 475ml of pre-warmed 
Overnight Express™ System medium, to make a total of 2 L bacterial culture, and incubated 
overnight on a shaking platform (37*0, 250 rpm, 16- 18h).
6.2.3 Protein extraction
The goal of protein production and extraction is to maximise the recovery of recombinant 
protein in the soluble fraction of a bacterial lysate. Five different protein extraction methods 
were tested to establish which gave the highest yield of soluble protein from the bacterial 
cells with the least amount of degradation (summarised in Table 6.2). For each method the 
amount of soluble and insoluble protein was compared by protein staining. The resultant 
pellet from each method was resuspended in 5ml 10mM Tris/1mM EDTA. This solution 
containing the insoluble protein fraction was compared to the clarified lysate containing the 
extracted soluble proteins by SDS-PAGE electrophoresis and protein staining (See Chapter 
2).
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Table 6.2. Summary of protein extraction methods.
Extraction Method Mechanism of protein extraction
French Press Lysis by forcing the cells through a narrow space at high pressure that breaks down inclusion bodies
Sonication Pulsed, high frequency sound waves to agitate and lyse cells.
B-PER Popper® reagent 
(Pierce) Bacterial cell lysis by mild, non-ionic detergent
BugBuster Master Mix 
(Novagen) Disruption of cell wall by a detergent mix
8M urea total protein 
extraction buffer Total cell lysis and denaturation of proteins
6.2.3.1 Protein extraction by pressure lysis
The French press mechanically disrupts the bacterial cell membrane by passing the 
bacterial solution through a narrow valve under high pressure. The press uses an external 
hydraulic pump to drive a piston within a larger cylinder that contains the sample. The highly 
pressurised solution is then squeezed past a needle valve. Once past the valve, the 
pressure drops to atmospheric pressure and generates shear stress that disrupts the cells 
(Vanderheiden etal. 1970).
The bacterial cells were pelleted by centrifugation (6,000 xg, 10 mins), and the resultant 
pellet was resuspended in 30ml 10mM Tris/1mM EDTA solution by gentle pipetting until a 
homogeneous cell suspension was achieved. The bacterial suspension was passed through 
a French press at 20,000 p.s.i. in a drop-wise manner into a pre-chilled tube on ice. The 
lysate was then centrifuged (16,000 xg, 20 min, 4*C) to separate the soluble and insoluble 
protein fractions.
6.2.3.2 Protein extraction by sonication
Sonication applies ultrasound energy to agitate the bacterial cells and disrupt cell 
membranes in order to release the cellular contents. For this method, the bacterial cells
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were centrifuged (6,000 xg, 10 mins), and the resultant pellet was resuspended in 5ml 10mM 
Tris/1mM EDTA solution by gentle pipetting until a homogeneous cell suspension was 
achieved. This was then placed on ice and subjected to sonication (4 x 30 sec pulses). The 
lysate was pelleted by centrifugation (16,000 xg, 20 min, 4*C) to remove any insoluble cell 
debris.
6.2.3.3 Protein extraction by B-PER®
Bacterial Protein Extraction Reagent (B-PER®, Pierce) utilises a proprietary, mild, non­
ionic detergent in 20 mM Tris-HCI (pH 7.5) for lysis of the bacterial cells and eliminates the 
need for mechanical disruption by sonication or French press techniques.
The bacterial suspension was treated with B-PER® according to the manufacturer’s 
guidelines. The bacterial cells were pelleted by centrifugation (5,000 xg, 10 mins), and the 
resultant pellet was resuspended in 2.5ml of B-PER® Reagent by gentle pipetting until a 
homogeneous cell suspension was achieved. The cell suspension was then incubated on a 
shaking platform (20 min, RT) before centrifugation (27,200 xg, 15 mins) to separate the 
soluble and insoluble protein fractions.
6.2.3.4 Protein extraction by BugBuster
Like B-PER®, BugBuster Protein Extraction Reagent (Novagen) is formulated for the 
gentle disruption of the cell wall of E. coli to liberate active proteins. It provides a simple, 
rapid, low-cost alternative to mechanical methods such as French Press or sonication for 
releasing expressed target protein in preparation for purification or other applications. The 
proprietary formulation utilises a detergent mix that is capable of cell wall perforation without 
protein denaturation.
The bacterial suspension was treated according to the manufacturer’s protocol. Briefly, 
the bacterial cells were harvested from liquid culture by centrifugation (10,000 xg, 10 min).
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The supernatant was then decanted, and the pellet was weighed to determine its wet weight. 
The pellet was resuspended in BugBuster reagent pre-warmed to RT by pipetting, using 5ml 
reagent per gram of wet cell paste. At this stage, Benzonase Nuclease (Novagen) was 
added to reduce the viscosity of the lysate (25U per ml Bugbuster). The cell suspension was 
incubated on a slow rotating mixer (20 min, RT) before centrifugation (16,000 xg, 20 min, 
4*C) to remove any insoluble cell debris.
S.2.3.5 Protein extraction by urea
Protein extraction by urea completely lyses the bacterial cells and results in near total 
protein extraction. However, proteins extracted by this method are generally not suitable for 
downstream applications, due to the chaotropic effects of urea on the proteins’ structure. 
Since this method should result in total protein extraction, it was used as a positive control to 
which the other methods were compared.
The bacterial cells were harvested from liquid culture by centrifugation (6,000 xg, 10 min). 
The supernatant was then decanted, and the wet weight of the pellet was determined. The 
pellet was resuspended in urea extraction buffer (100 mM NaH2P04, 10 mM Tris, 8 M urea) 
using 5ml reagent per gram of wet cell paste, and incubated on a rotating mixer (RT, 3 hrs), 
before centrifugation (16,000 xg, 20 min, 4*0) to remove any insoluble cell debris.
6.2.4 Microinjection of bacterially produced ID8 into HL-1 ceiis
Bacterially-produced ID8 was microinjected into resting and ouabain-treated HL-1 cells 
following exactly the same protocol as previously described for in vitro synthesised proteins 
(Sections 4.2.4. and 5.2.1, respectively). Following microinjection, the cells were imaged 
and the ROIs analysed by SALVO, as described in previous chapters.
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6.3 Results
6.3.1 Selection of a suitable protein extraction technique
Untransformed bacterial cells were induced according to the manufacturer’s 
recommended protocol, and five different protein extraction methods were investigated to 
establish which method gave the highest yield of soluble protein with the least amount of 
degradation. Urea extraction was used as the positive control as it completely lyses the 
bacterial cells and results in near total protein extraction. However, urea is not suitable for 
the extraction of proteins which will be used in downstream applications due to its chaotropic 
effects which would disrupt the thee-dimensional structure of the protein and prevent protein 
re-folding.
The reagents had varying efficacy, indicated by the yield and the amount of soluble 
versus insoluble protein extracted (Figure 6.1). B-PER® and Bugbuster were not suitable for 
this extraction, as the soluble lysate contained no proteins >71 kDa. Sonication did extract 
high molecular weight protein, but a high level of insoluble protein persisted. The French 
press gave the highest yield of soluble protein and had the additional advantage of 
eliminating the use of any detergent which may affect downstream processes. Based on 
these results, the French Press was chosen as the method of choice for extracting the I- 
Domain protein from the large scale bacterial cultures.
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French press Sonication B-PER BugBuster 8M Urea
200 kD a-*
133 kDa->
71 kDa—►
42k D a -*
31kDa-^
Figure 6.1. Optimisation of protein extraction from bacterial cells
SDS-PAGE gel (10%) stained with Imperial Protein Stain, showing the amount of soluble (S) and 
insoluble (I) extracted by five different protein extraction techniques. The protein samples were 
normalised for cell number, and each lane contains 1/20 of the resuspension volume for each 
extraction method (equivalent to 10ml of original bacterial culture).
6.3.2 Protein Induction by IPTG
The full-length l-Domain was transformed into E. coli BL21 derivatives, Rosetta™ 2(DE3) 
bacterial cells, which are optimised for the expression of large or ‘difficult-to-express’ 
proteins. Single colonies were isolated and inoculated into 10ml of LB and induced as 
described above (Section 6.2.2.1). Although French Press lysis was optimal, since these 
small scale cultures were required purely for diagnostic purposes to test and optimise IPTG 
induction, and not required any downstream applications, the proteins were extracted from 
the bacterial cells by urea lysis (Section 6.2.3.5).
Induction of bacterial protein expression by IPTG failed to produce any significant 
amounts of full-length l-Domain protein, under any of the 39 conditions tested (Figure 6.2). 
The Imperial-stained gels showed that there was no visible protein product at 106 kDa, the 
anticipated molecular weight of the recombinant l-Domain. Furthermore, the S-tag blots
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failed to detect any product at 106 kDa, but under some conditions the S-tag showed a high 
level of degradation product. To eliminate the possibility that these proteins were an artefact 
of non-specific expression of endogenous bacterial proteins or due to non-specific S-tag 
detection, bacterial cells expressing the l-Domain were compared with cells expressing only 
pET-29(b). It was found that in cells expressing pET-29(b), S-tag detection produced a 
single discrete band at 18 kDa, with no degradation or non-specific binding (Figure 6.3).
Another possibility was that the protein degradation observed in Figure 6.2 was due to the 
harsh cell lysis conditions imposed by the urea extraction buffer. To investigate this 
possibility, the induction conditions giving the best protein yield at each temperature were 
selected (denoted by *  on Figure 6.2). These were chosen as the optimal conditions at 
each temperature, based on the amount of protein produced and detected, with the least 
degradation. The inductions were repeated, and 2 L bacterial culture was pelleted and 
resuspended in 200ml 10mM Tris/1mM EDTA, before the cells were lysed by passing 
through the French press as described in Section 6.2.3.1. Once again, Imperial-stained 
SDS-PAGE gels failed to show any protein product at 106 kDa, corresponding to the I- 
Domain, and S-tag-based techniques continued to show a high level of degradation product 
but no intact product at 106 kDa (Figure 6.4).
A number of alterations to this strategy were investigated, including the addition of a 
range of different protease inhibitors, all of which failed to eliminate the substantial levels of 
protein degradation. It was therefore concluded that IPTG was not a suitable inducer for full 
length l-Domain protein, as it resulted in multiple truncated fragments but does not produce 
any detectable levels of full-length protein.
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Figure 6.2. Testing the induction conditions to optimise the production of l-Domain protein in 
an IPTG-induced bacterial system.
A total of 39 conditions were tested in an attempt to identify the optimal set of conditions for the 
production of l-Domain protein in E. coli. Left-hand panels -  Imperial-stained SDS-PAGE gels (10%) 
of full length l-Domain extracted from bacterial culture, showing the optimal induction conditions at 
each of the temperatures tested. Right-hand panels -  S-Tag blots of an equivalent gel; shows that 
although the protein profiles may be similar despite varying conditions the level of detectable protein 
produced is variable. Each lane contains 1/20 of the resuspension volume for each extraction method 
(equivalent to 100ml of original bacterial culture). Lanes marked with *  were selected for further 
investigation, as shown in Figure 6.4.
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Figure 6.3. Expression of l-Domain and pET29-(b) in Rosetta™ 2(DE3) cells
Bacterially expressed l-Domain (ID) and pET29-(b) proteins pET29-(b) produces one discrete band 
with no non-specific binding by S-tag detection. Each lane contains 1/20 of the resuspension volume 
for each extraction method (equivalent to 100ml of original bacterial culture). The multiple bands seen 
following ID expression are thus an artefact of the ID protein, possibly via degradation or alternative 
transcription sites.
200 kDa 
133 kDa 
71 kDa
42 kDa 
31 kDa 
16 kDa
Imperial Protein Stain S-tag
*
I  *
Induction (mM IPTG) - 0.1
Temperature 12*C
Induction Time 24 h
- 0.25
30TC 
6 h
0.1 0.1 0.25 0.1
37*C 
6 h
12*C 
24 h
30*0 
6 h
37*C 
6 h
Figure 6.4. IPTG induction conditions selected for large-scale culture
Left panel -  Protein stained 10% SDS-PAGE gel of full length l-Domain extracted from bacterial 
culture, showing the optimal induction conditions at each of the temperatures tested (100pl). Right 
panel -  S-Tag blot of an equivalent gel; shows that although the protein profiles may be similar 
despite varying conditions, the level of detectable protein produced varies. Each lane contains 1/20 of 
the resuspension volume for each extraction method (equivalent to 100ml of original bacterial culture)
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6.3.3 Successful expression and purification of i f f
While the optimisation of protein induction conditions was being carried out, simultaneous 
studies of l-Domain proteins produced in vitro were taking place (Chapters 3-5) and the 
marked effects of ID8 in cardiac cells was emerging. In light of this, the expression and 
purification of ID8 in a bacterial system was attempted. Since the expression of full-length I- 
Domain showed potential problems using IPTG as an inducer, an alternative induction 
system was used for this -  The Overnight Express™ Autoinduction System (Novagen) -  
which is optimised for high-level protein expression with IPTG-inducible pET vectors.
ID8 was expressed using this system (Section 6.2.2.2) and subsequently extracted by 
French Press lysis (Section 6.2.3.1). Unlike the proteins synthesised in vitro in Chapter 3, 
the resultant lysate was then purified using the His-GraviTrap Ni2+-affinity method followed 
by S-tag cleavage (Chapter 2 Sections 2.3.7 and 2.3.8) rather than with Mag-Z beads. The 
MagZ purification system is optimised for the purification of target His-tagged proteins from 
RRL, and is not suitable for purification of large volumes of bacterial lysate. The eluate from 
His-GraviTrap Ni2+-affinity purification (Figure 6.5 A, lane 1) was subjected to purification 
with S-tag affinity (Figure 6.5 A, lanes 2-7). The thrombin-treated eluate (Figure 6.5 A, Lane 
8) showed a band corresponding to ID8 which can be clearly seen by both Imperial staining 
and immunodetection by anti-His antibody. The finding that this band was approximately 1.7 
kDa smaller than those seen in lanes 1-7, was encouraging and pointed to the successful 
removal of the S-tag by thrombin cleavage, as outlined in Figure 6.5 (Panel B).
210
Chapter 6
A
200 000 
133 000
71 000
C> ®  O '
£*■4? s_ta9 purification
c >  J ? _______wash eluates
/
^  S-tag purification
-£■ wash eluateseT ---------------------------
1 2 3 4 5 6
42 000 
31 000
16 000
Imperial anti-His
Thrombin
cleavage
Purified protein after 
S-tag cleavage
S-tag
1.7kDa
Figure 6.5. Purification of ID6 from bacterial cells
Panel A: Eluates from the Ni2+ affinity and S-protein affinity systems were separated by SDS-PAGE 
(10% (v/v)), and visualised with Imperial protein stain and His-tag detection. Each lane contains 1/20 
of the resuspension volume for each extraction method (equivalent to 100ml of original bacterial 
culture). Panel B: Schematic depicting the mechanism of protein purification by S-tag affinity and 
thrombin cleavage. As seen by His-tag detection, the purified protein is -1.7 kDa smaller than the 
uncleaved protein, due to the loss of the S-tag.
Imperial staining of the thrombin-treated eluate shows that there was a small amount of 
‘non-target’ proteins present in addition to the thrombin-cleaved ID6. To eliminate these 
contaminating proteins the eluate was run through size-exclusion filter (Microcon) with a cut­
off of 30,000 MW, so only proteins below this size remained in the purified eluate. The 
purified eluate was then loaded onto an SDS-PAGE gel to confirm the presence of purified
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ID8 by protein staining, and detection with S-tag, ab1093 and anti-His antibody as described 
previously (Chapter 2). Protein staining showed that the majority of contaminating proteins 
>30 kDa were successfully removed, and the target protein was successfully detected by 
western blotting (Figure 6.6). The bacterially produced ID8 was compared to ID8 produced in 
the cell-free RRL system (Chapter 3) in order to confirm that the protein was of the correct 
size. As expected, the thrombin-cleaved bacterially-produced ID8 was not detected by S- 
tag, and ran approximately 1.7 kDa smaller than that produced in vitro, again corroborating 
the removal of the S-tag by thrombin cleavage.
16 300
Imperial
Jp S> <£> <p
^  ■$) ^  / ' */ r
/ ) V  X T  / ) X  ^
200 000
133 000
7 1 000 —►
42 000
31 000“ *
S-tag 1093 His-tag
Figure 6.6. Successful purification and detection of bacterially produced ID8
ID8 (right-hand lanes) purified from bacterial culture by Ni2+ affinity followed by S-protein affinity 
systems were separated by SDS-PAGE (10% (v/v)), and visualised with Imperial protein stain and 
detected by S-tag, ab1093 and His-tag detection. Non-purified in wfro-synthesised ID8 (Left-hand 
lanes) was used to illustrate the size difference in bacterially-produced ID8 after S-tag cleavage. Each 
lane contains 1/20 of the resuspension volume for each extraction method (equivalent to 100ml of 
original bacterial culture).
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6.3.4 Effect of bacterially-produced IDP on resting cells
Following the assessment of the changes in HL-1 Ca2+ handling phenotype induced by 
microinjection of ID8 protein produced in a cell-free RRL system (Chapter 4), the effect of 
bacterially produced ID8 was also investigated to validate the results discussed previously. 
SALVO analysis (Figure 6.7) revealed that bacterially-produced ID8 caused a significant 
change in every parameter measured, when compared with the effects of RRL ( * )  or ID8 
produced in vitro (#). However, despite these marked alterations in cellular Ca2+-handling 
parameters, the synchrony remained comparable to that seen in cells injected with RRL, in 
vitro synthesised ID8 and WT HL-1 cells (Figure 6.8). These findings support the results 
discussed in the previous chapter, and under these experimental conditions, substantial 
changes in Ca2+ handling were well tolerated by the cells and did not abolish intercellular 
synchrony.
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Figure 6.7. SALVO analysis of the effects of bacterially produced ID8 on HL-1 myocyte 
monolayers.
Spatio-temporal Ca2+ handling parameters in HL-1 myocytes injected with bacterially-produced ID8 
(ID8 bact, spotted), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± 
SEM, n = 7-9, 15-20 cells per experiment. The total number of cells is indicated in brackets). *  
represents p<0.05 when compared with RRL-injected ouabain-treated HL-1 myocytes. # represents 
p<0.05 when compared with ouabain-treated HL-1 cells injected with ID8 produced in vitro. Values for 
HL-1 WT cells (light grey), and in vitro proteins (RRL black, ID8 white) shown here from the results 
shown in Chapter 5.
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Figure 6.8. Ml of bacterially-produced IDB does not alter synchronicity
Synchronicity within ouabain-treated HL-1 myocytes injected with bacterially-produced ID5 (ID8 bact, 
spotted), plotted from SALVO analysis of Ca +-dependent Fluo-4 fluorescence (mean ± SEM, n = 7-9, 
15-20 cells per experiment. The total number of cells is indicated in brackets). *  represents p<0.05 
when compared with RRL-injected ouabain-treated HL-1 controls. Values for HL-1 WT cells (light 
grey) shown here are from Figure 5.6, and were not included in statistical analyses with injected cells.
6.3.5 Effect of bacterially-produced IDB on ouabain-treated HL-1 cells
Because of the striking effects of in w'fro-produced ID6 on rescuing ouabain-induced 
dyssynchrony, the effect of bacterially-produced IDB on ouabain-treated HL-1 myocytes was 
also investigated (Figure 6.9). Bacterially-produced ID6 was associated with different 
alterations to those observed with in vitro synthesised ID6 (shown in Chapter 5). There were 
pronounced differences in the ratio of totahinter-transient noise (C), transient length and area 
(E & F respectively), and the rate of oscillation (I) -  all of which were not affected by ID6 
produced in vitro. However, despite large alterations in basal Ca2+ cycling, bacterially- 
produced ID6 restored the synchrony in the ouabain-treated monolayer to 55.14% ± 4.80, 
which was comparable to both cells containing in vitro produced ID8 (34.6% ± 2.43) and WT 
HL-1s (49. 4% ± 4.19). These compelling findings further corroborated the results seen in 
Chapter 5, and showed the potential utility of ID8 in normalising intercellular coupling and 
synchrony.
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Figure 6.9. SALVO analysis of the effects of bacterially produced ID8 on HL-1 myocyte 
monolayers pre-treated with 100 nM ouabain
Spatio-temporal Ca2+ handling parameters in ouabain-treated HL-1 myocytes injected with bacterially- 
produced ID8 (ID8 bact, spotted), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence 
(mean ± SEM, n = 5-7, 15-20 cells per experiment. The total number of cells is indicated in brackets). 
*  represents p<0.05 when compared with RRL-injected ouabain-treated HL-1 myocytes. # 
represents p<0.05 when compared with ouabain-treated HL-1 cells injected with ID8 produced in vitro. 
Values for HL-1 WT cells (light grey), and in vitro proteins (RRL black, ID8 white) shown here from the 
results shown in Chapter 5.
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Figure 6.10. Bacterially-produced ID6 restores synchrony in dyssynchronous ouabain-treated 
HL-1 myocytes.
Synchronicity within ouabain-treated HL-1 myocytes injected with bacterially-produced ID6 (ID8 bact, 
spotted), plotted from SALVO analysis of Ca +-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 
15-20 cells per experiment. The total number of cells is indicated in brackets). *  represents p<0.05 
when compared with RRL-injected ouabain-treated HL-1 controls. Values for HL-1 WT cells (light 
grey) shown here are from Figure 5.6, and were not included in statistical analyses with injected cells.
6.3.6 Bystander effect
In the previous chapter, it was observed that non-microinjected cells displayed the same 
changes in Ca2+-handling phenotype as those cells which had been microinjected with ID8 
produced in vitro, and was termed the ‘bystander effect’. The experiments described in this 
chapter further support this phenomenon by showing that it is also reproduced by bacterially- 
produced ID8 in both resting and ouabain-treated HL-1 myocytes. Figures 6.11 -  6.14 show 
that in the majority of the parameters, including synchrony, any change exhibited by 
microinjected cells is mirrored in non-injected cells in the same field of view.
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6.3.6.1 The bystander effect in HL-1 cells
Figure 6.11 and 6.12 show SALVO analysis of HL-1 myocytes cells which have not been 
microinjected, compared to those in the same field of view which have been injected. With 
the exception of the totakinter-transient noise ratio (C) and transient rate up (G), there was 
no significant difference between the injected and non-injected cells.
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Figure 6.11. SALVO analysis shows a bystander effect in non-injected HL-1 myocytes
Non-injected HL-1 myocytes (-) exhibit the same alterations in most spatio-temporal Ca2+ handling 
parameters as those injected with bacterially-produced ID6 (+), plotted from SALVO analysis of Ca2+- 
dependent Fluo-4 fluorescence (mean ± SEM, n = 5-9, 15-20 cells per experiment). *  represents 
p<0.05 between injected cells and non-injected bystander cells. Data for in vitro RRL and ID8 is taken 
from Chapter 4, and shown here for comparison.
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Figure 6.12. Bystander cells not injected with ID6 showed a comparable level of synchrony as 
those containing IDB
Non-injected bystander cells (-) showed the comparable restoration of cellular synchrony as those 
injected with bacterially-produced ID8 (+) in the same field of view, plotted from SALVO analysis of 
Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-9, 15-20 cells per experiment). There was 
no significant difference between injected cells and bystanders within any data set. Data for in vitro 
RRL and ID8 is taken from Chapter 4, and shown here for comparison.
6.3.6.2 Bystander effect in ouabain-treated HL-1 cells
In ouabain-treated cells, there was a significant difference in the length (E) and area (F) of 
the transient, and in the length to decay (H ) between cells injected with RRL and those not 
injected (Figure 6.13). Most importantly, the restoration of synchrony in ouabain-treated 
cells microinjected with bacterially-produced ID8 also extended to cells that had not been 
transduced with the recombinant protein (Figure 6.14).
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Figure 6.13. SALVO analysis shows a bystander effect in non-injected ouabain-treated HL-1 
myocytes
Non-injected HL-1 myocytes (-) exhibit the same alterations in most spatio-temporal Ca2+ handling 
parameters as those injected with bacterially-produced ID6 after incubation with 100 nM ouabain (+), 
plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 15-20 
cells per experiment). *  represents p<0.05 between injected cells and non-injected bystander cells. 
Data for in vitro RRL and ID is taken from Chapter 4, and shown here for comparison.
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Figure 6.14. Ouabain-treated bystanders not injected with ID8 showed a comparable level of 
synchrony as those containing ID8
Non-injected bystander cells (-) showed the comparable restoration of cellular synchrony as those 
injected with bacterially-produced ID8 (+) in the same field of view, plotted from SALVO analysis of 
Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 5-7, 15-20 cells per experiment). There was 
no significant difference between injected cells and bystanders within any data set. Data for in vitro 
RRL and ID8 is taken from Chapter 4, and shown here for comparison.
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6.4 Discussion
6.4.1 Expression of 1-Domain proteins in a bacterial expression system
The use of BL21-derived bacterial cells for the expression of full-length l-Domain protein 
in a classical IPTG-induced system was unsuccessful despite the investigation of an array of 
different conditions. There are many possible reasons for this, including the size and 
composition of the protein. In addition to this, our data suggested that in this instance, 
induction with IPTG caused a variety of stress responses in the cell such as proteolytic 
degradation and/or initiation at multiple sites of transcription (Donovan et al. 1996; Kosinski 
& Bailey 1991).
The use of an autoinduction system was better suited for the expression of l-Domain 
proteins, and successfully expressed ID6 which was subsequently purified and used for 
microinjection into HL-1 myocytes.
6.4.2 Bacterially-produced ID3 modifies cellular Ca2+ handling differently to /D8 
produced in vitro without altering synchrony
This chapter has provided further support for the observations of Chapters 4 and 5, by 
showing that perturbation of various aspects of Ca2+ handling, at least under the conditions 
tested, did not ablate intercellular synchrony (summarised in
Table 6.3). However, it is intriguing that in ouabain-treated cells, alteration of these 
parameters was associated with a restoration of synchrony. This validates the observations 
discussed in previous chapters and suggests that the extent of intercellular synchrony is 
controlled by the complex interplay between an array of Ca2+ signalling parameters. Further 
work is necessary here to delineate the mechanistic basis of these findings.
Figures 6.7, 6.8, 6.9 and 6.10 profound differences in the bioactivity of ID6 fragments 
generated in vitro or bacterial expression methodologies. This could be due to a number of 
reasons. The bacterially synthesised proteins have undergone S-tag cleavage as part of the
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large-scale purification process, and this may enhance the bioactivity of the proteins. 
Additionally, bacterial expression systems allow for secondary modification of proteins, 
which does not occur in cell free systems. Furthermore, the bacterially-produced sample 
contains detectable amounts of several truncated ID species which were detected by 
ab1093 (Figure 6.6). These truncated fragments may be bioactive, and therefore may 
cumulatively increase the ID6 phenotype observed in microinjected cells.
Some or all of the considerations may contribute to the stark differences observed on 
Ca2+ handling parameters. Notably, the restoration of synchrony is equivalent in both 
methodologies. Further work will be necessary to determine how discrepant mechanisms 
can result in a comparable effect on synchrony - a robust index of intra- and inter-cellular 
Ca2+ handling - and indeed, how this is determined by the source of the protein.
Table 6.3. Summary of alterations of spatio-temporal Ca2+ handling parameters
Total Noise
Intertransient
Noise
Totaklntertransent
Noise
Am
plitude
Transient Length
>
CD
Q)
Rate 
Up
Length 
to 
Decay
Rate 
of O
scillation
S
ynchronicity
HL-1 + RRL X —
HL-1 + IDB X — X — — — X — — —
HL-1 + bact IDB X X X X X X X X X —
HL-1 + oua +RRL X — — X X X — X X —
HL-1 + oua +IDB X X — X — — X X — *
HL-1 + oua + 
bact IDB X X X X X X X X X *
Table summarising the changes observed in microinjected cells compared with controls, as discussed 
above. (-) refers to an unchanged parameter; (X )  indicates a significant change compared to the 
appropriate control; (4s) indicates a significant increase in cellular synchronicity.
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6.4.3 Effect of bacterially-produced ID? on arrhythmic HL-1 myocytes
The previous chapter reported the striking effect of ID8 produced in vitro on the 
restoration of synchrony in dyssynchronous ouabain-treated HL-1 cells, to a level which is 
comparable to that seen in WT HL-1 cells. This observation was validated by the 
demonstration here that bacterially-produced ID8 also restored synchrony and provided 
further support that this phenomenon was not an artefact of the expression system used to 
produce the protein.
6.4.4 Bystander effect
Chapter 5 reported that cells not subjected to microinjection displayed the same 
alterations in Ca2+ handling as neighbouring cells which had been injected with ID8 produced 
in vitro. Importantly, this observation was also reproduced here using bacterially produced 
ID8, and showed that the existence of a ‘bystander1 effect in our experiments is robust and 
not dependent on the source of the injected protein. A strong bystander effect has 
significant implications for the therapeutic modulation of synchrony in the intact myocardium 
and this will be discussed in more detail in Chapter 8.
The results presented here persuasively show that microinjection of a discrete and 
identifiable cell population triggered changes in neighbouring cells (a phenomenon termed 
the bystander effect). This phenomenon is more fully appraised in Chapter 8. It should be 
noted that in all experiments presented in this thesis, the findings must be interpreted in the 
knowledge of an existing bystander effect. Despite several experimental manipulations, we 
were not able to block this effect (see Chapter 8). Consequently, it is accepted that a 
limitation of the conclusions presented in this thesis is that we did not separate out the 
distinct effects of recombinant RyR2 fragments in isolated populations of microinjected cells, 
versus those results obtained in the presence of a bystander effect. Ongoing experiments 
are presently addressing this issue.
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Determining the effects of IDi® on IP3R- 
dependent Ca2* signalling in HEK cells
Chapter 7
7.1 Introduction
7.1.1 Inositol 1,4,5-trisphosphate receptors
Inositol 1,4,5-trisphosphate receptors (IP3R) are large tetrameric channels (approximately 
250-300 kDa) that belong to a superfamily of ion channels with six TM domains. They are 
unique in exhibiting dual regulation of channel opening by two second messengers, IP3 and 
Ca2+ and are responsible for the generation and control of diverse and complex Ca2+ signals 
(Dawson 1997; Taylor 1998).
Although RyRs are the principal Ca2+ release channels within cardiomyocytes, they are 
not the only route for Ca2+ to be mobilised from intracellular stores. Cardiac myocytes also 
express IP3Rs, albeit at -1 00-fold lower levels than RyRs. Although IP3Rs absolutely require 
lnsP3 for activation, they can also be considered as CICR channels, since cytosolic Ca2+ has 
a bimodal effect on IP3R open probability similar to its actions on RyR (Roderick et al. 2003). 
IP3Rs are structurally and functionally similar to RyRs. They have the same tetrameric 
quatrefoil structure and similarly possess carboxy-terminal transmembrane helices that form 
the ion pore and a large cytoplasmic amino-terminal portion (Bootman & Roderick 2008) 
(Figure 7.1). Like RyRs, three isoforms of IP3R have been identified (Blondel et al. 1994; 
Iwai et al. 2005; Newton et al. 1994; Yamada et al. 1994; Yamamoto-Hino et al. 1994). 
Although each isoform has a different affinity to IP3, biochemical analysis showed a similar 
affinity of the IP3-binding core to IP3 for each of the isoforms thus revealing that the IP3- 
binding suppressor domain linked to the N-terminal side of the binding core may be 
responsible for the isoform-specific tuning of IP3-binding affinity (Iwai et al. 2007).
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Figure 7.1. Five-domain structural model IP3R
The structure of IP3R (depicted here as IP3R1) is divided into five functional domains. The binding of 
IP3 is transduced by the N-terminal and internal coupling domains to the gatekeeper domain, which 
triggers a conformational change in the activation gate formed within the transmembrane/ channel- 
forming domain (Mikoshiba 2007).
The three-dimensional structure of IP3R1 has been visualised by several groups using EM 
(da Fonseca et al. 2003; Hamada et al. 2002, 2003; Jiang et al. 2002b; Sato et al. 2004; 
Serysheva et al. 2003) that revealed a reversible transition between two distinct structures 
with four-fold symmetry -  a ‘windmill’ structure and a ‘square’ structure (Figure 7.2). 
Supporting biochemical studies suggested that transition from the ‘square’ to the ‘windmill’ 
conformation was promoted by Ca2+ via the relocation of four peripheral IP 3-binding 
domains. The structure in the absence of Ca2+, as reconstructed using EM, shows a 
‘mushroom-like’ appearance, similar to RyR, consisting of a large square-shaped head and a
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small channel domain linked by four thin bridges. The ‘windmill-like’ form that occurs in the 
presence of Ca2+ also contains four bridges connecting the IP3-binding domain with the 
channel domain, verifying the Ca2+-dependence of the three-dimensional structure of IP3R 
(Mikoshiba 2007).
i  *
+Ca2+
%
-Ca2
Square Windmill
Figure 7.2. Model for the global structural changes that occur within IP3R1
Proposed 3D model for the large-scale redistribution of the IP3-binding domains. The plausible IP3- 
binding cores (blue) are liganded with IP3 (red molecules) and a 38-kDa fragment by Lys-C digestion 
(green) (Mikoshiba 2007).
The previous chapters showed that ID8 modulated RyR2 Ca2+ release, presumably by 
altering intra-molecular rearrangement -  a mechanistic feature common to both RyR2 and 
IP3R. Like RyR, the structure of IP3R has traditionally been divided into functional domains: 
the N-terminal ligand-binding domain; the modulatory/coupling domain; and the C-terminal 
transmembrane/channel-forming domain (Furuichi et al. 1989, 1994). Studies have 
suggested that the channel-forming domain of IP3R1 is necessary to keep the channel 
closed, and that the binding of IP3 is transduced by long-range modulation of N-terminal and 
internal coupling domains to the gatekeeper domain, which triggers a conformational change 
the transmembrane channel-forming domain (Mikoshiba 2007).
As discussed in Chapter 3, bioinformatic comparisons revealed striking structural 
homology between sub-fragments of the RyR2 l-Domain and l-Domain-like regions of IP3R,
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despite the absence of any notable primary sequence homology between these two Ca2+ 
release channels (Appendix II). In light of this, the study of RyR2 l-Domain fragments, that 
exhibited profound effects on RyR2-dependent Ca2+ handling, was extended to investigate 
their effects on IP3R channel regulation.
7.1.2 The role of IP3R in cardiac arrhythmias
There is good evidence that IP3Rs are associated with cardiac arrhythmias. IP3-induced 
Ca2+ release from the SR and the nuclear envelope may initiate arrhythmias and alter gene 
expression to induce hypertrophy and HF, as discussed above. In support of this, many 
signalling systems that converge on IP3R, most notably the sympathetic, the renin- 
angiotensin (RA) and the endothelin systems, are activated during cardiac diseases 
associated with arrhythmias, pathological hypertrophy and HF. Substantive evidence 
suggests that IP3 signalling may be involved in the development and/or maintenance of atrial 
fibrillation, reperfusion arrhythmias, ankyrin-B-related arrhythmias, diabetic cardiomyopathy, 
hypertrophy and HF (summarised in Figure 7.3).
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Figure 7.3. Overview of cardiac IP3R signalling and its involvement in EC coupling, excitation- 
transcription (ET) coupling and arrhythmias.
Schematic drawing of an adult cardiac myocyte showing parts of the sarcolemma, the nucleus, the SR 
and the myofilaments. G protein-coupled receptors (GPCR) increase cytoplasmic IP3 concentration 
via activation of phospholipase C (PLC). EC-coupling is mediated by CICR from the SR through 
RyR2. Cytoplasmic Ca2+ binds to the myofilaments and initiates contraction. IP3-induced Ca2+ 
release from the SR through IP3Rs may contribute to EC-coupling by increasing the Ca2+ transient 
and thus contraction. On the other hand, IP3-induced Ca2+ release from the SR may trigger further 
Ca2+ release through neighbouring RyR2 with subsequent activation of sarcolemmal NCX. This 
induces arrhythmias via generation of DADs and triggered activity. IP3-induced SR Ca2+ release also 
generates pro-arrhythmic Ca2+ alternans (Kockskamper et al. 2008).
Furthermore, a recent study by Domeier et al. (2008) reported that lnsP3R activation 
underlies the positive inotropic action of endothelin-1 (ET-1) on ventricular myocytes. ET-1 
is a potent vasoconstrictive hormone that has been shown to have inotropic, arrhythmic, and 
hypertrophic effects on cardiomyocytes. Despite the relatively low levels of lnsP3R in 
cardiac cells, they can influence cardiac Ca2+ signalling by contributing to systolic Ca2+ 
increases because of the ability to act as ‘feed-forward’ CICR channels (Figure 7.3). Binding
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of IP3 to IP3Rs primes them for activation by Ca2+, and also increases their sensitivity to Ca2+ 
(Kockskamper et al. 2008). Therefore, with substantial increases of intracellular IP3 
concentrations as may occur following stimulation of cardiomyocytes with Gq protein-coupled 
agonists, IP3Rs can become activated at normal diastolic Ca2+ levels, or during the recovery 
of a stimulated Ca2+ transient (Gilbert et al. 1991). The promiscuous opening of IP3Rs during 
the otherwise quiescent diastolic period under these conditions is therefore the cause of 
arrhythmic Ca2+ transients and their associated electrical activity (Mackenzie et al. 2002).
It has also been shown that IP3Rs in heart tissue respond weakly to IP3, resulting in a 
slow Ca2+ release (Kentish et al. 1990). It is thought that this slow release prevents the Ca2+ 
generated by IP3 from inducing CICR. Instead, the Ca2+ generated by IP3 has been found to 
initiate slow Ca2+ oscillations (Zhu & Nosek 1991) that potentially have at least three acute 
effects on the cardiac AP. Firstly, they can stimulate a transient inward current (lti) evoking 
DADs so that triggered activity can develop in otherwise quiescent ventricular muscle 
(Woodcock et al. 2000). Secondly, slowed repolarisation caused by elevated [Ca2+]i favours 
conditions for Ca2+ re-entry (Kleber & Fast 1997); and thirdly, it can cause intercellular 
uncoupling with conduction slowing (Woodcock et al. 2000). Any of these alterations in 
myocardial electrical activity are potentially pro-arrhythmic. Furthermore, IP3 has been 
reported to activate NCX (Gilbert et al. 1991), which may also be arrhythmogenic.
7.1.3 HEK293 cells as a model system
The HEK cell line has been extensively used as an expression tool for recombinant 
proteins since it was generated over 25 years ago by Graham et al. (1977). The 
transformation of human embryonic kidney (HEK) cells following exposure to sheared 
fragments of human adenovirus type 5 (Ad5) DNA generated the widely used HEK293 cell 
line. This permanently transformed cell line has incorporated Ad5 into chromosome 19 of 
the host genome, a modification used subsequently for the generation of transcription 
incompetent human adenoviral vectors (Thomas & Smart 2005). The current commercially
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available source of HEK cell is from the original transformation (Graham et al. 1977). 
Although of epithelial origin, its biochemical machinery is capable of carrying out most of the 
post-translational folding and processing required to generate functional, mature protein from 
a wide spectrum of both mammalian and non-mammalian nucleic acids.
The principal attributes which have made the HEK cell a popular choice of model system 
to study receptor channels include its quick and easy reproduction and maintenance; 
amenability to transfection using a wide variety of methods; high efficiency of transfection 
and protein production; faithful translation and processing of proteins; and small cell size 
with minimal processes appropriate for voltage-clamp experimentation. These, and other 
attributes, also mean that complementary biochemical/cell biological evaluations of 
expressed proteins can be performed in parallel with functional analyses to establish 
detailed pharmacological and biophysical profiles for the action of new drugs and their 
targets (Thomas & Smart 2005).
Though popular as a transient expression system, this cell type has also been widely 
employed in stable transfection studies, and has been utilised for functional and biochemical 
studies on ionic channel proteins. Given its RyR-null status, HEK cells have proven useful in 
expressing all three isoforms of RyR for structure-function studies (Rossi et al. 2002; Xiao et 
al. 2002). Consequently, in this thesis HEK293 cells were used as a well-characterised, 
IP3R sufficient, RyR2-deficient model in which to investigate the effects of l-Domain sub­
fragment proteins on IP3R-dependent cellular Ca2+ handling.
7.1.4 The use of ‘noise’ analysis to analyse Ca2* transients
Unlike HL-1 cell monolayers, HEK cells do not exhibit large, spontaneous intercellular 
Ca2+ release and thus the mode of data analysis used extensively for HL-1 cells experiments 
(SALVO) was not a suitable analysis tool for the analysis of agonist-evoked Ca2+ signalling in 
HEK cells. Instead cellular noise was analysed by looking at signal variability (SV), which 
quantifies subtle changes in cellular Ca2+ cycling and can be used to determine cell-to-cell
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signal variability, in addition to agonist-induced changes within the same cell (George et al. 
2006).
7.1.4.1 Relative signal variability (RSV)
George et al. (2006) developed a novel calculation to assess relative changes in Ca2+ 
signal variability (SV) within a cell following the administration of Ca2+ channel agonists, 
termed the relative signal variability (RSV). The SV is calculated by the sum of point-to-point 
differences in Ca2+-dependent fluorescence signals and as such is not influenced by agonist- 
induced gradients or background ‘drift’ in the data.
RSV (see Figure 7.4) is calculated by comparing the SV in a signal trace following cellular 
activation (i.e. by Ca2+ channel openers) (SVB) to the pre-activation SV in the same trace 
(SVA) i.e.
RSV = SVb/SVa
SV = (B-A)+(C-B)+(D-C)+(E-D)+(F-E)+(G-F)+(H-G)+(I-H)+(J-I)+(K-J)+(L-K)+(M-L)
B
post-activationpre-activation
SV SV,
Figure 7.4. Calculation of SV and RSV
Panel A: Schematic illustration for calculating signal variability (SV), where SV is the sum of point-to- 
point differences in Ca2+ signals over a set time. Panel B: Schematic illustration for calculating 
relative signal variability (RSV) as a change in cellular Ca2+ handling before (SVA) and after (SVB) 
agonist administration in the same cell.
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7.1.4.2 Indicators of signal variability
Studies in our laboratory have clearly demonstrated the limited utility of some commonly 
used indices of signal variability, including the F-ratio, coefficient of variance (CoV) and 
standard deviation (Fry 2008) since all of these indices of signal variability are significantly 
influenced by the inherent gradient or ‘drift’ frequently present in our confocal experiments 
(Figure 7.5).
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Figure 7.5. Correlation between common indices of signal variability and gradient
Gradient in the fluorescent signal was associated with an increase in signal variability as determined 
by standard deviation (A), variance (B), CoV (C) and log transformed variance (D). r2 refers to the 
gradient of the slope calculated by linear regression; p is the probability that the slope is significantly 
different to zero. Data are taken from fluo4-loaded HEK cells and was kindly supplied by Debra Fry 
(Fry 2008).
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Analysis of Ca2+ traces from different non-stimulated cells was therefore performed using 
signal variability (SV) normalised to mean fluorescence (SVm), a novel indicator of signal 
variability. As shown in Figure 7.6, SVm is largely independent of gradient and the signal 
intensity of the Fluo-4 loaded cells (mean fluorescence), and therefore provides a suitable 
and robust indicator of signal variability in this experimental system.
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Figure 7.6. Signal variability (SV) normalised to mean fluorescence (SVm) is independent of 
fluorescence and gradient.
Scatter plots of data obtained from HEK cells (n=221) showing the relationship between SV with mean 
fluorescence (A) and gradient (B), and SVm with mean fluorescence (C) and gradient (D). r2 refers to 
the gradient of the slope calculated by linear regression; p is the probability that the slope significantly 
different to zero. Data were taken from fluo4-loaded HEK cells and was supplied by Debra Fry (Fry 
2008).
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7.1.5 Objectives of this chapter
This chapter investigated the effect of Ml of l-Domain proteins into HEK cells, by studying 
changes in agonist-evoked IP3R-dependent Ca2+ transients, as opposed to the 
spontaneously oscillating Ca2+ signals in HL-1 cardiac cells. This chapter aimed to 
determine whether recombinant ID8 can modulate IP3R as would be predicted from 
bioinformatic analysis. The study was also extended to investigate the effects IDA and IDC 
on IP3R-dependent signalling using the fragments synthesised in vitro (Chapter 3).
7.1.6 Specific Hypothesis
In consideration of the putative structural homology between RyR2 ID sub-fragments and 
specific regions of the IP3R (Appendix 2) it may be expected that a possible interaction 
between these two regions modulates IP3R channel activity. We test this hypothesis in the 
present chapter.
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7.2 Methods
7.2.1 Preparation of HEK293 ceils for Ml
HEK293 cells were cultured and harvested as described in Chapter 2. The harvested cell 
pellet was resuspended in supplemented DMEM (Invitrogen) before plating onto poly-lysine 
coated glass chambers (14 mm diameter, 0.1 mm thickness, MatTek) at a density of 5 x 104 
cells/chamber. The cells were initially applied to the poly-lysine-coated chambers under a 
200pl meniscus, and allowed to adhere to the glass for between 4 and 6 h before the 
chamber was flooded with an additional 1800pl of supplemented DMEM. These were left to 
adhere to the glass for 24 hours (37°C, 5% C 02, ~80% humidity) before being used for Ml 
experiments. It is important that HEK cells are not allowed to grow beyond 50-60% 
confluency, as at this stage the loss of adhesion makes Ml more difficult.
7.2.2 Ml of recombinant protein and cellular Ca2*imaging
Cells were prepared for Ml as described above, before loading with Fluo-4AM (10 pM in 
20% (w/v) pluronic acid F-127 dissolved in DMSO) in non-supplemented DMEM pre-warmed 
to 37*0. The dye-containing solution was added to each chamber as a 200 pi meniscus and 
incubated for 30 minutes (37*0, 5% CO 2, ~80% humidity). The cells were then immersed in 
a further 1800pl pre-warmed non-supplemented media 15 minutes prior to Ca2+ imaging. 
Ca2+ dependent Fluo-4AM fluorescence was imaged using a Leica RS2 confocal microscope 
with an oil immersion 40x objective lens, using an Argon/Krypton laser (excitation at 488nm, 
and the fluorescence emission detected at 500nm). 8-bit scaled data were acquired every 
200 ms (5 Hz) in a field of view at 512 x 209 pixel resolution. Resting cells were imaged for 
1 minute (300 frames) prior to Ml in order to obtain a measurement of basal fluorescence 
levels.
Proteins synthesised and purified as described in Chapter 3 were injected into HEK293 
cells using the optimal conditions determined in Chapter 4. The MagZ-purified protein
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(Chapter 3) in injection buffer (100mM potassium chloride, 5mM potassium phosphate, pH 
7.4; using chelex-treated dH20 ), was co-injected with Alexa-647 dye conjugated to a 10,000 
MW dextran (1pg/ml stock) as a non-transferable cellular marker of injection that enables the 
identification of microinjected cells, in a protein:buffer:dye of 1:2:1 (v/v) ratio. Approximately 
twenty cells per field of view were injected within a time frame of < 2 minutes, and allowed to 
recover for 5 minutes. After this time cells were imaged for 60 seconds (300 frames) before 
the addition of caffeine or carbachol, followed by imaging for a further 60 seconds (300 
frames) as summarised in Figure 7.7. In every Ml experiment, RRL without l-Domain 
protein, yet processed using MagZ-purification under exactly the same conditions as the 
RRL samples in which the l-Domain protein was synthesised, was used as a control for the 
reasons discussed previously (Chapter 4).
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Figure 7.7. Schematic of Ml experiments with HEK293 cells.
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Data were acquired from regions of interest (ROIs) representing global Ca2+ 
environments, typically approximately 50 pm2 in area (~ 200 pixels). These were collected 
and analysed using Leica confocal software (Leica Microsystems, Heidelberg, Germany). 
Further analysis was carried out using Microsoft Excel software and Graphpad Prism, in 
order to quantify the transient parameters outlined in Figure 7.8.
max
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\ra te  dow n
amplitude
rate up
mean
baseline
SV,SV,
Figure 7.8. Quantifying intracellular Ca2+ signalling in HEK293 cells
Schematic diagram illustrating Ca2+ transient analysis parameters in HEK293 cells.
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7.3 Results
7.3.1 Ml of recombinant proteins and markers in HEK293 cells
l-Domain proteins synthesised and purified as described in Chapter 3, were successfully 
microinjected into HEK293 cells, using the parameters optimised previously (Chapter 4). 
The use of a 647-alexa conjugated dye enabled the easy visual detection of microinjected 
cells (Figure 7.9, E). As with HL-1 myocytes, cell phenotype and Fluo-4 fluorescence 
appeared to be unaltered by Ml, indicating that Ml conditions were minimally invasive and 
well-tolerated by the cell (Figure 7.9, B and D respectively).
c
E
Fluo-4 Alexa 647
Figure 7.9. Ml of proteins into HEK293 cells
Panel A: Phase contrast image of the field of view, the arrowhead shows the tip of the microcapillary 
moved to a focal plane above the cells. Panels B & C: Fluorescent signals prior to Ml. Panels D & 
E: the same field of view 5 minutes after Ml with Alexa 547 dextran. The Fluo-4 loaded cells appear 
unchanged (D) while the microinjected cells are clearly identifiable (E). Scale bar: 25 pm
/
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7.3.2 Effect of l-Domain proteins on IP3R carbachol-induced Ca2+ transients
Although the data presented above suggested that, under optimised conditions, Ml was 
well tolerated by HEK cells, I previously showed that Ml procedure modulated cellular 
phenotype and signalling (Chapters 4 and 5). Therefore, as before, a number of rigorous 
controls, including the use of MagZ-treated RRL that had not been used for producing I- 
Domain protein, were performed.
It was found that Ml of RRL or ID fragments altered the proportion of cells responding to 
carbachol compared to WT HEK cells (Figure 7.10). The number of cells responding to 
0.1 mM carbachol was reduced from 86% in WT HEK cells to 60% in those injected with RRL 
containing no recombinant protein. Ml of ID6 or IDC into the HEK cells markedly reduced 
carbachol-evoked Ca2+-release at carbachol concentration of 0.1 mM, and the percentage of 
responding cells was decreased to 25% and 19% respectively.
Microinjected cells exhibiting a response to 
carbachol
100 n
60
*
20
sP O'-
0
0.001 0.01 0.1 
C arbachol (m M )
Figure 7.10. Ml of l-Domain proteins reduces the percentage of cells responding to 0.1 mM 
carbachol.
Line chart depicting the proportion of cells responding to carbachol as a percentage of the total cells 
imaged, before (HEK) or after microinjection with RRL or ID proteins, n > 100 cells per data point.
HEK
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7.3.2.1 Effect of l-Domain proteins on Ca2+ transient characteristics
As discussed above, Ca2+ transient modulation was investigated using noise analysis. 
Analysis of carbachol-induced Ca2+ transient characteristics in those cells which did respond 
to 0.1 mM carbachol showed that injection of RRL into HEK cells did not alter the amplitude, 
rate up, or rate down of the transients (Figure 7.11). In contrast, Ml of the l-Domain 
fragments, in most cases, significantly changed these parameters compared to the RRL- 
injected controls. Injection of IDA significantly increased both the rate up and rate down of 
the transients. IDB and IDC both significantly decreased the amplitude of the carbachol- 
induced Ca2+ transient. IDC was also linked to a significant increase in rate up and rate down 
of the transient. The rate down in ID6 could not be determined, partially because of the very 
small number of IDB-injected cells which responded to 0.1 mM carbachol, but also because in 
those cells which did respond, only a small fraction displayed a Ca2+ transient which returned 
to basal Ca2+ levels (Figure 7.11, B).
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Figure 7.11. l-Domain proteins blunt carbachol-evoked Ca2+ transients
Panel A: Changes in carbachol-induced Ca2 transients after Ml of ID fragments (mean ± SEM, n=5- 
7, 15-20 cells per experiment). *  represents p<0.001 when compared with RRL-injected HEK cells; 
nd; not determined Panel B: Representative traces of carbachol-induced Ca transients in WT and 
injected HEK cells. Arrow heads indicate point of carbachol addition.
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Interestingly, as observed in HL-1 myocytes, non-injected HEK cells (‘bystanders’) in the 
same field of view showed similarly altered Ca2+ transients to those which had been injected 
with ID proteins (Figure 7.12). In every case, there is no significant difference between the 
injected and non-injected cells, and this finding further corroborated the results obtained in 
HL-1 myocytes after injection of bacterial- or in wYro-synthesised ID6.
Am plitude
Microinjected cells
Non-microinjected 
‘bystander’ cells
RRL ID -A  ID-B ID-C
Rate up
7 i
RRL ID -A  ID-B ID-C
Rate down
2
RRL ID A  ID B  ID C
Figure 7.12. Changes in carbachol-evoked Ca2+ transients were also seen in non-injected cells
Changes in carbachol-induced Ca2+ transients after Ml of ID fragments were seen in bystander cells 
(striped bars) as well as microinjected cells (solid bars) (mean ± SEM, n=5-7, 15-20 cells per 
experiment). Data for microinjected cells is taken from Figure 7.11. There was no significant 
difference between microinjected and bystander cells for any ID fragment.
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The addition of 5 mM EGTA, a Ca2+ chelator, to cell medium prior to the addition of 
carbachol (0.001 -  0.1 mM), reduced the magnitude of carbachol-evoked Ca2+ release to 
similar levels in cells exposed to 0.1 mM and 0.01 mM carbachol (Figure 7.13). 
Contrastingly, cells bathed in normal medium (containing approximately 1.3mM Ca2+), 
exhibited a significantly increased Ca2+ release evoked by 0.1 mM carbachol compared to 
0.01 mM. These data indicate that the addition of 0.1 mM carbachol triggers Ca2+ influx, while 
the Ca2+ response at 0.001 mM and 0.01 mM are due largely to Ca2+ release from 
intracellular stores. Given that both ID8 and IDC reduced Ca2+ transients in response to 0.1 
mM carbachol (Figure 7.11), the data suggest that these fragments may affect some mode 
of Ca2+ influx.
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Figure 7.13. Removal of extracellular Ca2+ limits cellular response to 0.1mM carbachol
Addition of 5mM EGTA to the culture medium did not affect carbachol-evoked Ca2+ transients at 0.001 
mM carbachol, but significantly reduced it at 0.1 mM (mean ± SEM, n = 4 ,15-20 cells per experiment). 
★ represents p<0.001 when compared to HEK cells in normal DMEM.
7.3.2.2 Effect of l-Domain proteins on cell ‘noise’ in carbachoi-responsive cells
SALVO analysis of HL-1 cells shows a modification of cellular noise in cells exposed to 
ID8. This was also investigated in HEK cells by calculating the SVm and relative signal RSV
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as described in the Methods section above. Basal and agonist-evoked signal variability 
(SVm and RSV respectively) in RRL-injected control cells was not significantly different to 
that determined in WT HEK cells (Figure 7.14). Injection of l-Domain proteins, however, 
significantly reduced the RSV in cells injected with IDB and IDC (Figure 7.14, B) in carbachol- 
responsive cells, while the SVm was significantly reduced with injection of all three truncated 
l-Domain proteins (Figure 7.14, A). As before, these changes were mirrored in the 
surrounding non-injected cells (Figure 7.14, C & D), as was the markedly reduced proportion 
of responding cells (IDB - 45%; IDC - 30%) compared to WT HEK cells (86%), though they 
remained more responsive than microinjected cells (ID8 - 25%; IDC -19% ).
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Figure 7.14. Ml of l-Domain fragments reduces cellular ‘noise’ in carbachol-responsive HEK 
cells
Panels A & B: Ml of ID fragments significantly reduced signal variability. Panels C & D: changes in 
cellular signal variability after Ml of ID fragments were seen in both microinjected (solid bars) and 
(mean ± SEM, n=5-7, 15-20 cells per experiment). *  represents p<0.05 when compared with RRL- 
injected HEK cells. There was no significant difference between microinjected and bystander cells for 
any ID fragment.
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7.3.2.3 Carbachol-induced Ca2*-transients are modulated by cellular noise
Interestingly, a comparison of the SVm in carbachol-responsive and non-responsive HEK 
cells showed a relationship between the SVm and whether or not a carbachol-induced Ca2+ 
transient was triggered by the addition of 0.1 mM carbachol. It was found that, in general, 
carbachol-responsive HEK cells had a mean resting SVm that was significantly higher than 
that measured in non-responsive cells (16.22 ± 0.34 versus 10.90 ± 0.32, p<0.05) (Figure 
7.15).
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Figure 7.15. A reduced resting SVm is associated with a lack of carbachol-evoked Ca2+ 
response in HEK cells
Resting SVm in carbachol-responsive cells is significantly higher than that in non-responsive cells, 
p<0.001. Bars indicate mean ± SEM, n >500 cells.
Figure 7.16 further shows that in cells responding to carbachol, some of the 
characteristics of the carbachol-evoked Ca2+ transients are linked, in some instances, to the 
basal signal variability pre-existing in those cells. As shown in Figure 7.14, SVm is reduced 
following exposure to ID fragments and this appears to modulate the amplitude and temporal 
kinetics of the Ca2+ transients, and the data presented in Figure 7.15 suggests that there is a 
link between reduced SVm and the absence of a carbachol-evoked Ca2+ in the cell. This 
observation was extended by the data shown in Figure 7.16, which shows that a reduced 
SVm may modulate certain aspects of the transients, and this is seen to different extents 
after exposure to different ID fragments, as summarised in .
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Figure 7.16. The relationship of SVm with amplitude and kinetic properties of carbachol 
induced Ca2+ response
r2 and p values for each scatterplot are summarised in Table 7.1
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Table 7.1. Correlation of SVm with carbachol-evoked Ca2+ transients
~ ~  " 1
Microinjected Bystander Microinjected Bystander Microinjected Bystander
r 2 P r2 P
Correlation
significantly
different?
r2 P r2 P
Correlation
significantly
different?
r2 P r 2 P
Correlation
significantly
different?
HEKWT n/a n/a 0.051 * n/a n/a n/a 0.004 ns n/a n/a n/a 0.062 * n/a
RRL 0.156 * 0.219 ** ns 0.019 ns 0.001 ns ns 0.056 ns 0.001 * * * ns
IDA 0.019 ns 0.385 * * * ns 0.121 * 0.428 * * * * 0.021 ns 0.188 * ns
IDB 0.964 * * * 0.459 * ns 0.775 * * 0.363 ** ns 0.276 ns 0.254
ns ns
IDC 0. 809 * * * 0.512 * * * * * * 0.026
ns 0.078 ns ns 0.094 ns 0.195
ns *
Abbreviations: r2 indicates the extent of correlation between x and y; p is the probability that r2 is significantly different to zero; 
ns -  not significant; * significant at p<0.05; ** significant at p<0.01; *** significant at p<0.001
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7.3.2.4 Effect of l-Domain proteins on cell ‘noise’ in non-responding cells
Notably, a significant proportion of cells transduced with ID fragments did not respond to 
carbachol, even at a concentration of 0.1 mM. We investigated whether this surprising 
finding was underpinned by changes in the homeostatic Ca2+ handling in these cells. ‘Noise’ 
analysis was chosen as an appropriate analytical tool since previous studies have shown the 
broad applicability of detailed signal variability analysis to Ca2+ cycling (George et al. 2006). 
In cells that did not exhibit carbachol-evoked Ca2+ transients, there was no significant 
difference between post- and pre-carbachol signals in WT HEK cells and the RRL-injected 
controls. However, consistent with the observations in carbachol-responsive cells, we 
determined a significant decrease in post-carbachol signals in cells microinjected with any of 
the three l-Domain fragments. Notably, this suppression of Ca2+ trace variability following 
carbachol addition was also evident in cells that had not been transduced with the l-Domain 
fragments and provided further evidence of the ‘bystander’ effect.
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Figure 7.17. Ml of l-Domain fragments reduces RSV in carbachol non- responsive HEK cells
Ml of ID fragments significantly reduced cellular noise after the addition of carbachol. Changes in 
cellular signal variability after Ml of ID fragments were seen in both microinjected (solid bars) and 
(mean ± SEM, n=5-7, 15-20 cells per experiment). *  represents p<0.05 when compared with RRL- 
injected HEK cells. There was no significant difference between microinjected and bystander cells for 
any ID fragment.
7.3.3 Effect of l-Domain proteins on IP3R caffeine-modulated Ca2+ handling
Next, we investigated the effect of the l-Domain proteins on cellular Ca2+ handling in 
response to the addition of caffeine, which does not induce a Ca2+ transient via IP3R. Ml of 
RRL did not alter the post-caffeine signals compared to WT HEK cells, but cells injected with 
IDa, ID8 or IDC displayed a dramatically decreased Ca2+ signal variability following addition of 
10mM (Figure 7.18).
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Figure 7.18. Ml of l-Domain fragments reduces RSV in response to caffeine addition
Ml of ID fragments significantly reduced cellular noise after the addition of caffeine. Changes in 
cellular signal variability after Ml of ID fragments were seen in both microinjected and non-injected 
bystander cells (mean ± SEM, n=5-7, 15-20 cells per experiment). *  represents p<0.05 when 
compared with RRL-injected HEK cells. There was no significant difference between microinjected 
and bystander cells for any ID fragment.
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7.4 Discussion
7.4.1 Ml of recombinant proteins in HEK293 cells and their effect on Ca2* handling
As in previous chapters, cells injected with RRL were used as controls for all Ml 
experiments. The data presented here shows that, unlike in HL-1 myocytes, the injection of 
RRL did not significantly alter Ca2+ handling in HEK cells, and RRL-injected cells produced 
similar carbachol-evoked responses to non-injected WT HEK cells. This could be due to 
multiple factors, including, but not limited to, (1) the possibility that the mode of Ca2+ cycling 
in HEK cells is fundamentally different than that occurring in HL-1 myocytes, or (2) given the 
large global Ca2+ oscillations characteristic of HL-1 cells, it may be easier for our 
experimental system to dissect alterations in HL-1 cell Ca2* handling.
Even noting the above considerations, the injection of ID proteins into HEK cells did 
profoundly affect cellular Ca2* handling phenotype. Specifically, it reduced IP3R-dependent 
Ca2* responses evoked by stimulation with 0.1 mM carbachol. This surprising finding 
confirmed and extended studies (Chapters 4, 5 and 6) that showed the modulatory effects of 
ID on RyR2-dependent signalling. In the present chapter, the effects of ID on IP3R- 
dependent Ca2* signalling are determined, entirely consistent with our bioinformatic analysis 
that revealed significant structural homology between ID and ID-like regions of IP3R. 
Furthermore, the demonstration that ID-mediated Ca2* modulation exists between different 
cell types (non-excitable and excitable) suggests that their effects are unlikely to be artefacts 
of the experimental conditions and techniques used.
It was also evident that Ca2* transient ‘shape’, which reflects the balance between ER 
efflux and sequestration mechanisms and a contributory role of PM Ca2* fluxes, was altered 
following Ml of ID fragments. Whether this occurs directly as a result of modulating IP3R, or 
as a downstream consequence of ID-mediated IP3R Ca2* signalling remains to be 
determined. We also cannot exclude the possibility that the ID fragments associate with, and 
modulate, other facets of HEK Ca2* handling machinery.
It is interesting that other work in our laboratory has recently shown that chronic
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expression of ID8 causes a profound downregulation of IP3R activity (Fry et al. 2007). In 
keeping with this finding, the small fraction of IDB-injected HEK cells which did respond to 
carbachol mostly exhibited a decreased amplitude followed by a sustained increase in 
intracellular Ca2+, where the transient did not return to basal levels. This decreased 
amplitude is concordant with a downregulation of IP3R, though the sustained increased Ca2+ 
levels may implicate IDB-linked inhibition of Ca2+ sequestration machinery, such as SERCA.
The contribution of influx of Ca2+ from the extracellular medium to carbachol-evoked Ca2+ 
transients was also shown by experiments where the Ca2+-chelator, EGTA was added to the 
culture medium prior to carbachol addition. The dampened Ca2+ response observed in cells 
pre-exposed to EGTA suggested that Ca2+ influx contributed to the amplitude of agonist- 
induced Ca2+ release at 0.1 mM carbachol. Clearly, the mechanistic basis of our findings in 
this context requires further investigation.
7.4.2 Effect of l-Domain proteins on cell ‘noise’
Subtle changes in cellular Ca2+ cycling in HEK cells were investigated and quantified by 
calculation of the signal variability due to agonist-induced changes within the same cell. 
Basal and agonist-evoked signal variability (SVm and RSV, respectively) in RRL-injected 
control cells were not significantly different to that determined in WT HEK cells. 
Contrastingly, Ml of l-Domain proteins significantly reduced the RSV in cells injected with ID8 
and IDC in carbachol-responsive cells, and the SVm was significantly reduced with injection of 
all three truncated l-Domain proteins. Since the SVm is an index of basal Ca2+ handling, 
derived from the actions of multiple Ca2+ signalling moieties (e.g. SERCA and IP3R), the 
observation that ID-fragments suppressed these fluxes may be a robust indicator that ID- 
targeted approaches may be useful in suppressing abnormally high levels of intracellular 
Ca2+ flux that frequently characterises cellular pathology (e.g. necrosis). Interestingly, a 
comparison of the SVm in carbachol-responsive and non-responsive HEK cells showed that, 
in general, mean resting SVm was significantly higher in carbachol-responsive HEK cells.
254
Chapter 7
This implies that the amplitude variability of resting Ca2+ fluxes is proportionally linked with 
the propensity of the cell to respond to 0.1 mM carbachol. It is tempting to speculate that the 
association between cellular ‘noise’ and agonist response may be a reflection of the relative 
stability of the Ca2+ release channels involved. This concept is supported by the 
observations that molecular instability of RyR2 correlates with increased intracellular Ca2+ 
fluxes (George et al. 2006; Yano et al. 2006).
7.4.3 Bystander effect in HEK cells
In agreement with the data presented in Chapters 5 and 6, a bystander effect was 
observed in non-injected HEK cells after Ml of any of the three truncated ID proteins. These 
observations together showed that the existence of a ‘bystander’ effect in our experiments is 
robust and not dependent on the source of the injected protein, or the cell type into which 
they are injected. In order to further corroborate this finding, the mechanisms underlying the 
bystander effect will be investigated in the context of cell-to-cell communication, and via the 
extracellular release of soluble factors. This will be discussed in more detail in Chapter 8.
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Insights into the mechanistic basis of
the bystander effect
Chapter 8
8.1 Introduction
8.1.1 The bystander effect
This thesis has provided compelling evidence for a bystander effect, whereby non­
injected cells showed the same Ca2+-handling phenotypes as adjacent cells that had been 
microinjected with l-Domain fragments. The bystander effect was corroborated in different 
cell types (HL-1 and HEK cells) and using recombinant proteins produced via distinct 
synthetic routes (bacterial expression and in vitro synthesis).
The ‘bystander effect’ is a phenomenon which has also regularly been reported in cells 
after exposure to ionising radiation treatment in cancer therapy, where irradiated cells may 
also transmit damage signals to non-irradiated cells in a population, leading to the 
occurrence of genetic damage effects in these ‘bystander’ cells that in themselves receive 
no radiation exposure (Chaudhry 2006; Little 2006; Morgan 2003; 2007). The recent interest 
in this phenomenon was stimulated by the findings of Nagasawa and Little (1992), who 
demonstrated that when cell monolayers were exposed to mean a-particle doses where as 
few as <1% of the nuclei were traversed by a single a-particle track, more than 30% of the 
non-irradiated cells exhibited effects associated with direct ionising radiation (Nagasawa & 
Little 1992). Since this study, numerous laboratories have reported in vivo and in vitro 
bystander effects in a wide variety of cell types, and following exposure to both particulate 
and electromagnetic radiation (Hamada et al. 2007b).
It has been proposed that there may be two basic mechanisms by which ‘damage’ signals 
may be transmitted from irradiated to non-irradiated cells. The first is by direct cell-to-cell 
contact often mediated by gap junction intercellular communication (GJIC) (Azzam et al. 
2001; Shao et al. 2003), whereas the second is by means of soluble factors released into 
the surrounding medium by irradiated cells (Azzam et al. 1998; Prise et al. 1998). There is 
substantial evidence that irradiated individuals may release clastogenic factors into their 
plasma that can induce chromosomal damage when transferred to cultured cells from 
normal donors (Emerit et al. 1994; Gemignani et al. 1999; Lloyd & Moquet 1985). Similar
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phenomena have been shown in rodent models, although in all cases the nature of these 
clastogenic factors has proven elusive (Morgan & Sowa 2007; Pant & Kamada 1977).
8.1.2 Objectives of this chapter
As discussed above, a bystander effect was reproducibly observed following the 
microinjection of l-Domain proteins into HEK293 and HL-1 cells. This chapter presents 
preliminary investigations into two mechanisms (GJIC and via extracellular transmission of 
soluble factors) that may potentially underlie the bystander effect observed in the 
experiments described in the preceding chapters.
8.1.3 Specific Hypothesis
The bystander effect is thought to be caused by two potential mechanisms -  GJIC and 
extracellular transfer of soluble substrates (i.e. a paracrine mechanism). Here, it is proposed 
that the injection of a dye into a single cell will identify GJIC as a potential mechanism if the 
dye is transferred from cell to cell. Similarly, the phenotypic effects of transferring the media 
surrounding microinjected cells onto physically separate non-microinjected cells can 
potentially identify the contribution of extracellular mechanisms to the observed 
phenomenon. This chapter specifically examines the hypothesis that a paracrine mechanism 
mediated by intercellular transfer of soluble effectors fundamentally contributes to the 
bystander effect.
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8.2 Methods
8.2.1 Lucifer Yellow
Lucifer Yellow (LY, 5% (w/v) in 0.3 M LiCI) was injected into the cytoplasm of a single cell 
in HL-1 or HEK cell monolayers prepared as described previously using the conditions 
optimised previously (Chapter 4). Direct intercellular transfer of dye that is absolutely 
dependent on GJIC, was viewed on the Zeiss Axiovert microscope using fluorescence filters 
450-490nm/510-520nm (HEK cells), or on the Leica RS2 confocal microscope using an 
Argon/Krypton laser (488nm/500nm) (HL-1 cells).
8.2.2 Medium transfer
8.2.2.1 HEK293 cells
HEK293 cells were cultured and harvested (Chapter 2) and prepared for microinjection as 
described in Section 7.2.1. Two chambers containing cells were set up and loaded with 
Fluo-4AM, as summarised in Figure 8.1. The cells in Chamber 1 were microinjected under 
the conditions optimised previously, and the medium surrounding them was transferred to 
Chamber 2 immediately after microinjection. The effects of different dilutions of transferred 
media were investigated as summarised in Table 8.1.
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Chamber 1 V.
Cells loaded with Fluo-4 
under a 200 pi meniscus
Chamber 2
Cells microinjected with 
RRL +/- IDB, under phase 
microscopy
60 mins
37°C / 5% CO.
15 mins
37°C / 5% CO,
Immersed cells in a further 
1800 pi warm media
Removed media from Chamber 2 
and transferred media from Chamber 1 
immediately after microinjection, to 
achieve required dilution of transferred 
media
60 mins 15 mins
Cells loaded with Fluo-4 
under a 200 pi meniscus
Immersed cells in a further 
1800 pi warm media
I
I  Cells allowed to 
5 mins | recover from 
microinjection
Cells imaged 
for 1 min
I  J
Ex 488 nm Em 500 nm
Figure 8.1. Summary of medium transfer experiment protocol with HEK293 cells
Table 8.1. Summary of medium dilution strategy
Required 
concentration of 
transferred medium
Volume of medium 
in Chamber 2 (pi)
Volume of medium 
transferred from 
Chamber 1 (pi)
Total volume of 
medium 
surrounding 
imaged cells (pi)
100% 0 2000 2000
75% 500 1500 2000
50% 1000 1000 2000
20% 1600 400 2000
10% 1800 200 2000
0% 2000 0 2000
8.2.2.2 HL-1 myocytes
HL-1 cells were cultured and harvested (Chapter 2) and prepared for microinjection as 
described in Section 4.2.1. As above, two chambers containing cells were set up and 
loaded with Fluo-4AM, as summarised in Figure 8.2. The cells in Chamber 1 were 
microinjected under the conditions optimised previously, and the medium surrounding them
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was transferred to Chamber 2 immediately after microinjection.
Cells microinjected with 
RRL +/- IDB, under phase 
microscopy
Chamber 1 V.
. 60 mins .
'  37°C / 5% CO, «
Cells loaded with Fluo-4  
under a 200 pi meniscus
Immersed cells in a further 
1800 pi warm media
. 15 mins
S ' 37°C 15% CO, 1C
Removed media (2000 pi) from 
Chamber 2  and transferred 
media from Chamber 1 
immediately after microinjection
Chamber 2 V 60 mins37°C 15% C02
15 mins ^
37°C 15% CO,
Cells loaded with Fluo-4 
under a 200 pi meniscus
Immersed cells in a further 
1800 pi warm media I Cells allowed to 
5 mins | recover from 
microinjection
Ex 488 nm Em 500 nm
Figure 8.2. Summary of medium transfer experiment protocol with HL-1 cardiomyocytes
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8.3 Results
8.3.1 Cell-to-cell coupling in HEK293 cells and HL-1 myocytes
LY transfer experiments revealed the presence of intercellular coupling by GJIC in HEK 
and HL-1 cell monolayers (Figure 8.3). HEK cells were poorly coupled, although the dye 
visibly spread between the cells up to 20 mins after injection (t  ^ = ~7 mins). A substantial 
proportion of the LY remained in the original microinjected cell (arrowed) throughout this time 
(Figure 8.3, A). Contrastingly, HL-1 myocytes which are known to exhibit a high level of 
cellular coupling when in a superconfluent state (Claycomb et al. 1998; White et al. 2004) 
displayed a much higher rate of dye transfer, with the amount of dye in the microinjected cell 
dropping to below the threshold of detection within 10 secs of Ml (Figure 8.3, B) (ty2 = ~2 
secs).
HEK293 cells were found to have a ty2 of approximately 7 minutes, while the t% of HL-1 
myocytes was dramatically lower, at ~2 secs (Figure 8.3, C & D respectively). The finding of 
GJIC, albeit at greatly different extents in HEK and HL-1 cells, suggests that cell-to-cell 
contact is one possible mechanism for the bystander effect in HEK293 cells. However, 
ongoing work in our laboratory has also shown the l-Domain linked bystander effect in 
spatially distinct cells, suggesting that cell-to-cell contact can not be the only means of 
communication between cells. Furthermore, cell-to-cell contact in HEK cells is limited due to 
their low confluency (50-60%), which may affect the speed of dye transfer. Higher 
confluencies could not practically be investigated, as HEK cells lose adherence properties at 
confluency >60%. However, even at higher cell densities, it is not anticipated that the speed 
of dye transfer in HEK cells could match that observed in HL-1 myocytes.
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Figure 8.3. Differential extents of cell-to-cell communication in HEK and HL-1 cells
Panel A\ Fluorescence microscopy images showing dye transfer in HEK cells after Ml of a single cell 
(arrowed). Numbers indicate time after Ml (mins). Scale bar 50 pm. Panel B. Confocal microscopy 
images showing dye transfer in HL-1 myocytes after Ml of a single cell. Numbers indicate time after 
Ml (secs). Scale bar 10 pm. Panels C & D: Line graphs showing dye transfer in HEK and HL-1 cells 
respectively.
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8.3.2 Medium transfer in HEK cells
In order to investigate if the trans-cellular exchange of soluble factors is triggered by 
injecting cells with ID fragments, the medium from chambers containing cells microinjected 
with ID8 was removed immediately after microinjection and applied to a chamber containing 
non-injected WT HEK cells. The strategy was augmented by performing these experiments 
with undiluted medium and also with medium diluted by 25-90% (with fresh medium). There 
was a relationship between the proportion of HEK cells that responded to 0.1 mM carbachol 
and the dilution of the transferred medium. At dilutions ranging from 10- 50% dilution, all of 
the cells (100%) responded to 0.1 mM carbachol. Strikingly, following exposure of cells to 
transferred medium that had been diluted to 25% only 8.75% of the cells responded, and this 
was decreased further with undiluted medium (4% carbachol responsive) (Figure 8.4, A).
Following on from data presented in Chapter 7 in which we revealed a link between 
carbachol responsiveness and the resting Ca2+ signal variability (Figure 7.15), here we 
determined an inverse relationship between RSV and the extent of medium dilution (Figure 
8.4, B). At up to 50% dilution, the RSV was not significantly different from the control cells, 
but there was a marked decrease at 25% dilution and again with undiluted medium, both of 
which were significantly lower than the control cells. Additionally, Figure 8.5 further shows 
some of the characteristics of the carbachol-evoked Ca2+ transients are linked to the basal 
signal variability pre-existing in those cells, and that this relationship is affected by the 
dilution of the media. Transfer of medium from cells injected with RRL had no effect on Ca2+ 
handling in non-injected cells (not shown).
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Figure 8.4. Dilution of transferred medium affects Ca 
cells.
2+ handling in carbachol-stimulated HEK
Panel A: Line chart depicting the proportion of cells responding to carbachol as a percentage of the 
total cells imaged, after transfer of medium from HEK cells injected with ID6, n > 70 cells per data 
point. Panel B: Transfer of medium from HEK cells injected with ID6 caused a significant decrease in 
RSV, as the concentration of transferred medium increased (mean ± SEM, n=4, 15-20 cells per 
experiment). ★ represents p<0.001 when compared with WT HEK cells.
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Figure 8.5. The relationship between resting SVm and carbachol-evoked Ca2+ transients in HEK 
cells is affected by transferred medium concentration
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8.3.3 Medium transfer in HL-1 myocytes
SALVO analysis (Figure 8.6) showed that, over a 5 minute period, transfer of media from 
cells microinjected with ID8 onto non-injected beating HL-1 myocytes significantly altered the 
total noise (A), transient length (E), length to decay (H) and rate of oscillation (I), when 
compared with control cells where medium from cells microinjected with RRL was 
transferred to non-injected beating HL-1 myocytes. As seen in previous chapters, these 
alterations in Ca2+ handling did not alter the overall synchronicity of the coupled monolayer 
(Figure 8.7).
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Figure 8.6. SALVO analysis of the effects of media transfer on HL-1 myocyte monolayers.
Spatio-temporal Ca2+ handling parameters in HL-1 myocytes exposed to media from cells injected with RRL (dashed line) or in wfro-produced ID8 
(solid line), plotted from SALVO analysis of Ca2+-dependent Fluo-4 fluorescence (mean ± SEM, n = 4, 15-20 cells per experiment) *  represents 
p<0.01 when compared with cells exposed to media from RRL-injected HL-1 myocytes. Values for HL-1 WT cells (X), shown here from the results 
shown in Chapter 4.
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Figure 8.7. Synchronicity is not affected by medium transfer
Synchronicity within HL-1 monolayers exposed to medium from cells injected with RRL (dashed line) 
or in wfro-produced ID8 (solid line), plotted from SALVO analysis of Ca2+-dependent Fluo-4 
fluorescence (mean ± SEM, n = 4, 15-20 cells per experiment). Values for HL-1 WT cells (x), shown 
here from the results No significant difference between RRL- or ID8- injected and WT HL-1 was 
observed.
268
Chapter 8
8.4 Discussion
This thesis has provided compelling evidence for a bystander effect, whereby non- 
injected cells showed comparable Ca2+-handling phenotypes as adjacent cells that had been 
microinjected with l-Domain fragments. The bystander effect was corroborated in different 
cell types (HL-1 and HEK cells) and using recombinant proteins produced via distinct 
synthetic routes (bacterial expression versus in vitro synthesis). It has been proposed that 
there may be two basic mechanisms by which ‘damage’ signals may be transmitted from 
irradiated to non-irradiated cells. Firstly by direct cell-to-cell contact often mediated by gap 
junction intercellular communication (GJIC) (Azzam et al. 2001; Shao et al. 2003), and 
secondly by means of soluble factors released into the surrounding medium by transduced 
cells (Azzam etal. 1998; Prise etal. 1998).
The first mechanism was investigated by the transfer of dye between coupled cells, and it 
was found that although the extent of coupling in HEK and HL-1 cells varied greatly between 
the two cell lines, cell-to-cell contact represents a mechanism that probably underpins 
intercellular communication in HEK and HL-1 cell population and likely contributes to the 
bystander effect in both instances. However, further in-depth analyses of connexin 
expression levels in both of these cell lines, as well as comprehensive control experiments 
using gap-junction blockers are required before GJIC can be considered as a bona fide 
mechanism underlying the bystander effect.
Studies that investigated the trans-cellular exchange of soluble factors revealed the 
possible involvement of an alternative pathway underlying the bystander effect. Media 
transferred from cells injected with ID8 onto non-microinjected cells had a profound effect on 
cellular Ca2+ handling in naive HEK and HL-1 cells. In HL-1 cells, the transfer of media from 
cells microinjected with ID8 onto non-injected beating HL-1 myocytes significantly altered 
multiple aspects of cellular Ca2+ handling behaviour, but not the synchronicity of the coupled 
monolayer. This supports the data presented in previous chapters, whereby HL-1 myocytes 
exhibited a robust plasticity that resulted in the preservation of cellular synchrony despite
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subtle changes in numerous facets of cellular Ca2+-handling. In HEK cells, the transfer of 
media markedly reduced the number of cells responding to 0.1 mM carbachol as well as 
significantly reducing the Ca2+ signal variability following carbachol stimulation. Furthermore, 
it was found that the dilution of the transferred media increased the proportion of cells that 
exhibited carbachol-evoked Ca2+ release and restored Ca2+ signal variability. The finding 
that the phenotypic effects of trans-media exchange were dependent on the extent of the 
dilution adds further support to our hypothesis that factors released from micro-injected cells 
could modulate Ca2+ signalling events in adjacent, non-microinjected cells. There are 
numerous candidate molecules that could be considered in this context (including ATP, 
reactive oxygen species, GSH), and their unequivocal identification is key to delineating the 
mechanisms underlying the bystander effect.
As discussed previously, the results presented throughout the thesis persuasively show 
that microinjection of a discrete population of cells is associated with a bystander effect, 
whereby it initiates similar phenotypic changes in neighbouring non-microinjected cells. So 
far, we were not able to block this effect, so it is accepted that the conclusions presented in 
this thesis require further evaluation in experiments that ultimately succeed in separating 
distinct effects in microinjected cells, versus those in the persistent presence of a bystander 
effect. Thus, that the findings from all experiments presented in this thesis must be 
interpreted in the context of an existing bystander effect.
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General discussion
Chapter 9
The aim of this thesis was to further elucidate the precise roles of functional motifs within 
the l-Domain. Specifically, I addressed their effects on cellular Ca2+ cycling using a peptide 
probe-based approach. My findings reveal novel insights into the mechanisms by which 
disruption of interdomain interactions via the l-Domain could result in abnormal Ca2+ 
handling (e.g. HF). Conversely in a therapeutic context, these studies present compelling 
evidence that targeting this region could normalise these abnormal interactions in cardiac 
disease.
9.1 Expression of l-Domain proteins
Propagation and isolation of the pET-29(b) expression cassettes containing truncated ID 
templates was successful, when carried out under the conditions optimised for the 
propagation of hRyR2 DNA that avoid spontaneous recombination or plasmid DNA 
degradation (George et al. 2005).
These expression cassettes were then used for the successful synthesis of ID proteins in 
a cell free RRL system, regardless of size, secondary structure, or hydrophobicity, which 
may have been difficult to achieve in a bacterial system. According to densitometric analysis 
of radiolabelled proteins and S-protein HRP conjugate detection, the four l-Domain proteins 
displayed broadly equivalent levels of expression, and immunodetection using the fusion 
protein epitopes at either end of the protein expression cassette confirmed that full-length 
recombinant proteins had been produced. However, expression of the l-Domain proteins in 
the WG extract was not successful, with only two of the proteins (IDA and IDC) being 
expressed by WG extract albeit in lower levels than by RRL, while ID and ID6 were not 
expressed at all. This was unexpected, as WG was anticipated to yield proteins in the range 
of two orders of magnitude higher than those produced in RRL (Alimov et al. 2000; Endo & 
Sawasaki 2006; Hino et al. 2008; Jermutus et al. 1998; Katzen et al. 2005; Vinarov et al. 
2006; Zhao et al. 2007), and may suggest an inherent incompatibility of the l-Domain 
proteins with the WG extract expression system (Chapter 3).
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The in wfro-synthesised l-Domain proteins were effectively isolated from RRL using a 
strategy based on magnetic zinc beads with a high affinity to poly-His-tagged proteins but 
not to haem groups, thus allowing the purification of the target protein without co-purification 
of haemoglobin present in the RRL. This strategy resulted in the removal of ~95% of 
contaminating background proteins, and permitted enrichment of the 1-Domain proteins that 
could be unequivocally identified using immunoblotting techniques.
The 1-Domain proteins were more difficult to express in a BL21-derived bacterial system. 
The expression of full-length l-Domain protein in a classical IPTG-induced system was 
unsuccessful despite the investigation of an array of different conditions, and resulted in 
numerous incomplete protein fragments with high levels of degradation, and no detectable 
full-length protein. As shown in Chapter 6, the use of an auto-induction system was found to 
be better suited for the expression of l-Domain proteins, and effectively expressed ID6 which 
was subsequently purified using sequential Ni2+-affinity and S-protein affinity to selectively 
bind the His- and S-tag, respectively.
Further work is required to set up rigorous control experiments, in order to accurately 
elucidate the effects of bacterially produced ID6. The bacterially produced protein potentially 
differs to the in vitro protein by (i) lacking the S-tag, which was cleaved during purification, (ii) 
being subject to secondary modification, (iii) containing truncated ID proteins in the purified 
sample, each of which could alter the proteins bioactivity in HL-1 cells (Figure 6.6).
The bacterially synthesised proteins have undergone S-tag cleavage as part of the large- 
scale purification process, and this may enhance the bioactivity of the proteins. Additionally, 
bacterial expression systems allow for secondary modification of proteins, which does not 
occur in cell free systems. Furthermore, the bacterially-produced sample contains several 
truncated ID species which were detected by ab1093 (Figure 6.6). These truncated 
fragments may be bioactive, and therefore may cumulatively increase the ID6 phenotype 
observed in microinjected cells.
Some or all of the considerations may contribute to the stark differences observed on 
Ca2+ handling parameters. Notably, the restoration of synchrony is equivalent in both
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methodologies. Further work will be necessary to determine how discrepant mechanisms 
can result in a comparable effect on synchrony - a robust index of intra- and inter-cellular 
Ca2+ handling - and indeed, how this is determined by the source of the protein.
9.2 Microinjection technique
Single cell Ml is a robust and reproducible technique which permits the precise control of 
the amount and timing of delivery, and was used in this thesis to deliver exogenous proteins 
to adherent HL-1 cardiomyocytes and HEK293 cells. It was accepted that the Ml procedure 
itself had altered some facets of cellular Ca2+ handling phenotype, but this was addressed by 
the use of robust control experiments. This is a limitation of the Ml approach, but we believe 
that in the context of this thesis, this disadvantage is far outweighed by the advantages of 
Ml, which including having precise control of the location and duration of sample delivery, as 
well as obtaining a clearly identifiable population of Ml cells, which may not be possible with 
other conventional sample delivery technologies such as transfection (e.g. Bioporter 
reagent) or electroporation.
Using carefully optimised conditions (see Chapter 4), Ml proved to be a minimally 
invasive delivery method which was well tolerated by cells without disruption of the tightly 
regulated cellular Ca2+ handling. This was corroborated by Ml of both cDNA, and protein 
fragments, in synchronously oscillating HL-1 myocytes and in non-excitable HEK cells.
Interestingly, Ml had differential effects on HEK and HL-1 cells, whereby Ml was not found 
to alter any of the Ca2+ handling parameters measured in HEK cells (Chapter 7), but did alter 
several parameters in HL-1 myocytes (Chapter 4). This may indicate an inherent difference 
in the modes of Ca2+ cycling between the two cell types, or that the absence of spontaneous 
oscillations in HEK cells indicates a simpler Ca2+ handling mechanism which is less easily 
perturbed. Importantly, although Ml was found to affect some facets of Ca2+ handling in HL- 
1 myocytes, it consistently did not alter the synchronicity of the HL-1 monolayers, suggesting 
that Ca2+ fluxes were not sufficiently disrupted by Ml to result in dyssynchrony. This
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indicates that although precise Ca2+ regulation is vital for maintaining regular, synchronous 
contractions in cardiac cells, the cells exhibit pronounced functional plasticity and are able to 
robustly compensate for a surprisingly large degree of disruption in Ca2+ while still 
maintaining an overall regulated synchronously beating state. At this stage, it is not possible 
to identify which parameter(s) determine the state of cell synchronicity, and more detailed
analyses of each of these interdependent parameters are required to provide an insight into
the mechanism underlying the regulation of synchronous contraction in cardiac myocytes. 
Ongoing studies in our laboratory are currently addressing this, and are already unravelling 
the complex and interdependent relationships between Ca2+ handling, rhythmicity and 
synchrony in coupled cardiac monolayers (Silvester et al. 2009).
9.3 The effect of ID? in HL-1 cardiomyocytes
Injection of ID6 appeared to have little effect in synchronous resting HL-1 cells and 
although subtle changes in some Ca2+ handling parameters were observed, they did not 
manifest as alterations in synchronicity (discussed in Chapter 5). Despite the small changes 
in noise and rate of Ca2+ release, which may imply some interaction with SERCA or altered 
modes of Ca2+ influx and/or efflux, the transient characteristics and synchronicity remained 
unchanged compared with the control cells.
In a model of ouabain-induced Ca2+-overload and intercellular dyssynchrony, which from 
a mechanistic perspective mimics the events underlying some forms of malignant human 
arrhythmia (i.e. chronic Ca2+ overload), ID8 restored synchrony in ouabain pre-treated cells, 
to a level which is comparable to that seen in WT HL-1 cells. This was observed after the 
injection of both in vitro- and bacterially-produced ID8 (Chapters 5 and 6, respectively)
Interestingly, the restoration of synchrony by ID8 was not observed in cells which 
contained ID8 prior to the addition of ouabain, implying that the potential beneficial effects of 
ID8 on normalising cellular Ca2+ cycling may be restricted to those cells in which Ca2+ cycling 
is already perturbed. The present data provides a platform for further investigating the
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therapeutic utility of specific intra-RyR2 epitopes e.g. as novel anti-arrhythmic moieties.
HL-1 cells provide a unique experimental system, which is ideal for a proof of concept 
study, as presented in this thesis. HL-1 cardiomyocytes are distinctive in their capacity to 
proliferate and be serially passaged without reverting to an embryonic phenotype (Claycomb 
et al. 1998; White et al. 2004), and are the only cultured cell line of cardiac origin which can 
form synchronously coupled beating monolayers suitable for imaging experiments. Further 
studies will need to address the physiological applicability of the results observed in HL-1 
cells, and if they can be reproduced in other experimental systems, such as computational 
modelling systems, canine wedge preparations, and animal models.
9.4 The effect of the l-Domain on IP3R-dependent Ca2+ handling
The IDB-mediated restoration of synchrony in dyssychronous HL-1 cells is likely to be 
associated with favourable intra-molecular conformational changes (Figure 5.21) -  a 
mechanistic feature common to both RyR2 and IP3R. Since bioinformatic comparisons 
revealed striking structural homology between sub-fragments of the RyR2 l-Domain and I- 
Domain-like regions of IP3R, the study of the l-Domain fragments was extended to 
investigate their effects on IP3R channel regulation, as described in Chapter 7.
ID proteins had a profound effect on cellular Ca2+ handling phenotype in HEK cells 
following IP3R stimulation by 0.1 mM carbachol. Transduction with l-Domain fragments 
altered both the extent of carbachol-evoked Ca2+ transient as well as the transient shape. 
Although this suggests the direct (and possibly indirect) involvement of components 
regulating intracellular Ca2+ it also suggests that these alterations in Ca2+ behaviour may be 
due to the ID fragments modulating some mode of Ca2+ influx, as indicated by the findings of 
experiments in which a chelator of extracellular Ca2+ (EGTA) was added to the culture media 
(Figure 7.13). This requires further investigation.
Additionally, a comparison of the SVm in carbachol-responsive and non-responsive HEK 
cells found a link between SVm and the propensity of cell to respond to carbachol. In
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general, carbachol-responsive HEK cells had a higher mean resting SVm> a finding that 
points towards an intriguing link between basal Ca2+ fluxes and agonist-evoked Ca2+ release. 
The concept that homeostatic Ca2+ fluxes ‘tunes’ the amplitude and temporal characteristics 
of agonist-evoked Ca2+ mobilisation is rapidly emerging (George et al. 2006; Silvester et al. 
2009).
9.5 The bystander effect
This thesis provides persuasive evidence for the existence of a ‘bystander effect’, 
whereby non-injected cells showed the same Ca2+-handling phenotypes as nearby cells that 
had been microinjected with l-Domain fragments. The ‘bystander effect’ has been regularly 
reported in the study of immunology, and in cancer therapy after exposure to ionising 
radiation treatment in cancer therapy, whereby irradiated cells may also transmit damage 
signals to non-irradiated cells in a population, leading to the occurrence of the same genetic 
effects in these ‘bystander’ cells that themselves receive no radiation exposure (Morgan & 
Sowa 2007), but to the best of our knowledge, this is the first report of a bystander effect in 
cardiac cells.
The bystander effect was observed in different cell types (HL-1 and HEK cells) and using 
recombinant proteins produced via distinct synthetic routes (bacterial expression and in vitro 
synthesis), and importantly, has also been observed in other distinct studies in our laboratory 
(Fry 2008). Taken together, these indicate that the bystander effect, that probably involves 
both direct intercellular communication (via GJIC) and an extracellular transfer route, is not 
simply an artefact of the cell-line, delivery technique or experimental conditions. Such a 
bystander effect may have important implications in arrhythmogenesis, whereby a relatively 
small number of asynchronous cells may be sufficient to underlie disruption of synchronicity 
in the heart. In addition, it may provide the conceptual basis for the therapeutic targeting of 
small, discrete cellular populations within the myocardium. To this end, a recent study by 
Marban and colleagues highlighted the therapeutic consequences of a bystander effect in
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the context of arrhythmia. Kashiwakura (Circulation 2006 114 1682-1686) showed a 
remarkable restoration of normal heart rhythm following the transduction of <2% of the 
myocardium with an adenovirus encoding a recombinant ion channel.
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Appendices
Appendix I
Appendix I  -  List o f Primers
All of the oligonucleotides used were designed to incorporate a 5’ EcoRI and a 3’ Xho\ 
restriction site (underlined), and had a Tm of 58-60*0.
Full length 1-Domain (aa 3722-4610)
Forward -  5f-GGCCGAATTCTGAGCTTCTATACCAGCAAGCCCGA-3'
Reverse -  5-GGCTCGAGTTCCAATTTCCGTGCCACTTCCTTTTC-31
IDa (aa 3722-4353)
Forward -  5'-GGCCGAATTCT GAGCTT CT ATACCAGCAAGCCCGA-3' 
Reverse -  S'-CGGCTCGAGGGGTTTCCTCTCTCCCTCCTC-S'
ID8 (aa 4353-4499)
Forward -  5'-GGCCGAATTCTCCCCTGGAAGCCGCCCTGCCC-3' 
Reverse -  5'-CGG CTCGAGGTTG CGAGCAAAATAGTTTAG-3'
IDC (aa 4353-4610)
Forward -  5,-GGCCGAATTCTCCCCTGGAAGCCGCCCTGCCC-3, 
Reverse — 5 '-GGCTCGAGTTCCAATTT CCGTGCCACTTCCTTTT C-3
311
Appendix II  -  Bioinform atic analysis o f RvR2 and IP3R l-domains
Appendix II
a-helix p-tum Extended Coil
R2
ID
(%) (%) strand (%) (%)
59.96 5.62 9.45 24.97
IDA 63.33 5.08 7.62 23.97
IDB 57.14 3.4 6.12 33.33
IDC 57.53 3.09 10.81 28.57
IP3R-1
IDA-like 54.54 4.25 11.15 30.05
IDB-like 51.82 3.64 10.93 33.60
IDC-like 56.90 5.08 11.14 26.88
IP3R-2
IDA-like 54.21 3.95 11.45 30.39
IDB-like 48.39 4.44 12.90 34.27
IDC-like 56.14 5.06 12.29 26.51
Table ii. Predicted structural motifs in RyR2 1-Domains and the l-Domain-like 
regions in IP3R.
Motifs were predicted using the SOPMA algorithm as described in Table i. The 
detailed organisation of these motifs within the RyR2 and IP3R is shown in Figure iii to 
v.
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Figure i. Hydropathy analysis of the human RyR21-Domain
Hydropathy analysis of the human RyR2 l-domain (residues 3722-4610) was performed using the 
Hopp-Woods algorithm as described in Table i. The hydrophobic scale is given in Figure ii. Positive and 
negative ranges correspond to hydrophilic and hydrophobic residues, respectively. The two TM regions 
(arrowed) correspond to TM1 and 2 according to the model of Tunwell et al.
Using the scale Hphob. I Hopp & Woods, the individual values for the 20 amino acids 
are:
Ala -0.500
Arg 3.000
Asn 0 .200
Asp 3.000
Cys -1.000
Gin 0.200
Glu 3.000
Gly 0 . 000
His -0.500
H e -1.800
Leu -1.800
Lys 3.000
Met -1.300
Phe -2.500
Pro 0.000
Ser 0.300
Thr -0.400
Trp -3 .400
Tyr -2.300
Val -1.500
Figure ii. Hydrophobicity scale
H= alpha helix / T= beta turn / E= extended strand / C=coil
□  Homology between RyR2 and IP3R-1 / IP3R-2
□  Homology between RyR2 and IP3R-1
□  Homology between RyR2 and IP3R-2
Figure iii- IDA-like region homology
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Figure iv - IDB-like region homology
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Figure v - IDC-like region homology
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